2014 Product Catalog



Innovative Research af America

Time Release Pellets for Biomedical Research

www.fmowsrdh.com

INNOVATIVE RESEARCH OF AMERICA

Most scientists agree that the three essential parameters in the success of a biomedical experiment are:

- A. The scientific problem formulated in a defined question.
- B. The laboratory animal, healthy and untraumatized.
- C. The process of active product delivery; the most problematic variable of all three!

For a third of a century, Innovative Research of America has assumed the leadership role in improved time release technology. The main mission is to standardize the technology of drug delivery. Our proven Time Release Hormone and Drug Pellets help investigators take charge of product delivery and expand their abilities to do meaningful and reproducible research.

ADVANTAGES OF THE PELLET DELIVERY SYSTEM

- a ready-to-administer pellet for a simple subcutaneous implantation.
- · a convenient long-term controlled product release in laboratory animals.
- a better method to avoid the "peak and valley" effects produced by conventional delivery methods.
- a new system to extend the product life against spontaneous and host-related breakdown.
- a dependable way to minimize the experimental variables.
- a more reliable approach for productive and reproducible research.



Ushering In The Age Of Innovative Research

HORMONE AND DRUG PELLETS FOR BIOMEDICAL RESEARCH

Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.

Because of this inadequacy, biomedical research is as confusing as it is challenging and as frustrating as it is creative. The options of scientists to address scientific questions are not only dependent, but are also limited by the process of active product delivery. Traditionally, product delivery into the experimental animal has been the procedure most subject to variables and the most difficult to standardize effectively. The very process of having to accurately administer drugs to experimental animals can become a logistic nightmare for scientists.

CHANGING THE TIME COURSE OF DRUG DELIVERY

The good news is that times have changed. Our proven *Drug Delivery Technology* is helping investigators eliminate the need for unreliable, intermittent injections. Since 1980, Innovative Research of America has been the leader in supplying scientists with long term continuous release pellets embedded with active products. Our technology provides finished products, in a ready-to-implant form, utilizing our Matrix-Driven Delivery (MDD) Pellet System. The pellets are intended for, although not limited to, simple—subcutaneous implantation in laboratory animals.

TABLE OF CONTENTS

Find a Product in this Cata	log 5
Ordering Information / Gen	eral Policy & Terms 6, 7, 44, 84
Sales of Anabolic Steroids	8
Category Index	10-15
Alkaloids Amino Acids Androgens Antibiotics Anti-Inflammatory Agents Anti-Neoplastics Catecholamines Corticoids and Diuretics	Estrogens Fatty Acids Nucleotide Related Products Progestins Prostaglandins Thyroids Vitamins
Placebo Pellets Information	n / Price Schedules 17-19
Alphabetical Product Listin	ng 21-42
	es
	nt Mice & Sample References 73-77 ns & Sample References 78-80
Trochar & Recommended I	mplantation Procedure81, 123
Doxycycline & Tetracycline	Pellets in Mice 85-86
Hormone + Hormone Pellet	s 89-92
Custom Pellets	93-108
	109-122
	Back of Catalog
	Inside Back Cover

*For further assistance, view our website at: www.innovrsrch.com



We Add Time To Your Day

PRODUCT DESIGN AND FEATURES

The unique engineering of the (MDD) Pellet System integrates the three principles of diffusion, erosion and concentration gradients. It generates a finished pellet with a biodegradable matrix that effectively and continuously releases the active product in the animal.

The pellet delivery system can help the investigator take charge of standardizing and reproducing research results. It helps overcome problems commonly encountered by researchers who employ conventional delivery methods.

The Pellet Implantation Methodology provides solutions to:

- ... consistency in timing repeated product administrations.
- ... controlling the amount of product administered.
- ... stability of the product preparation.
- ... safety of the experimenter.
- ... neurophysiological trauma to the animal from excessive handling.
- ... freeing valuable research time.
- ... eliminating unnecessary and unstimulating laboratory practices.

Scientists from several research disciplines have documented in scientific literature that our Pellet Delivery System is effective, consistent, reproducible, economical, reliable, and safe for the animal. See Selected References on pages 109-122.



PRODUCT SPECIFICATIONS

AVAILABLE SHAPES AND SIZES

Stock pellets are round and range in diameter from 1/8" (3 mm) to 1/2" (1.25 cm) depending on the dose and the release rate. Our Custom Pellets Department will also design various pellet shapes and smaller sizes (Page 94) to meet your research needs. Please refer to the **Custom Pellets** section on pages 93-108.

AVAILABLE DOSAGES

Most of the stock products in this catalog are available in 20 different dosages ranging from 1 microgram (0.001 mg) per pellet up to 200 milligrams (200 mg) per pellet within the specified release rate. Doses of pellets listed in this catalog reflect the total amount of net active product released over the indicated period of time.

AVAILABLE RELEASE RATES

Stock products are designed to release continuously for 21 days, 60 days, or 90 days. Please refer to our **Custom Pellets** section on pages 93-108 for other release rates tailored for the duration of the experiment.

AVAILABLE PRODUCTS

In our continuing quest to make available new stock items that are particularly in demand, we have added several products to the original categories. In addition to the listed pelletized products, Innovative Research of America has an efficient Custom Pellets Department to prepare products that are not available as stock items.

SELECTED REFERENCES

A sample of publications that employed our delivery system in a broad spectrum of products can be found on pages 109-122.



Consistent Dose-Dependent Release

FINDING A PRODUCT IN THIS CATALOG

The PRODUCTS in this catalog are arranged in ALPHABETICAL ORDER and are identified by a CATALOG NUMBER and a PRICE SCHEDULE with a PAGE NUMBER.

The catalog number and price schedule reflect a release rate of 21 days, 60 days, or 90 days. To illustrate with 17ß-Estradiol as an example:

EXA	MPLE	\$				
Product 21-Day Release		60-Day Release		90-Day Release		
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule Page Number
7ß - Estradiol	E - 121	B-21/48	SE - 121	B-60/49	NE - 121	B-90/50
7ß - Estradiol	E - 121	B-21/48	SE - 121	B-60/49	NE - 121	

The above example indicates that 17ß-Estradiol is available in three release forms each having a different catalog number and price code, i.e.

E - 121 is a 21-day release form with a price code of B-21, found on page 48.

SE - 121 is a 60-day release form with a price code of B-60, found on page 49.

NE - 121 is a 90-day release form with a price code of B-90, found on page 50.

The PAGE NUMBER next to the PRICE SCHEDULE indicates the page where the actual price for the product appears.

When ordering please use the PRODUCT NAME, CATALOG NUMBER, RELEASE RATE and DOSE. Most products are available in 20 different dosages. Products are sold in Lots of 25, 50, 100, and 200 pellets. Please indicate the quantity of pellets being ordered.

Beginning on Page 10 we have grouped some of our catalog items in related categories alphabetically. We hope the listing will help in noting items of potential interest.



ORDERING INFORMATION

Internet / E-Mail

http://www.innovrsrch.com (website) pellets@innovrsrch.com (e-mail)

IRA's website features our company profile,

the latest product technology and on-line ordering.

· Mail

Innovative Research of America, Inc. 2 North Tamiami Trail Suite 404 Sarasota, Florida 34236 USA

· Phone

(941) 365-1406 (941) 365-1506 (800) 421-8171 (USA/Canada)

· Fax


(941) 365-1703 (941) 365-1803 (800) 643-4345 (USA/Canada) (800) 648-6030 (USA/Canada)

X OX

AMERICAN EXPRESS, VISA AND MASTERCARD ACCEPTED. Purchase Order Forms are in the back of the catalog.

Custom Pellets Information Form on page 95.

THE DIFFERENCE IS CONSISTENCY AND UNIFORMITY.



Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank 1800 Second St., Suite 100 Sarasota, Florida 34236 Routing # (ABA) 263191387 Electronic Transfers # 263191387

In favor of: Innovative Research of America 2 North Tamiami Trail Suite 404 Sarasota, FL 34236 Checking Account: #0000147816154 Swift Code: BRBTUS33



GENERAL POLICY AND TERMS

POLICY

All products in this catalog are sold for investigational use in laboratory animals only and are not intended for diagnostic or drug use.

Sales are made to qualified research scientists and recognized institutions.

Products that you receive because of your error are not returnable for credit.

Any product shipped to you that includes an error on our part may be returned to us immediately for replacement. Prices are subject to change without notice.

TERMS

30 days net/FOB Sarasota, Florida USA.

Prepayment in U. S. Dollars through a U.S. Bank is required on all orders from outside the United States until credit is established.

Bank Wire Payment Information can be found on the International Order Form located in the back of this catalog. In addition to bank wires and institutional checks, we also accept payment by Mastercard, Visa and American Express.

Please provide your account number, the name on the card and expiration date when placing an order.

Recipient is responsible for all duties and taxes on any orders shipped outside of the United States.

SHIPPING

All orders of stock items will be shipped within seven days from receipt of order. Custom Pellet orders will be shipped within 4-6 weeks.

Standing orders will be shipped upon customer request and invoicing will be concurrent with shipments. Orders are shipped via Federal Express. Shipping and handling is added based on the invoice total.

Recipient is responsible for all duties and taxes on any orders shipped outside of the United States.



SALE OF CONTROLLED ANABOLIC STEROIDS within the United States

(Telephone orders will not be accepted - orders & copy of DEA license may be mailed or faxed)

Before we can prepare any orders of Anabolic Steroid Pellets, the Drug Enforcement Administration (DEA) requires us to obtain:

- 1. A valid photocopy of the investigator's DEA Registration containing Schedule 3N.
- A written Purchase Order showing the investigator's DEA Registration Number and proper shipping address.

CONTACT INNOVATIVE RESEARCH OF AMERICA
BY PHONE, MAIL, FAX OR E-MAIL
FOR MORE ORDERING INFORMATION - SEE PAGE 6

SALE OF CONTROLLED ANABOLIC STEROIDS outside the United States (International)

WE NO LONGER SHIP ANABOLIC STEROIDS outside the United States (International)

DEA Controlled Anabolic Steroids

Androstenediol

Androstenedione

5α-Dihydrotestosterone

Fluoxymesterone

Mesterolone

Mesterone

Methandriol

Methandriol Dipropionate

19-Nortestosterone

19-Nortestosterone 17-Decanoate

19-Nortestosterone 17-Dipropionate

Stanozolol

Testosterone

Testosterone Acetate

Testosterone Benzoate

Testosterone Cypionate

Testosterone Enanthate

Testosterone 17ß-Hemisuccinate

Testosterone Propionate



Time Release Pellets ... Always On Time

See pages 73-80 regarding Hormone/Anti-Hormone products for Immuno-Deficient Mice and specific references.



Your Research Time Is Under Your Control



CATEGORY INDEX

On the following 6 pages, we have grouped some of our Catalog items in related categories. Hopefully this listing will help in noting items of potential interest.

ALKALOIDS

cis-Aconitic Acid trans-Aconitic Acid

Aconitine

Anisodamine Anisodine

Arecoline Atropine

Atropine Methyl Bromide

Berberine Boldine

Bromocriptine Mesylate

Brucine

Calycanthine (-) Cotinine Crotaline

Cytisine

Dihydroergotamine

Emetine

Eserine (Physostigmine)

Eucatropine (+) Glaucine Homatropine L-Hyoscyamine

Nicotine

Nicotinic Acid Noscapine

L-Phenylephrine Physostigmine (Eserine)

Puerarin Quinidine Quinine

Scopine Securinine

Solasodine (-) Sparteine Spermidine

Spermine

Strychnine Theobromine Theophylline Tomatidine Tomatine Tropine

Tropinone Veratrine Vincamine Yohimbine

AMINO ACIDS

N-Acetyl-L-Cysteine N-Acetyl-L-Glutamine N-Acetylimidazole

B-Alanine D-Alanine

L-Alanine D-Arginine L-Arginine

D-Asparagine L-Asparagine

D-Aspartic Acid L-Aspartic Acid D-Cysteine L-Cysteine

D-Cystine L-Cystine

D-Glutamic Acid L-Glutamic Acid D-Glutamine

L-Glutamine Glycine D-Histidine L-Histidine

D-Isoleucine

L-Isoleucine D-Leucine L-Leucine

D-Lysine L-Lysine D-Methionine L-Methionine D-Phenylalanine

L-Phenylalanine D-Proline L-Proline

D-Serine

L-Serine

D-Threonine L-Threonine D-Tryptophan L-Tryptophan D-Tyrosine

L-Tyrosine D-Valine L-Valine

ANDROGENS

Androstenediol

Androstenedione

5α-Androsterone 5β-Androsterone

Cyproterone Acetate

Dehydroepiandrosterone Dehydroepiandrosterone Acetate

Dehydroepiandrosterone Sulfate

5a-Dihydrotestosterone 5ß-Dihydrotestosterone

Fluoxymesterone

Flutamide

Gossypol Acetate

Mesterolone (Methyl Testosterone)

Mesterone

Methandriol (Methyl Androstendiol)

Methandriol Dipropionate

Methyl Androstenediol (Methandriol)

Methyl Testosterone (Mesterolone)

Nandrolone (19-Nortestosterone)

19-Nortestosterone (Nandrolone)

19-Nortestosterone 17-Decanoate

19-Nortestosterone 17-Dipropionate

19-Nortestosterone 17-Propionate

Stanozolol

Testosterone

Testosterone Acetate

Testosterone Benzoate

Testosterone Cypionate Testosterone Enanthate

Testosterone 17ß-Hemisuccinate

Testosterone Propionate



Reliable Delivery System For Global Discoveries

ANTIBIOTICS

Acetarsone Albendazole Amantadine

6-Aminopenicillanic Acid

Amoxicillin Amphotericin B Ampicillin Bacitracin

Beclomethasone Benzylpenicillinic Acid

Cefadroxil
Cefamandole
Cefazolin
Cefmetazole
Cefoperazone
Cefotaxime
Cefoxitin

Cefsulodin Ceftriaxone Cephalexin Cephaloglycin Cephalothin Cephapirin

Chloramphenicol Chloramphenicol Base

Chlorpheniramine

Cinchonidine

Cinnarizine

Clofoctol Clotrimazole Cloxacillin

Colchicine D-Cycloserine Diaveridine

Dicloxacillin Doxycycline Econazole

Enoxacin Erythromycin Ethambutol Flumequine Geneticin

Gentamicin Sulfate

Gramicidin
Guaifenesin
Indoprofen
Isoxicam
Ketoprofen
Melphalan
Metronidazole
Minocycline

Monensin Moxalactam

Mycostatin (Nystatin)

Neomycin Sulfate

Novobiocin

Nystatin (Mycostatin)
Oxytetracycline
D-Penicillamine
DL-Penicillamine
L-Penicillamine

Penicillin-G (Benzylpenicillin)

Piromedic Acid Polymyxin B Sulfate

Primaquine Puromycin Pyrazinamide Quinacrine Rifampicin Rifamycin Spiramycin

Streptomycin Sulfate Sulfabenzamide Tetracycline Thiabendazole Thiacetazone Thiamphenicol Vancomycin

Xanthinol Nicotinate

ANTI-INFLAMMATORY AGENTS

Allopurinol
Aspirin
Chloroquine
Diclofenac
Flufenamic Acid
Flurbiprofen
Ibuprofen

Indomethacin Levamisole Meclizine Mefenamic Acid Naproxen Niflumic Acid Nimesulide Phenylbutazone
Piroxicam
Probenecid
Sulfinpyrazone
Sulindac
Zomepirac

We Add A Little Time To Your Day



ANTI-NEOPLASTICS

Actinomycin D (Dactinomycin)

Adriamycin (Doxorubicin)

Asparaginase

Busulfan (Myleran)

Chlorambucil

Cyclophosphamide (Cytoxan)

Cytarabine (Cytosine Arabinoside)

Cytoxan (Cyclophosphamide)

Dactinomycin (Actinomycin D)

Daunorubucin (Daunomycin)

Doxorubicin (Adriamycin)

5-Fluorouracil

Kanamycin Lomustine

Mechlorethamine

6-Mercaptopurine

Methotrexate

Mithramycin A

Mitomycin C

Myerlan (Busulfan)

Oncovin (Vincristine)

cis-Platinum

trans-Platinum

Streptozotocin

6-Thioguanine

Velban (Vinblastine)

Vinblastine (Velban)

Vincristine (Oncovin)

CATECHOLAMINES AND RELATED PRODUCTS

Acebutolol

Acetopromazine (Acepromazine)

Acepromazine (Acetopromazine)

N-Acetylprocainamide

Aimaline

Alprenolol

Aminophylline

Amiodarone

Amitriptyline Amrinone

Antazoline

Atenolol

Caffeine

Captopril

Carbamazepine

Carbinoxamine

Centrophenoxine

(Meclofenoxate)

Chlorcyclizine

Chlorothiazide

Chlorpromazine

Chlorthalidone

Chlorzoxazone

Cimetidine

Clomipramine

Clonidine

Clopamide

Cromolyn

Cyclizine

Cymarin

Cyproheptadine

Deoxyepinephrine (Epinine)

Desipramine

Digitonin

Digitoxin

Digoxin

Dimenhydrinate

Disopyramide (Anti-arrhythmic)

D-Dopa

DL-Dopa

L-Dopa

Dopamine (3-Hydroxytyramine)

Doxepin

Doxylamine

Drofenine

Edrophonium Enalapril

Ephedrine

Epinephrine

Epinine (Deoxyepinephrine)

Flunarizine

Forskolin

Guanabenz

Guanethidine

Haloperidol Harmaline

Harmine

Histamine

Hydralazine

5-Hydroxydopamine 6-Hydroxydopamine

5-Hydroxy-L-Tryptophan 3-Hydroxytyramine (Dopamine)

Imipramine (Anti-depressant)

Isoproterenol

Isoxsuprine

Khellin

Labetalol

Lanatoside C

Lidocaine

Meclofenoxate (Centrophenoxine)

Methoxamine

Methyl L-Dopa

Metoclopramide

Metoprolol

Minoxidil

Nadolol

Naloxone

Naltrexone

Naphazoline Neostigmine

Nifedipine

Nifenazone

Norepinephrine

Nortriptyline

Ouabain

Papaverine

Perphenazine

Phenelzine

Pheniramine

Pindolol

Prazosin

Procainamide

Promethazine

Propranolol

Pyrilamine

Rescinnamine

Reserpine

Salbutamol

Serotonin

Timolol

Tolazoline

Tranylcypromine

Tripelennamine Verapamil



It's Time For Clear, Consistent Results

CORTICOIDS AND DIURETICS

Acetazolamide d-Aldosterone

Adrenal Cortex Acetone Powder

Adrenosterone Amcinonide Amiloride

Aminoglutethimide Betamethasone

Cortexolone

Cortexolone Acetate

Corticosterone

Corticosterone 21-Acetate

Cortisone

Cortisone Acetate Demeclocycline Deoxycorticosterone

Deoxycorticosterone Acetate (DOCA)

Desoximetasone Dexamethasone

Dexamethasone 21-Acetate

Ethacrynic Acid Fludrocortisone

Fludrocortisone Acetate

Flumethasone Flumisolide Fluocinolone Furosemide

Hydrochlorothiazide Hydrocortisone Hydorcortisone 21-Acetate

Hydrocortisone 21-Hemisuccinate

Hydrocortisone 21-Phosphate

D-Mannitol Methazolamide

Methyl Prednisolone

Metyrapone
Prednisolone
Prednisone
Spironolactone
Triamcinolone

Triamcinolone Acetonide Triamcinolone Diacetate

Triamterene

ESTROGENS AND ANTI-ESTROGENS

Chlorotrianisene

Dienestrol (Dehydrostilbestrol)

Dienestrol Diacetate Diethylstilbestrol

d-Equilenin

Equilin Equilin-Methyl Ether

170-Estradiol

B-Estradiol 17-Acetate

B-Estradiol 3-Benzoate

B-Estradiol 17-Cypionate

B-Estradiol Diacetate

B-Estradiol Dipropionate B-Estradiol 3-Methyl Ether

ß-Estradiol Propionate

B-Estradiol 17-Valerate

Estriol

Estriol 3-Benzyl Ether

Estriol Triacetate

Estrone

Estrone Acetate

Estrone Hemisuccinate

Estrone 3-Methyl Ether

Estrone 3-Sulfate

17\alpha-Ethynylestradiol

Hexestrol (Dihydro-DES)

Mestranol (17a-Ethynylestradiol.

3-Methyl Ether)

Nafoxidine

Tamoxifen (Free Base)

Tamoxifen Citrate



FATTY ACIDS

Arachidic Acid (saturated)

Arachidonic Acid (unsaturated)

Lauric Acid (saturated)

Lignoceric Acid (contains 24 carbon atoms)

Linoleic Acid (unsaturated)

Linolenic Acid (unsaturated)

Myristic Acid (saturated)

Nervonic Acid (contains 24 carbon atoms)

Oleic Acid (unsaturated)

Palmitic Acid (saturated)

Palmitoleic Acid (unsaturated)

Sodium Butyrate

Stearic Acid (saturated)

NUCLEOTIDE RELATED PRODUCTS

Adenosine

8-Azaadenine

5-Azacytidine

5-Azacytosine

8-Azaguanine

8-Azahypoxanthine

7-Azaindole

6-Azathymine

5-Azauracil

6-Azauracil

6-Azauridine

8-Bromoadenosine 3':5'-Cyclic Monophosphate

5-Bromo-2'-Deoxyuridine

Cytosine

3-Deazauracil

3-Deazauridine

Nº02-Dibutyryladenosine-31:51-Cyclic Monophosphate

Guanosine

Hydroxyurea

5-lodo-2'-Deoxyuridine

Thymidine

Uridine

PROGESTINS

Chlormadinone Acetate

Clomiphene Citrate

Danazol (Weak progestin)

16-Dehydropregnenolone

16-Dehydropregnenolone Acetate

16-Dehydroprogesterone

Ethisterone

17α-Hydroxypregnenolone

11a-Hydroxyprogesterone

17α-Hydroxyprogesterone

Medroxyprogesterone Acetate

Megestrol Acetate

Norethindrone

Norethindrone Acetate

Norethynodrel

Norgestrel

Pregnenolone

Progesterone



Use Time To Your Advantage

PROSTAGLANDINS

Prostaglandin A₁ Prostaglandin B₂ Prostaglandin B₂ Prostaglandin D₃ Prostaglandin E_1 Prostaglandin E_2 Prostaglandin $F_{1\alpha}$ Prostaglandin $F_{2\alpha}$ Prostaglandin I_2 (Prostacyclin)

THYROIDS

3,5-Diiodo-DL-Thyronine
3,5-Diiodo-L-Thyronine
Methimazole (Antithyroid)
Methyl Thiouracil (Antithyroid)
Potassium Iodide
6-n-Propyl-2-Thiouracil (Antithyroid)
Sodium Iodide
Thiobarbital

Thyroglobulin
Thyroid Releasing Hormone
Thyroid Stimulating Hormone
DL-Thyronine
D-Thyroxine
L-Thyroxine
3,3', 5-Triiodo-DL-Thyronine
3,3', 5-Triiodo-L-Thyronine

VITAMINS

Retinol

Acetyl-L-Carnitine

DL-Carnitine

B-Carotene

7-Dehydrocholesterol (Provitamin D_s)

Ergosterol (Provitamin D)

Folic Acid

Folinic Acid

Inositol

DL-α-Lipoic Acid (Oxidized thioctic acid)

Niacin

Niacinamide

Retinal (Vitamin A Aldehyde)

Retinoic Acid (All trans)

13-cis-Retinoic Acid

Retinol Acetate
Retinol Palmitate
Vitamin B₁ (Thiamine)
Vitamin B₂ (Riboflavin)
Vitamin B₆ (Pyridoxine)
Vitamin B₁₂ (Cyanocobalamin)
Vitamin C (Ascorbic acid)
Vitamin D₂ (Ergocalciferol)
Vitamin D₃ (Cholecalciferol)
Vitamin E (Tocopherol)
Vitamin H (d-Biotin)
Vitamin K₁
Vitamin K₃ (Menadione)

ADVANTAGES OF OUR MDD PELLET SYSTEM

- Saves time
- Ready-to-implant
- Insures controlled product release over time
- Avoids "peak and valley" effects
- Guarantees consistent product preparation
- Extends product life against spontaneous breakdown
- Extends product life against host-related breakdown
- Minimizes experimental variables
- Insures safety of the researcher
- Reduces neurophysiological trauma to the animal/ no cressive handling
- · Generates more meaningful and reproducible results
- Superior to conventional delivery methods
- Enhances experimental efficiency
- Frees valuable time for creative research
- Saves money



PLACEBO / CONTROL PELLETS

Placebo/Control pellets are used in experiments as the proper control to interpret biological results obtained with pellets containing active product.

Matching Placebo pellets contain all the components of the hormone or drug pellet except the active product itself. The carrier-binder excepients of the matrix include Cholesterol, Lactose, Celluloses, Phosphates and Stearates.

Stock Placebo pellets are available in 20 different doses corresponding to those of active product pellets. Each dose is offered in either 21 Day, 60 Day, or 90 Day Release form.

Although the matrixes in Placebo pellets have a different composition for different active products, they are all assigned the same catalog number and are offered at the same price schedule.

When inquiring or placing an order, please specify the active product you wish to correspond the Placebo pellets for. Please see the following examples:

Catalog No.	Description	Dose in mg/pellet	Release in Days
C-111	Placebo for "Active Product"*	mg/pellet	21 Day
SC-111	Placebo for "Active Product"*	mg/pellet	60 Day
NC-111	Placebo for "Active Product"*	mg/pellet	90 Day

^{*}In place of "Active Product" specify the hormone or drug you are utilizing in your study.

The following three pages are universal dose /price schedules in all three release rates (21 Day, 60 Day, and 90 Day) and are applicable as a matching Placebo for all products in the catalog except special physical size and preparations (page 94) which can be found under the Custom Pellet section on pages 93-108.

*Please inquire directly with us if further assistance is required regarding a product of interest.



Use Placebo Pellets For Proper Control

PLACEBO PELLETS

PRICE SCHEDULE

Cat. No. C-111

TWENTY-ONE DAY RELEASE

Dose	PRI	CE/NUMBER O	F PELLETS	
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$697	\$1362	\$2649	\$4816
0.010	\$697	\$1362	\$2 649	\$4816
0.025	\$697	\$1362	\$2649	\$4816
0.05	\$697	\$1362	\$2649	\$4816
0.1	\$697	\$1362	\$2649	\$4816
0.25	\$697	\$1362	\$2649	\$4816
0.5	\$697	\$1362	\$2649	\$4816
1,5	\$697	\$1362	\$2649	\$4816
2.5	\$697	\$1362	\$2649	\$4816
5.0	\$697	\$1362	\$2649	\$4816
7.5	\$702	\$1379	\$2674	\$4858
10.0	\$702	\$1379	\$2674	\$4858
15.0	\$702	\$1379	\$2674	\$4858
25.0	\$707	\$1386	\$2674	\$4875
35.0	\$707	\$1386	\$2674	\$4875
50.0	\$707	\$1386	\$2674	\$4875
75.0	\$707	\$1386	\$2674	\$4875
100.0	\$718	\$1406	\$2734	\$4945
150.0	\$718	\$1406	\$2734	\$4945
200.0	\$723	\$1415	\$2744	\$4964

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE*.

Sixty and Ninety day price schedules are on the following two pages.



PLACEBO PELLETS

PRICE SCHEDULE

Cat. No. SC-111

SOCIETIVA PAR

Dose	PR	TOP/NUMBER	OF PELLETS	
mg/peller	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$731	\$1418	\$2751	\$4974
0.010	\$731	\$1418	\$2751	\$4974
0.025	\$731	\$1418	\$2751	\$4974
0.05	\$731	\$1418	\$2751	\$4974
0.1	\$731	\$1418	\$2751	\$4974
0,25	\$731	\$1418	\$2751	\$4974
0.5	\$73 1	\$1418	\$2751	\$4974
1.5	\$731	\$1418	\$2751	\$4974
2.5	\$731	\$1418	\$2751	\$4974
5.0	\$731	\$1418	\$2751	\$4974
7.5	\$738	51444	\$2789	\$5038
10.0	\$738	\$1444	\$2789	\$5038
15.0	\$738	\$1444	\$2789	\$5038
25.0	\$744	\$1454	\$2804	\$5063
35.0	\$744	\$1454	\$2804	\$5063
50.0	\$744	\$1454	\$2804	\$5063
75.0	\$744	\$1454	\$2804	\$5063
100.0	\$762	\$1484	\$2879	\$516 8
150.0	\$762	\$ 1484	\$2879	\$5168
200.0	\$770	\$1498	\$2894	\$5197

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE*.



PLACEBO PELLETS


PRICE SCHEDULE

Cat. No. NC-111

NINETY DAY RELEASE

Dose	CONTRACTOR SERVICE AND ASSESSMENT OF THE PARTY OF THE PAR	CE/NUMBER C	OF PELLETS	
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$764	\$1474	\$2849	\$5128
0.010	\$764	\$1474	\$2849	\$5128
0.025	\$764	\$1474	\$2849	\$5128
0.05	\$764	\$1474	\$2849	\$5128
0.1	\$764	\$1474	\$2849	\$5128
0.25	\$764	\$1474	\$2849	\$5128
0.5	\$764	\$1474	\$2849	\$5128
1.5	\$764	\$1474	\$2849	\$5128
2.5	\$764	\$1474	\$2849	\$5128
5.0	\$764	\$1474	\$2849	\$5128
7.5	\$774	\$1508	\$2903	\$5216
10.0	\$774	\$1508	\$2903	\$5216
15.0	\$774	\$1508	\$2903	\$5216
25.0	\$782	\$1522	\$2923	\$5250
35.0	\$782	\$1522	\$2923	\$5250
50.0	\$782	\$1522	\$2923	\$5250
75.0	\$782	\$1522	\$2923	\$5250
100.0	\$806	\$1562	\$3023	\$5390
150.0	\$806	\$1562	\$3023	\$5390
200.0	\$816	\$1580	\$3043	\$5428

A combination of multiple dosages in one lot, for any specified product, is also available. *PLEASE INQUIRE*.




The Research Puzzle Need Not Be Unsolved



TIME RELEASE PELLETS FOR BIOMEDICAL RESEARCH IN LABORATORY ANIMALS

Multi-Step Injections Are a Continuous Pain in DRUG DELIVERY

One-Step Continuous Release Pellets Are the Best Alternative



PELLETS
FOR
INNOVATIVE
RESEARCH

Our Team at IRA is working to meet the responsibility that Innovative Science demands and Innovative Scientists deserve.



Active Product Delivery To All Corners Of The Earth



RA

Introduction to Alphabetical Product Listing

The PRODUCT NAMES in this catalog are arranged in ALPHABETICAL ORDER and are identified by their individual CATALOG NUMBERS including a PRICE SCHEDULE and corresponding PAGE NUMBER. The catalog number and price schedule reflect a release rate of 21 Days, 60 Days, or 90 Days.

To illustrate with Acetazolamide as an example, please view the following table:

Product Name	21 Day Release		60 D	ay Release	90 Day Release		
	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	Catalog Number	Price Schedule/ Page Number	
Acetazolamide	D-111	C21 / 51	SD-111	C60 / 52	ND-111	C90 / 53	

The above example indicates the stock product Acetazolamide is available in three release forms each having a different catalog number and price code, i.e.

D-111 is a 21 Day Release form with a price code of C-21, found on page 51. SD-111 is a 60 Day Release form with a price code of C-60, found on page 52. ND-111 is a 90 Day Release form with a price code of C-90, found on page 53.

The PAGE NUMBER next to the PRICE SCHEDULE indicates the page where the actual price for the product appears.

When placing an order, please include the PRODUCT NAME, CATALOG NUMBER, DOSE IN MG/PELLET and RELEASE RATE. Most of our products are available in 20 different doses. Products are normally sold in lots of 25, 50, 100, and 200 pellets. Please indicate the quantity of pellets to be ordered.

Beginning on page 10, we have grouped some of our catalog items by related categories alphabetically. We hope the listing will help in noting items of potential interest.

*Please inquire directly with us if further assistance is required regarding a product of interest.





Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day	Release	60-Day	Release	90-Day Release	
Product	Catalog Prio Number Pa	ce Schedule/ ge Number	Catalog Prio Number Pa	ce Schedule/ ge Number	Catalog Pric Number Pag	
Acebutolol	C-101	B-21/48	SC-101	B-60/49	NC-101	B-90/50
2-Acetamidofluorene (2-AAF)	A-102	A-21/45	SA-102	A-60/46	NA-102	A-90/4
Acetarsone	B-165	B-21/48	SB-165	B-60/49	NB-165	B-90/50
Acetazolamide	D-111	C-21/51	SD-111	C-60/52	ND-111	C-90/5
Acetopromazine	C-102	B-21/48	SC-102	B-60/49	NC-102	B-90/50
Acetyl-L-Carnitine	V-272	B-21/48	SV-272	B-60/49	NV-272	B-90/50
N-Acetyl-L-Cysteine	Q-212	B-21/48	SQ-212	B-60/49	NQ-212	B-90/50
N-Acetyl-L-Glutamine	Q-272	B-21/48	SQ-272	B-60/49	NQ-272	B-90/50
N-Acetylimidazole	Q-273	B-21/48	SQ-273	B-60/49	NQ-273	B-90/50
N-Acetylprocainamide	C-106	A-21/45	SC-106	A-60/46	NC-106	A-90/4
cis-Aconitic Acid	K-111	B-21/48	SK-111	B-60/49	NK-111	B-90/5
trans-Aconitic Acid	K-112	C-21/51	SK-112	C-60/52	NK-112	C-90/5
Aconitine	K-113	E-21/57	SK-113	E-60/58	NK-113	E-90/5
Actinomycin D (Dactinomycin)	Z-110	H-21/60	SZ-110	H-60/61	NZ-110	H-90/6
Adenosine	N-111	C-21/51	SN-111	C-60/52	NN-111	C-90/5
Adrenal Cortex Acetone Powder	G-116	B-21/48	SG-116	B-60/49	NG-116	B-90/5
Adrenosterone	G-117	B-21/48	SG-117	B-60/49	NG-117	B-90/50
Adriamycin (Doxorubicin)	Z-180	H-21/60	SZ- 180	H-60/61	NZ-180	H-90/6
Ajmaline	C-135	B-21/48	SC-135	B-60/49	NC-135	B-90/5
ß-Alanine	Q-131	C-21/51	SQ-131	C-60/52	NQ-131	C-90/5
D-Alanine	Q-111	B-21/48	SQ-111	B-60/49	NQ-111	B-90/5
LE-Alanine	Q-121	C-21/51	SQ-121	C-60/52	NQ-121	C-90/5
Albendazole	B-166	B-21/48	SB-166	B-60/49	NB-166	B-90/5
d-Aldosterone	M-151	H-21/60	SM-151	H-60/61	NM-151	H-90/6
Allopurinol	I-111	B-21/48	SI-111	B-60/49	NI-111	B-90/50
Alloxan	A-103	A-21/45	SA-103	A-60/46	NA-103	A-90/4
Alprenolol	C-431	D-21/54	SC-431	D-60/55	NC-431	D-90/5

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day Release		60-Day I	Release	90-Day Release	
Product	Catalog Price Number Page	Schedule/ Number	Catalog Price Number Page		Catalog Price Number Page	
Althiazide	A-104	B-21/48	SA-104	B-60/49	NA-104	B-90/5
Amantadine	B-167	B-21/48	SB-167	B-60/49	NB-167	B-90/50
Amcinonide	G-118	A-21/45	SG-118	A-60/46	NG-118	A-90/4
Amiloride	D-181	B-21/48	SD-181	B-60/49	ND-181	B-90/5
Aminoacetonitrile	A-105	B-21/48	SA-105	B-60/49	NA-105	B-90/5
α-Aminoacetophenone	A-106	A-21/45	SA-106	A-60/46	NA-106	A-90/4
m-Aminoacetophenone	A-107	B-21/48	SA-107	B-60/49	NA-107	B-90/5
p-Aminoacetophenone	A-108	B-21/48	SA-108	B-60/49	NA-108	B-90/5
Aminoglutethimide	G-281	D-21/54	SG-281	D-60/55	NG-281	D-90/5
6-Aminopenicillanic Acid	B-111	B-21/48	SB-111	B-60/49	NB-111	B-90/5
Aminophylline	C-125	C-21/51	SC-125	C-60/52	NC-125	C-90/5
Aminopyrine	A-109	B-21/48	SA-109	B-60/49	NA-109	B-90/5
Amiodarone	A-112	B-21/48	SA-112	B-60/49	NA-112	B-90/5
Amitriptyline	C-451	C-21/51	SC-451	C-60/52	NC-451	C-90/5
Amoxicillin	B-112	B-21/48	SB-112	B-60/49	NB-112	B-90/5
Amphotericin B	B-113	D-21/54	SB-113	D-60/55	NB-113	D-90/5
Ampicillin	B-114	B-21/48	SB-114	B-60/49	NB-114	B-90/5
Amrinone	C-107	A-21/45	SC-107	A-60/46	NC-107	A-90/4
Androstenediol (See Controlled Substances Page 8)	A-131	B-21/48	SA-131	B-60/49	NA-131	B-90/5
Androstenedione (See Controlled Substances Page 8)	A-121	B-21/48	SA-121	B-60/49	NA-121	B-90/5
5α-Androsterone	A-141	C-21/51	SA-141	C-60/52	NA-141	C-90/5
5ß-Androsterone	A-101	D-21/54	SA-101	D-60/55	NA-101	D-90/5
Anisodamine	K-114	B-21/48	SK-114	B-60/49	NK-114	B-90/5
Anisodine	K-115	B-21/48	SK-115	B-60/49	NK-115	B-90/5
Antazoline	C-461	C-21/51	SC-461	C-60/52	NC-461	C-90/5
Arachidic Acid	F-111	A-21/45	SF- 111	A-60/46	NF- 111	A-90/4
Arachidonic Acid	F-161	A-21/45	SF- 161	A-60/46	NF-161	A-90/4

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ule/ ber

/50

/50

147

/50

/50

/47

/50

/50

/56

/50

/53

/50

/50

/53

/50

/56

/50

/47

/50

/50

/53

/56

/50

/50

/53

/47

	21-Day	21-Day Release			90-Day Release	
Product	Catalog Pric Number Pag		Catalog Pric	ce Schedule/ ge Number	Catalog Pric	
Arecoline	K-116	C-21/51	SK-116	C-60/52	NK-116	C-90/53
D-Arginine	Q-141	B-21/48	SQ-141	B-60/49	NQ-141	B-90/50
L-Arginine	Q-151	C-21/51	SQ-151	C-60/52	NQ-151	C-90/53
Asparaginase	Z-120	H-21/60	SZ-120	H-60/61	NZ-120	H-90/62
D-Asparagine	Q-161	C-21/51	SQ-161	C-60/52	NQ-161	C-90/53
L-Asparagine	Q-171	C-21/51	SQ-171	C-60/52	NQ-171	C-90/53
D-Aspartic Acid	Q-181	C-21/51	SQ-181	C-60/52	NQ-181	C-90/53
L-Aspartic Acid	Q-191	C-21/51	SQ-191	C-60/52	NQ-191	C-90/53
Aspirin	X-121	C-21/51	SX-121	C-60/52	NX-121	C-90/53
Atenolol	C-221	B-21/48	SC-221	B-60/49	NC-221	B-90/50
Atropine	K-117	C-21/51	SK-117	C-60/52	NK-117	C-90/53
Atropine Methyl Bromide	K-118	C-21/51	SK-118	C-60/52	NK-118	C-90/53
8-Azaadenine	N-121	B-21/48	SN-121	B-60/49	NN-121	B-90/50
5-Azacytidine	N-131	A-21/45	SN -131	A-60/46	NN-131	A-90/47
5-Azacytosine	N-141	C-21/51	SN-141	C-60/52	NN-141	C-90/53
8-Azaguanine	N-151	C-21/51	SN-151	C-60/52	NN-151	C-90/53
8-Azahypoxanthine	N-161	C-21/51	SN-161	C-60/52	NN-161	C-90/53
7-Azaindole	N-171	B-21/48	SN-171	B-60/49	NN-171	B-90/50
6-Azathymine	N-181	B-21/48	SN-181	B-60/49	NN-181	B-90/50
5-Azauracil	N-191	B-21/48	SN-191	B-60/49	NN-191	B-90/50
6-Azauracil	N-201	C-21/51	SN-201	C-60/52	NN-201	C-90/53
6-Azauridine	N-211	B-21/48	SN-211	B-60/49	NN-211	B-90/50
Bacitracin	B-115	B-21/48	SB-115	B-60/49	NB-115	B-90/50
Baclofen	B-110	A-21/45	SB-110	A-60/46	NB-110	A-90/47
Beclomethasone	B-116	D-21/54	SB-116	D-60/55	NB-116	D-90/56
Benzylpenicillinic Acid	B-117	D-21/54	SB- 117	D-60/55	NB-117	D-90/56
Berberine	K-119	C-21/51	SK-119	C-60/52	NK-119	C-90/53

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day Release		60-Day Release		90-Day Release	
Product	Catalog Pric	ce Schedule/ ge Number	Catalog Pri Number Pa	ce Schedule/ ge Number	Catalog Pri Number Pa	ce Schedule ge Number
Betamethasone	G-191	L-21/63	SG-191	L-60/64	NG-191	L-90/65
Boldine	K-120	C-21/51	SK-120	C-60/52	NK-120	C-90/53
8-Bromoadenosine 3':5' Cyclic Monophosphate	N-221	M-21/66	SN-221	M-60-67	NN-221	M-90/68
Bromocriptine Mesylate	C-231	E-21/57	SC-231	E-60/58	NC-231	E-90/59
5-Bromo-2'-Deoxyuridine (BrDU)	N-231	B-21/48	SN-231	B-60/49	NN-231	B-90/50
Brucine	K-122	C-21/51	SK-122	C-60/52	NK-122	C-90/53
Busulfan (Myleran)	Z-130	B-21/48	SZ-130	B-60/49	NZ-130	B-90/50
Caffeine	C-191	C-21/51	SC-191	C-60/52	NC-191	C-90/5
Calycanthine	K-123	B-21/48	SK-123	B-60/49	NK-123	B-90/50
Camptothecin	C-116	E-21/57	SC-116	E-60/58	NC-116	E-90/59
Captopril	C-117	B-21/48	SC-117	B-60/49	NC-117	B-90/50
Carbamazepine	C-113	C-21/51	SC-113	C-60/52	NC-113	C-90/5
Carbinoxamine	C-471	C-21/51	SC-471	C-60/52	NC-471	C-90/5
DL-Carnitine	V-271	C-21/51	SV-271	C-60/52	NV-271	C-90/5
ß-Carotene	V-215	C-21/51	SV-215	C-60/52	NV-215	C-90/5
Casodex (bicalutamide)	We can cu	stom make a	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE,
Cefadroxil	B-170	A-21/45	SB-170	A-60/46	NB-170	A-90/47
Cefamandole	B-171	A-21/45	SB-171	A-60/46	NB-171	A-90/47
Cefazolin	B-172	A-21/45	SB-172	A-60/46	NB-172	A-90/47
Cefmetazole	B-173	A-21/45	SB-173	A-60/46	NB-173	A-90/47
Cefoperazone	B-174	A-21/45	SB-174	A-60/46	NB-174	A-90/47
Cefotaxime	B-175	A-21/45	SB-175	A-60/46	NB-175	A-90/47
Cefoxitin	B-176	A-21/45	SB-176	A-60/46	NB-176	A-90/47
Cefsulodin	B-177	A-21/45	SB-177	A-60/46	NB-177	A-90/47
Ceftriaxone	B-178	A-21/45	SB-178	A-60/46	NB-178	A-90/47
Centrophenoxine (Medlofenoxate)	C-115	C-21/51	SC-115	C-60/52	NC-115	C-90/5
Cephalexin	B-118	B-21/48	SB-118	B-60/49	NB-118	B-90/50

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ise

nber 1/65

0/53

0/68

1/59

)/50

)/53

)/50

)/53

)/50

)/59

)/50

0/53

0/53

0/53

0/53

RE)

)/47

)/47

3/47

)/47

3/47

)/47

3/47

)/47

)/47

0/53

0/50

	21-Day	21-Day Release			90-Day Release	
Product	Catalog Prio	e Schedule/ ge Number	Catalog Pri Number Pa	ce Schedule/ ge Number	Catalog Pri Number Pa	ce Schedule ge Number
Cephaloglycin	B-119	D-21/54	SB-119	D-60/55	NB-119	D-90/56
Cephalothin	B-120	B-21/48	SB-120	B-60/49	NB-120	B-90/50
Cephapirin	B-121	B-21/48	SB-121	B-60/49	NB-121	B-90/50
Chlorambucil	Z-140	A-21/45	SZ-140	A-60/46	NZ-140	A-90/47
Chloramphenicol	X-131	C-21/51	SX-131	C-60/52	NX-131	C-90/53
Chloramphenicol Base	B-123	C-21/51	SB-123	C-60/52	NB-123	C-90/53
Chlorcyclizine	C-145	B-21/48	SC-145	B-60/49	NC-145	B-90/50
Chlormadinone Acetate	P-221	A-21/45	SP-221	A-60/46	NP-221	A-90/47
Chloroquine	I-112	C-21/51	SI-112	C-60/52	NI-112	C-90/53
Chlorothiazide	C-155	C-21/51	SC-155	C-60/52	NC-155	C-90/53
Chlorotrianisene	E-201	C-21/51	SE-201	C-60/52	NE-201	C-90/53
Chlorpheniramine	B-124	C-21/51	SB-124	C-60/52	NB-124	C-90/53
Chlorpromazine	C-241	C-21/51	SC-241	C-60/52	NC-241	C-90/53
Chlorthalidone	C-175	B-21/48	SC-175	B-60/49	NC-175	B-90/50
Chlorzoxazone	C-185	C-21/51	SC-185	C-60/52	NC-185	C-90/53
Cimetidine	C-372	B-21/48	SC-372	B-60/49	NC-372	B-90/50
Cinchonidine	B-154	C-21/51	SB-154	C-60/52	NB-154	C-90/53
Cinnarizine	B-125	C-21/51	SB-125	C-60/52	NB-125	C-90/53
Clemastine	C-120	B-21/48	SC-120	B-60/49	NC-120	B-90/50
Clemizole	C-119	C-21/51	SC-119	C-60/52	NC-119	C-90/53
Clenbuterol	C-118	H-21/60	SC-118	H-60/61	NC-118	H-90/62
Glofoctol	C-104	C-21/51	SC-104	C-60/52	NC-104	C-90/53
Clomiphene Citrate	P-211	B-21/48	SP-211	B-60/49	NP-211	B-90/50
Clomipramine	C-103	C-21/51	SC-103	C-60/52	NC-103	C-90/53
Clonidine	C-251	B-21/48	SC-251	B-60/49	NC-251	B-90/50
Clopamide	C-105	B-21/48	SC-105	B-60/49	NC-105	B-90/50
Clotrimazole	B-126	B-21/48	SB-126	B-60/49	NB-126	B-90/50

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day Release		60-Day Release		90-Day Releas	
Product		ice Schedule/ age Number		ce Schedule/ ge Number	Catalog Pri Number Pa	
Cloxacillin	B-127	B-21/48	SB-127	B-60/49	NB-127	B-90/5
Colchicine	B-155	A-21/45	SB-155	A-60/46	NB-155	A-90/4
Cortexolone	G-301	B-21/48	SG-301	B-60/49	NG-301	B-90/5
Cortexolone Acetate	G-311	B-21/48	SG-311	B-60/49	NG-311	B-90/5
Corticosterone	G-111	A-21/45	SG-111	A-60/46	NG-111	A-90/4
Corticosterone 21-Acetate	G-171	A-21/45	SG-171	A-60/46	NG-171	A-90/4
Cortisone	G-121	B-21/48	SG-121	B-60/49	NG-121	B-90/5
Cortisone Acetate	G-181	B-21/48	SG-181	B-60/49	NG-181	B-90/5
(-)Cotinine	K-124	A-21/45	SK-124	A-60/46	NK-124	A-90/4
Coumarin (1, 2 Benzopyrone)	C-112	C-21/51	SC-112	C-60/52	NC-112	C-90/5
Cromolyn	C-195	B-21/48	SC-195	B-60/49	NC-195	B-90/5
Crotaline	K-125	D-21/54	SK-125	D-60/55	NK-125	D-90/5
Cyclizine	C-108	A-21/45	SC-108	A-60/46	NC-108	A-90/4
Cyclophosphamide (Cytoxan)	Z-150	A-21/45	SZ-150	A-60/46	NZ-150	A-90/4
D-Cycloserine	B-128	B-21/48	SB-128	B-60/49	NB-128	B-90/5
Cymarin	C-382	D-21/54	SC-382	D-60/55	NC-382	D-90/5
Cyproheptadine	C-481	A-21/45	SC-481	A-60/46	NC-481	A-90/4
Cyproterone Acetate	C-114	E-21/57	SC-114	E-60/58	NC-114	E-90/5
D-Cysteine	Q-201	C-21/51	SQ-201	C-60/52	NQ-201	C-90/5
L-Cysteine	Q-211	C-21/51	SQ-211	C-60/52	NQ-211	C-90/5
D-Cystine	Q-221	D-21/54	SQ-221	D-60/55	NQ-221	D-90/5
L-Cystine	Q-231	C-21/51	SQ-231	C-60/52	NQ-231	C-90/5
Cytarabine (Cytosine Arabinoside)	Z-160	D-21/54	SZ-160	D-60/55	NZ-160	D-90/5
Cytisine	K-126	E-21/57	SK-126	E-60/58	NK-126	E-90/5
Cytosine	N-241	C-21/51	SN-241	C-60/52	NN-241	C-90/5
Danazol	P-251	D-21/54	SP-251	D-60/55	NP-251	D-90/5
Daunorubucine	Z-170	H-21/60	SZ-170	H-60/61	NZ-170	H-90/6

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase

nber 1/50

1/47

1/50

1/50

1/47

1/47

1/50

1/50

1/47

1/53

1/50

1/56

1/47

1/47

1/50

1/56

1/47

1/59

1/53

1/53

1/56

1/53

1/56

/59

1/53

1/56

1/62

Product	21-Day Release Catalog Price Schedule/ Number Page Number		60-Day Release Catalog Price Schedule/ Number Page Number		90-Day Release Catalog Price Schedule/ Number Page Number	
3-Deazauridine	N-261	A-21/45	SN-261	A-60/46	NN-261	A-90/47
Decamethonium Bromide	D-112	B-21/48	SD-112	B-60/49	ND-112	B-90/50
Defroxamine Mesylate	D-113	D-21/54	SD-113	D-60/55	ND-113	D-90/56
7-Dehydrocholesterol	V-281	C-21/51	SV-281	C-60/52	NV-281	C-90/53
Dehydrocholic Acid	D-114	C-21/51	SD-114	C-60/52	ND-114	C-90/53
Dehydroepiandrosterone (DHEA)	A-111	B-21/48	SA-111	B-60/49	NA-111	B-90/50
Dehydroepiandrosterone Acetate	D-115	B-21/48	SD-115	B-60/49	ND-115	B-90/50
Dehydroepiandrosterone Sulfate	D-116	D-21/54	SD-116	D-60/55	ND-116	D-90/56
16-Dehydropregnenolone	P-271	B-21/48	SP-271	B-60/49	NP-271.	B-90/50
16-Dehydropregnenolone Acetate	P-281	B-21/48	SP-281	B-60/49	NP-281	B-90/50
16-Dehydroprogesterone	P-261	B-21/48	SP-261	B-60/49	NP-261	B-90/50
Demeclocycline	D-121	B-21/48	SD-121	B-60/49	ND-121	B-90/50
Deoxycholic Acid	D-110	C-21/51	SD-110	C-60/52	ND-110	C-90/53
Deoxycorticosterone (poc)	M-111	B-21/48	SM-111	B-60/49	NM-111	B-90/50
Deoxycorticosterone Acetate (DOCA)	M-121	A-21/45	SM-121	A-60/46	NM-121	A-90/47
Desipramine	C-491	B-21/48	SC-491	B-60/49	NC-491	B-90/50
Desoximetasone	D-107	D-21/54	SD-107	D-60/55	ND-107	D-90/56
Dexamethasone	G-131	D-21/54	SG-131	D-60/55	NG-131	D-90/56
Dexamethasone 21-Acetate	G-201	D-21/54	SG-201	D-60/55	NG-201	D-90/56
Dexamethasone 21-Phosphate	D-108	D-21/54	SD-108	D-60/55	ND-108	D-90/56
Diaveridine	B-129	D-21/54	SB-129	D-60/55	NB-129	D-90/56
N ⁶ -0 ² -Dibutyryladenosine- 3':5'-Cyclic Monophosphate	N-271	L-21/63	SN-271	L-60/64	NN-271	L-90/65
Diclofenac	X-135	B-21/48	SX-135	B-60/49	NX-135	B-90/50
Dicloxacillin	B-156	B-21/48	SB-156	B-60/49	NB-156	B-90/50
Dienestrol	E-181	C-21/51	SE-181	C-60/52	NE-181	C-90/53
Dienestrol Diacetate	E-191	C-21/51	SE-191	C-60/52	NE-191	C-90/53

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day Release		60-Day Release		90-Day Release	
Product	Catalog Pri Number Pa	ice Schedule/	Catalog Pri Number Pa	ce Schedule/ ge Number	Catalog Pri Number Pa	
Diethylstilbestrol (DES)	E-151	B-21/48	SE-151	B-60/49	NE-151	B-90/50
Digitoxin	C-196	B-21/48	SC-196	B-60/49	NC-196	B-90/50
Digoxin	C-271	B-21/48	SC-271	B-60/49	NC-271	B-90/50
Dihydroergotamine	K-127	E-21/57	SK-127	E-60/58	NK-127	E-90/59
5α-Dihydrotestosterone (See Controlled Substances Page 8)	Special	Dosing For	Immuno-D	eficient Mi	ce. See pa	ges 78-80
5α-Dihydrotestosterone (See Controlled Substances Page 8)	A-161	A-21/45	SA-161	A-60/46	NA-161	A-90/4
5ß-Dihydrotestosterone	D-106	D-21/54	SD-106	D-60/55	ND-106	D-90/5
3,5-Diiodo-DL-Thyronine	T-231	B-21/48	ST- 231	B-60/49	NT-231	B-90/5
3,5-Diiodo-L-Thyronine	T-241	B-21/48	ST- 241	B-60/49	NT-241	B-90/5
Dimenhydrinate	C-205	C-21/51	SC-205	C-60/52	NC-205	C-90/5
9,10-Dimethyl-1,2-Benzanthracene	D-117	A-21/45	SD-117	A-60/46	ND-117	A-90/4
Dipyridamole	D-101	B-21/48	SD-101	B-60/49	ND-101	B-90/5
Dipyrone	D-102	C-21/51	SD-102	C-60/52	ND-102	C-90/5
Disopyramide	C-500	B-21/48	SC-500	B-60/49	NC-500	B-90/5
Disulfiram	D-109	C-21/51	SD-109	C-60/52	ND-109	C-90/5
D-Dopa	C-501	B-21/48	SC-501	B-60/49	NC-501	B-90/5
DL-Dopa	C-502	C-21/51	SC-502	C-60/52	NC-502	C-90/5
L-Dopa	C-503	C-21/51	SC-503	C-60/52	NC-503	C-90/5
Dopamine	C-151	C-21/51	SC-151	C-60/52	NC-151	C-90/5
Doxepin	C-325	B-21/48	SC-325	B-60/49	NC-325	B-90/5
Doxycycline	B-168	A-21/45	SB-168	A-60/46	NB-168	A-90/4
Doxylamine	C-504	C-21/51	SC-504	C-60/52	NC-504	C-90/5
Drofenine	D-103	C-21/51	SD-103	C-60/52	ND-103	C-90/5
Droperidol	D-104	A-21/45	SD-104	A-60/46	ND-104	A-90/4
Dropropizine	D-105	C-21/51	SD-105	C-60/52	ND-105	C-90/5
ß-Ecdysone	E-103	H-21/60	SE-103	H-60/61	NE-103	H-90/6
Econazole	B-181	B-21/48	SB-181	B-60/49	NB-181	B-90/5

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

ase

dule/ nber

)/50

)/50

)/50

)/59 -**80**

)/47

)/56

)/50

)/50

)/53

)/47

)/50

)/53

)/50

)/53

)/50

)/53

)/53

)/53

)/50

)/47

)/53

)/53

)/47

)/53

)/62

)/50

	21-Day Release Catalog Price Schedule/ Number Page Number		60-Day Release Catalog Price Schedule/ Number Page Number		90-Day Release Catalog Price Schedule/ Number Page Number	
Product						
Edrophonium	C-122	A-21/45	SC-122	A-60/46	NC-122	A-90/47
Emetine	K-128	B-21/48	SK-128	B-60/49	NK-128	B-90/50
Enalapril	C-999	A-21/45	SC-999	A-60/46	NC-999	A-90/47
Enoxacin	B-182	A-21/45	SB-182	A-60/46	NB-182	A-90/47
Ephedrine	C-201	C-21/51	SC-201	C-60/52	NC-201	C-90/53
Epinephrine	C-131	C-21/51	SC-131	C-60/52	NC-131	C-90/53
Epinine (Deoxyepinephrine)	C-141	D-21/54	SC-141	D-60/55	NC-141	D-90/56
d-Equilenin	E-231	D-21/54	SE-231	D-60/55	NE-231	D-90/56
Equilin	E-211	D-21/54	SE-211	D-60/55	NE-211	D-90/56
Equilin-Methyl Ether	E-221	D-21/54	SE-221	D-60/55	NE-221	D-90/56
Ergosterol	V-291	C-21/51	SV- 291	C-60/52	NV-291	C-90/53
Erythromycin	B-130	B-21/48	SB-130	B-60/49	NB-130	B-90/50
Esculetin	E-101	B-21/48	SE-101	B-60/49	NE-101	B-90/50
Esculin	E-102	C-21/51	SE-102	C-60/52	NE-102	C-90/53
Eserine (Physostigmine)	K-129	B-21/48	SK-129	B-60/49	NK-129	B-90/50
17α-Estradiol	E-131	D-21/54	SE-131	D-60/55	NE-131	D-90/56
17ß-Estradiol	Special	Dosing For	Immuno-D	eficient Mic	ce. See pa	ges 73-77.
17ß-Estradiol	E-121	B-21/48	SE-121	B-60/49	NE-121	B-90/50
ß-Estradiol 17-Acetate	E-271	B-21/48	SE-271	B-60/49	NE-271	B-90/50
ß-Estradiol 3-Benzoate	E-281	B-21/48	SE-281	B-60/49	NE-281	B-90/50
ß-Estradiol 17-Cypionate	E-291	B-21/48	SE-291	B-60/49	NE-291	B-90/50
ß-Estradiol Diacetate	E-301	B-21/48	SE-301	B-60/49	NE-301	B-90/50
ß-Estradiol Dipropionate	E-311	B-21/48	SE-311	B-60/49	NE-311	B-90/50
ß-Estradiol 3-Methyl-Ether	E-321	B-21/48	SE-321	B-60/49	NE-321	B-90/50
17ß-Estradiol+Progesterone (See Page 89)						
ß-Estradiol Propionate	E-371	D-21/54	SE-371	D-60/55	NE-371	D-90/56
ß-Estradiol 17-Valerate	E-203	B-21/48	SE-203	B-60/49	NE-203	B-90/50

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

	21-Day Release		60-Day Release		90-Day Release	
Product	Catalog Pri Number Pa	ice Schedule/ ige Number	Catalog Pri Number Pa	ce Schedule/ ge Number	Catalog Pri Number Pa	
Estriol	E-141	B-21/48	SE-141	B-60/49	NE-141	B-90/5
Estriol 3-Benzyl Ether	E-391	D-21/54	SE-391	D-60/55	NE-391	D-90/5
Estriol Triacetate	E-401	A-21/45	SE-401	A-60/46	NE-401	A-90/4
Estrone	E-111	B-21/48	SE-111	B-60/49	NE-111	B-90/5
Estrone Acetate	E-411	B-21/48	SE-411	B-60/49	NE-411	B-90/5
Estrone Hemisuccinate	E-421	D-21/54	SE-421	D-60/55	NE-421	D-90/5
Estrone 3-Methyl Ether	E-261	B-21/48	SE-261	B-60/49	NE-261	B-90/5
Estrone 3-Sulfate	E-431	A-21/45	SE-431	A-60/46	NE-431	A-90/4
Ethacrynic Acid	D-131	C-21/51	SD-131	C-60/52	ND-131	C-90/5
Ethambutol	B-131	C-21/51	SB-131	C-60/52	NB-131	C-90/5
Ethisterone	P-191	B-21/48	SP-191	B-60/49	NP-191	B-90/5
17α-Ethynylestradiol	E-241	B-21/48	SE-241	B-60/49	NE-241	B-90/5
Eucatropine	K-130	D-21/54	SK-130	D-60/55	NK-130	D-90/5
Fludrocortisone	M-131	B-21/48	SM-131	B-60/49	NM-131	B-90/5
Fludrocortisone Acetate	M-171	B-21/48	SM-171	B-60/49	NM-171	B-90/5
Flufenamic Acid	X-115	C-21/51	SX-115	C-60/52	NX-115	C-90/5
Flumequine	F-103	C-21/51	SF- 103	C-60/52	NF-103	C-90/5
Flumethasone	F-104	L-21/63	SF-104	L-60/64	NF-104	L-90/6
Flunarizine	C-206	C-21/51	SC-206	C-60/52	NC-206	C-90/5
Flunisolide	F-102	D-21/54	SF- 102	D-60/55	NF-102	D-90/5
Fluocinolone	F-107	D-21/54	SF-107	D-60/55	NF-107	D-90/5
5-Fluorouracil	Z-190	B-21/48	SZ- 190	B-60/49	NZ-190	B-90/5
Fluoxymesterone (See Controlled Substances Page 8)	A-241	A-21/45	SA-241	A-60/46	NA-241	A-90/4
Fluphenazine	F-105	C-21/51	SF- 105	C-60/52	NF-105	C-90/5
Flurbiprofen	X-125	B-21/48	SX-125	B-60/49	NX-125	B-90/5
Flutamide	A-152	B-21/48	SA-152	B-60/49	NA-152	B-90/5
Folic Acid	V-301	C-21/51	SV-301	C-60/52	NV-301	C-90/5

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

dule/ nber

)/56

)/47

)/50

)/50

)/56

1/50

1/47

)/53

)/53

)/50

)/50

)/56

)/50

)/50

)/53

)/53

/65

)/53

)/56

)/56

)/50

1/47

)/53

1/50

)/50

)/53

	21-Day	Release	60-Day	Release	90-Day Release		
Product		ice Schedule/ ige Number	Catalog Pri Number Pa	ce Schedule/ ge Number		ce Schedule ge Number	
Folinic Acid	V-311	D-21/54	SV-311	D-60/55	NV-311	D-90/56	
Forskolin	F-106	H-21/60	SF- 106	H-60/61	NF-106	H-90/62	
Furosemide	D-141	C-21/51	SD-141	C-60/52	ND-141	C-90/53	
Geneticin	B-132	D-21/54	SB-132	D-60/55	NB-132	D-90/56	
Gentamicin Sulfate	B-133	B-21/48	SB-133	B-60/49	NB-133	B-90/50	
Gitoxin	G-104	B-21/48	SG-104	B-60/49	NG-104	B-90/50	
Glafenine	G-105	B-21/48	SG-105	B-60/49	NG-105	B-90/50	
(+)Glaucine	K-131	D-21/54	SK-131	D-60/55	NK-131	D-90/56	
Gliadin	G-106	C-21/51	SG-106	C-60/52	NG-106	C-90/53	
Globin	G-107	A-21/45	SG-107	A-60/46	NG-107	A-90/47	
D-Glutamic Acid	Q-241	D-21/54	SQ-241	D-60/55	NQ-241	D-90/56	
L-Glutamic Acid	Q-251	C-21/51	SQ-251	C-60/52	NQ-251	C-90/53	
D-Glutamine	Q-261	D-21/54	SQ-261	D-60/55	NQ-261	D-90/56	
L-Glutamine	Q-271	C-21/51	SQ-271	C-60/52	NQ-271	C-90/53	
Glutathione (Oxidized)	G-103	B-21/48	SG-103	B-60/49	NG-103	B-90/50	
Glutathione (Reduced)	G-102	C-21/51	SG-102	C-60/52	NG-102	C-90/53	
Glyburide	G-101	C-21/51	SG-101	C-60/52	NG-101	C-90/53	
Glycine	Q-281	C-21/51	SQ-281	C-60/52	NQ-281	C-90/53	
Gossypol Acetate	A-291	D-21/54	SA-291	D-60/55	NA-291	D-90/56	
Gramicidin	B-134	A-21/45	SB-134	A-60/46	NB-134	A-90/47	
Gramine	G-109	C-21/51	SG-109	C-60/52	NG-109	C-90/53	
Guaiazulene	G-110	B-21/48	SG-110	B-60/49	NG-110	B-90/50	
Guaifenesin	G-112	C-21/51	SG-112	C-60/52	NG-112	C-90/53	
Guanabenz	G-113	N-21/69	SG-113	N-60/70	NG-113	N-90/71	
Guanethidine	G-114	C-21/51	SG-114	C-60/52	NG-114	C-90/53	
7 Guanidine	G-115	C-21/51	SG-115	C-60/52	NG-115	C-90/53	
Guanosine	N-281	C-21/51	SN-281	C-60/52	NN-281	C-90/53	

	21-Day Release		60-Day Release		90-Day Release	
Product		ice Schedule/ age Number	Catalog Pric	ce Schedule/ ge Number	Catalog Prio	
Haloperidol	C-505	B-21/48	SC-505	B-60/49	NC-505	B-90/50
Harmaline	C-506	B-21/48	SC-506	B-60/49	NC-506	B-90/5
Harmalol	H-104	A-21/45	SH-104	A-60/46	NH-104	A-90/4
Harmane	H-105	A-21/45	SH-105	A-60/46	NH-105	A-90/4
Harmine	C-507	B-21/48	SC-507	B-60/49	NC-507	B-90/5
Harmol	H-106	A-21/45	SH-106	A-60/46	NH-106	A-90/4
Hecogenin	H-107	B-21/48	SH-107	B-60/49	NH-107	B-90/5
Hecogenin Acetate	H-108	B-21/48	SH-108	B-60/49	NH-108	B-90/5
Hexestrol (Dihydro-DES)	E-161	C-21/51	SE-161	C-60/52	NE-161	C-90/5
Histamine	C-281	C-21/51	SC-281	C-60/52	NC-281	C-90/5
D-Histidine	Q-291	D-21/54	SQ-291	D-60/55	NQ-291	D-90/5
L-Histidine	Q-301	C-21/51	SQ-301	C-60/52	NQ-301	C-90/5
Homatropine	K-132	C-21/51	SK-132	C-60/52	NK-132	C-90/5
Hydralazine	C-291	C-21/51	SC-291	C-60/52	NC-291	C-90/5
Hydrochlorothiazide	D-151	C-21/51	SD-151	C-60/52	ND-151	C-90/5
Hydrocortisone	G-141	B-21/48	SG-141	B-60/49	NG-141	B-90/5
Hydrocortisone 21-Acetate	G-211	B-21/48	SG-211	B-60/49	NG-211	B-90/5
Hydrocortisone 21-Hemisuccinate	G-221	B-21/48	SG-221	B-60/49	NG-221	B-90/5
Hydrocortisone 21-Phosphate	G-231	B-21/48	SG-231	B-60/49	NG-231	B-90/5
5-Hydroxydopamine	H-101	D-21/54	SH-101	D-60/55	NH-101	D-90/5
6-Hydroxydopamine	H-102	D-21/54	SH-102	D-60/55	NH-102	D-90/5
17α-Hydroxypregnenolone	P-121	C-21/51	SP-121	C-60/52	NP-121	C-90/5
11α-Hydroxyprogesterone	P-151	C-21/51	SP-151	C-60/52	NP-151	C-90/5
17α-Hydroxyprogesterone	P-141	C-21/51	SP-141	C-60/52	NP-141	C-90/5
5-Hydroxy-L-Tryptophan	H-103	B-21/48	SH-103	B-60/49	NH-103	B-90/5
Hydroxyurea	N-291	C-21/51	SN-291	C-60/52	NN-291	C-90/5
L-Hyoscyamine	K-134	C-21/51	SK-134	C-60/52	NK-134	C-90/5

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

dule/ ober

/50

1/47

/47

1/50

/47

1/50

/50

1/53

1/53

1/56

1/53

1/53

1/53

1/53

1/50

1/50

/50

1/50

1/56

1/56

1/53

1/53

1/53

1/50

1/53

1/53

	21-Day	Release	60-Day	Release	90-Day Release	
Product		ce Schedule/ ge Number	Catalog Pric Number Pag		Catalog Pric Number Pag	
Ibuprofen	X-181	B-21/48	SX-181	B-60/49	NX-181	B-90/50
Imipramine	C-508	C-21/51	SC-508	C-60/52	NC-508	C-90/53
Indomethacin	X-151	B-21/48	SX-151	B-60/49	NX-151	B-90/50
Indoprofen	1-101	B-21/48	SI-101	B-60/49	NI-101	B-90/50
Indoxyl Acetate	1-102	B-21/48	SI-102	B-60/49	NI-102	B-90/50
Inosine	1-103	C-21/51	SI-103	C-60/52	NI-103	C-90/53
Inositol	V-321	C-21/51	SV-321	C-60/52	NV-321	C-90/53
5-lodo-2'-Deoxyuridine	N-302	B-21/48	SN-302	B-60/49	NN-302	B-90/50
D-Isoleucine	Q-311	D-21/54	SQ-311	D-60/55	NQ-311	D-90/56
L-Isoleucine	Q-321	C-21/51	SQ-321	C-60/52	NQ-321	C-90/53
Isoproterenol	C-171	C-21/51	SC-171	C-60/52	NC-171	C-90/53
Isopyrin	I-104	B-21/48	SI-104	B-60/49	NI-104	B-90/50
Isoxicam	1-105	B-21/48	SI-105	B-60/49	NI-105	B-90/50
Isoxsuprine	I-106	B-21/48	SI-106	B-60/49	NI-106	B-90/50
Kainic Acid	K-101	D-21/54	SK-101	D-60/55	NK-101	D-90/56
Kanamycin	Z-200	B-21/48	SZ-200	B-60/49	NZ-200	B-90/50
Ketamine	K-102	B-21/48	SK-102	B-60/49	NK-102	B-90/50
Ketoprofen	K-103	C-21/51	SK-103	C-60/52	NK-103	C-90/53
Khellin	C-215	C-21/51	SC-215	C-60/52	NC-215	C-90/53
Labetalol	C-301	C-21/51	SC-301	C-60/52	NC-301-	C-90/53
Lanatoside C	C-225	D-21/54	SC-225	D-60/55	NC-225	D-90/56
Lauric Acid	F-121	C-21/51	SF-121	C-60/52	NF-121	C-90/53
D-Leucine	Q-331	D-21/54	SQ-331	D-60/55	NQ-331	D-90/56
L-Leucine	Q-341	C-21/51	SQ-341	C-60/52	NQ-341	C-90/53
Levamisole	I-113	B-21/48	SI-113	B-60/49	NI-113	B-90/50
Lidocaine	C-311	C-21/51	SC-311	C-60/52	NC-311	C-90/53
Lignoceric Acid	F-211	B-21/48	SF-211	B-60/49	NF-211	B-90/50

	21-Day Release		60-Day	Release	90-Day Release		
Product		rice Schedule/ age Number		ce Schedule/ ge Number	Catalog Pri Number Pa	ce Schedul ge Numbe	
Linoleic Acid	F-171	B-21/48	SF-171	B-60/49	NF-171	B-90/50	
Linolenic Acid	F-181	B-21/48	SF-181	B-60/49	NF-181	B-90/50	
DL-α Lipoic Acid	V-331	B-21/48	SV-331	B-60/49	NV-331	B-90/50	
L-Lobeline	L-101	D-21/54	SL- 101	D-60/55	NL-101	D-90/56	
Lomustine	L-102	B-21/48	SL-102	B-60/49	NL-102	B-90/50	
D-Lysine	Q-351	D-21/54	SQ-351	D-60/55	NQ-351	D-90/5	
L-Lysine	Q-361	C-21/51	SQ-361	C-60/52	NQ-361	C-90/5	
D-Mannitol	D-161	C-21/51	SD-161	C-60/52	ND-161	C-90/5	
Mechlorethamine	Z-210	A-21/45	SZ-210	A-60/46	NZ-210	A-90/4	
Meclizine.	I-114	C-21/51	SI-114	C-60/52	NI-114	C-90/5	
Medroxyprogesterone Acetate (MPA)	P-161	A-21/45	SP-161	A-60/46	NP-161	A-90/4	
Mefenamic Acid	I-115	C-21/51	SI-115	C-60/52	NI-115	C-90/5	
Megestrol Acetate	P-231	B-21/48	SP-231	B-60/49	NP-231	B-90/5	
Melatonin	M-101	B-21/48	SM-101	B-60/49	NM-101	B-90/5	
Melphalan	B-135	D-21/54	SB-135	D-60/55	NB-135	D-90/5	
6-Mercaptopurine	Z-220	B-21/48	SZ-220	B-60/49	NZ-220	B-90/5	
Mesterolone (See Controlled Substances Page 8)	M-103	D-21/54	SM-103	D-60/55	NM-103	D-90/5	
Mesterone (See Controlled Substances Page 8)	M-102	C-21/51	SM-102	C-60/52	NM-102	C-90/5	
Mestranol	E-251	B-21/48	SE-251	B-60/49	NE-251	B-90/5	
Methandriol (See Controlled Substances Page 8)	A-231	C-21/51	SA-231	C-60/52	NA-231	C-90/5	
Methandriol Dipropionate (See Controlled Substances Page 8)	A-261	B-21/48	SA-261	B-60/49	NA-261	B-90/5	
Methazolamide	M-104	B-21/48	SM-104	B-60/49	NM-104	B-90/5	
Methimazole	T-151	C-21/51	ST-151	C-60/52	NT-151	C-90/5	
D-Methionine -	Q-371	C-21/51	SQ-371	C-60/52	NQ-371	C-90/5	
L-Methionine	Q-381	C-21/51	SQ-381	C-60/52	NQ-381	C-90/5	
Methotrexate	Z-230	E-21/57	SZ-230	E-60/58	NZ-230	E-90/5	
Methoxamine	C-235	D-21/54	SC-235	D-60/55	NC-235	D-90/5	

ase

dule/ nber

1/50

/50

1/50

1/56

1/50

1/56

1/53

1/53

147

1/53

147

1/53

/50

/50

156

/51

/56

/53

150

/53

/50

150

153

/53

153

/59

/56

	21-Day	Release	60-Day	Release	90-Day Release	
Product	Catalog Pri Number Pa	ice Schedule/ ige Number	Catalog Pric Number Pag		Catalog Pric Number Pag	
Methyl L-Dopa	C-509	B-21/48	SC-509	B-60/49	NC-509	B-90/50
Methyl Prednisolone	G-241	D-21/54	SG-241	D-60/55	NG-241	D-90/56
Methyl Testosterone (See Mesterolone) (See Controlled Substances Page 8)	M-103	D-21/54	SM-103	D-60/55	NM-103	D-90/56
Methyl Thiouracil	T-161	C-21/51	ST-161	C-60/52	NT-161	C-90/53
1-Methyl-D-Tryptophan	We can co	istom make ai	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE)
1-Methyl-DL-Tryptophan	We can ci	ıstom make aı	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE)
1-Methyl-L-Tryptophan	We can co	ustom make a	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE)
Metoprolol	C-510	C-21/51	SC-510	C-60/52	NC-510	C-90/53
Metronidazole	B-179	B-21/48	SB-179	B-60/49	NB-179	B-90/50
Metyrapone	M-141	C-21/51	SM-141	C-60/52	NM-141	C-90/53
Mifepristone (RU-486)	We can co	ustom make a	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE)
Minocycline	B-169	D-21/54	SB-169	D-60/55	NB-169	D-90/56
Minoxidil	C-255	E-21/57	SC-255	E-60/58	NC-255	E-90/59
Mithramycin A	Z-240	H-21/60	SZ-240	H-60/61	NZ-240	H-90/62
Mitomycin C	Z-250	H-21/60	SZ-250	H-60/61	NZ-250	H-90/62
Monensin	B-157	B-21/48	SB-157	B-60/49	NB-157	B-90/50
Moxalactam	B-180	A-21/45	SB-180	A-60/46	NB-180	A-90/47
Myristic Acid	F-131	C-21/51	SF-131	C-60/52	NF-131	C-90/53
Nadolol	N-102	D-21/54	SN-102	D-60/55	NN-102	D-90/56
Nafoxidine	E-441	E-21/57	SE-441	E-60/58	NE-441	E-90/59
Naloxone	C-511	D-21/45	SC-511	D-60/46	NC-511	D-90/47
Naltrexone	We can co	ustom make a	ny dose and a	ny release tin	ne. (PLEASE	INQUIRE)
Nandrolone (19-Nortestosterone) (See Controlled Substances Page 8)	A-251	B-21/48	SA-251	B-60/49	NA-251	B-90/50
Naphazoline	C-513	C-21/51	SC-513	C-60/52	NC-513	C-90/53
Naproxen	X-221	C-21/51	SX-221	C-60/52	NX-221	C-90/53
Neomycin Sulfate	B-136	C-21/51	SB-136	C-60/52	NB-136	C-90/53
Neostigmine	C-123	B-21/48	SC-123	B-60/49	NC-123	B-90/50

	21-Day	Release	60-Day	Release	90-Day	Release
Product		ce Schedule/ ge Number	Catalog Pri Number Pa	ce Schedule/ ge Number	Catalog Pri Number Pa	
Nervonic Acid	F-221	A-21/45	SF-221	A-60/46	NF-221	A-90/47
Niacin	V-341	C-21/51	SV-341	C-60/52	NV-341	C-90/5
Niacinamide	V-351	C-21/51	SV-351	C-60/52	NV-351	C-90/5
Nicotine	K-135	B-21/48	SK-135	B-60/49	NK-135	B-90/5
Nicotinic Acid	K-136	B-21/48	SK-136	B-60/49	NK-136	B-90/5
Nifedipine	C-321	B-21/48	SC-321	B-60/49	NC-321	B-90/5
Nifenazone	C-124	B-21/48	SC-124	B-60/49	NC-124	B-90/5
Niflumic Acid	X-116	B-21/48	SX-116	B-60/49	NX-116	B-90/5
Nimesulide	N-104	C-21/51	SN-104	C-60/52	NN-104	C-90/5
Nitro-L-Arginine	N-101	C-21/51	SN-101	C-60/52	NN-101	C-90/5
Norepinephrine	C-121	B-21/48	SC-121	B-60/49	NC-121	B-90/5
Norethindrone	P-171	B-21/48	SP-171	B-60/49	NP-171	B-90/5
Norethindrone Acetate	P-181	A-21/45	SP-181	A-60/46	NP-181	A-90/4
Norethynodrel	P-201	B-21/48	SP-201	B-60/49	NP-201	B-90/5
Norgestrel	P-241	D-21/54	SP-241	D-60/55	NP-241	D-90/5
19-Nortestosterone (Nandrolone) (See Controlled Substances Page 8)	A-251	B-21/48	SA-251	B-60/49	NA-251	B-90/5
19-Nortestosterone 17-Decanoate (See Controlled Substances Page 8)	A-252	A-21/45	SA-252	A-60/46	NA-252	A-90/4
19-Nortestosterone 17-Propionate (See Controlled Substances Page 8)	A-321	B-21/48	SA-321	B-60/49	NA-321	B-90/5
Nortriptyline	C-402	C-21/51	SC-402	C-60/52	NC-402	C-90/5
Noscapine	C-514	C-21/51	SC-514	C-60/52	NC-514	C-90/5
Novobiocin	B-137	B-21/48	SB-137	B-60/49	NB-137	B-90/5
Nystatin (Mycostatin)	B-138	B-21/48	SB-138	B-60/49	NB-138	B-90/5
Oleic Acid	F-191	B-21/48	SF-191	B-60/49	NF-191	B-90/5
Ouabain	C-331	B-21/48	SC-331	B-60/49	NC-331	B-90/5
Oxytetracycline	B-139	C-21/51	SB-139	C-60/52	NB-139	C-90/5
Palmitic Acid	F-141	C-21/51	SF-141	C-60/52	NF-141	C-90/5
Palmitoleic Acid	F-201	A-21/45	SF-201	A-60/46	NF-201	A-90/4

dule/ nber

)/53

1/53

1/50

1/50

1/50

1/50

1/50

1/53

1/53

1/50

1/50

1/47

1/50

1/56

/50

147

/50

1/53

/53

/50

/50

/50

/50

1/53

/53

147

	21-Day	21-Day Release		Release	90-Day Release		
Product		ice Schedule/ age Number	Catalog Pri Number Pa	ce Schedule/ ge Number		ce Schedule ge Number	
Papaverine	C-341	B-21/48	SC-341	B-60/49	NC-341	B-90/50	
D-Penicillamine	B-140	B-21/48	SB-140	B-60/49	NB-140	B-90/50	
DL-Penicillamine	B-141	B-21/48	SB-141	B-60/49	NB-141	B-90/50	
L'Penicillamine	B-142	B-21/48	SB-142	B-60/49	NB-142	B-90/50	
Penicillin-G (Benzylpenicillin)	B-143	C-21/51	SB-143	C-60/52	NB-143	C-90/53	
Phenelzine Phenelzine	C-515	C-21/51	SC-515	C-60/52	NC-515	C-90/53	
Pheniramine	C-516	B-21/48	SC-516	B-60/49	NC-516	B-90/50	
D-Phenylalanine	Q-391	C-21/51	SQ-391	C-60/52	NQ-391	C-90/53	
L-Phenylalanine	Q-401	C-21/51	SQ-401	C-60/52	NQ-401	C-90/53	
Phenylbutazone	I-116	C-21/51	SI-116	C-60/52	NI-116	C-90/53	
L-Phenylephrine	C-517	B-21/48	SC-517	B-60/49	NC-517	B-90/50	
Physostigmine (See Eserine)	K-129	B-21/48	SK-129	B-60/49	NK-129	B-90/50	
Pimozide	P-116	A-21/45	SP-116	A-60/46	NP-116	A-90/47	
Pindolol	C-351	B-21/48	SC-351	B-60/49	NC-351	B-90/50	
Piroxicam	X-231	B-21/48	SX-231	B-60/49	NX-231	B-90/50	
Placebo Control Pellets	C-111	See page 17	SC-111	See page 18	NC-111	See page	
cis-Platinum	Z-260	D-21/54	SZ-260	D-60/55	NZ-260	D-90/56	
trans-Platinum	Z-266	D-21/54	SZ-266	D-60/55	NZ-266	D-90/56	
Polymyxin B Sulfate	B-144	C-21/51	SB-144	C-60/52	NB-144	C-90/53	
Potassium lodide	T-167	C-21/51	ST-167	C-60/52	NT-167	C-90/53	
Prazosin	C-265	E-21/57	SC-261	E-60/58	NC-261	E-90/59	
Prednisolone	G-151	B-21/48	SG-151	B-60/49	NG-151	B-90/50	
Prednisone	G-161	B-21/48	SG-161	B-60/49	NG-161	B-90/50	
Pregnenolone	P-111	C-21/51	SP-111	C-60/52	NP-111	C-90/53	
Probenecid	I-117	C-21/51	SI-117	C-60/52	NI-117	C-90/53	
Probucol	P-113	B-21/48	SP-113	B-60/49	NP-113	B-90/50	
Procainamide	C-519	C-21/51	SC-519	C-60/52	NC-519	C-90/53	

Product	21-Day	21-Day Release		Release	90-Day Release	
		ce Schedule/ ge Number	Catalog Pric Number Pag		Catalog Pric Number Pag	
Procaine	P-112	C-21/51	SP-112	C-60/52	NP-112	C-90/53
Proflavine	P-115	C-21/51	SP-115	C-60/52	NP-115	C-90/53
Progesterone	P-131	B-21/48	SP-131	B-60/49	NP-131	B-90/50
Proglumide	P-114	C-21/51	SP-114	C-60/52	NP-114	C-90/5
D-Proline	Q-411	D-21/54	SQ-411	D-60/55	NQ-411	D-90/56
L-Proline	Q-421	C-21/51	SQ-421	C-60/52	NQ-421	C-90/5
Promethazine	C-421	C-21/51	SC-421	C-60/52	NC-421	C-90/5
Propranolol	C-361	C-21/51	SC-361	C-60/52	NC-361	C-90/5
6-n-Propyl-2-Thiouracil	T-141	C-21/51	ST-141	C-60/52	NT-141	C-90/5
Prostacyclin (See Prostaglandin I ₂)	R-120	N-21/69	SR-120	N-60/70	NR-120	N-90/7
Prostaglandin A ₁	R-111	N-21/69	SR-111	N-60/70	NR-111	N-90/7
Prostaglandin A ₂	R-112	N-21/69	SR-112	N-60/70	NR-112	N-90/7
Prostaglandin B ₁	R-113	N-21/69	SR-113	N-60/70	NR-113	N-90/7
Prostaglandin B ₂	R-114	N-21/69	SR-114	N-60/70	NR-114	N-90/7
Prostaglandin D ₂	R-115	N-21/69	SR-115	N-60/70	NR-115	N-90/7
Prostaglandin E ₁	R-116	N-21/69	SR-116	N-60/70	NR-116	N-90/7
Prostaglandin E ₂	R-117	N-21/69	SR-117	N-60/70	NR-117	N-90/7
Prostaglandin F _{1 α}	R-118	N-21/69	SR-118	N-60/70	NR-118	N-90/7
Prostaglandin F ₂	R-119	N-21/69	SR-119	N-60/70	NR-119	N-90/7
Prostaglandin I ₂ (Prostacyclin)	R-120	N-21/69	SR-120	N-60/70	NR-120	N-90/7
Puerarin	K-139	D-21/54	SK-139	D-60/55	NK-139	D-90/5
Puromycin	B-145	E-21/57	SB-145	E-60/58	NB-145	E-90/5
Putrescine	P-117	C-21/51	SP-117	C-60/52	NP-117	C-90/5
Pyrazinamide	P-118	C-21/51	SP-118	C-60/52	NP-118	C-90/5
Pyrilamine	C-520	C-21/51	SC-520	C-60/52	NC-520	C-90/5
Quinacrine	B-160Q	C-21/51	SB-160Q	C-60/52	NB-160Q	C-90/5
Quinidine	C-367	C-21/51	SC-367	C-60/52	NC-367	C-90/5

Dose/Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.

dule/ iber

/53

/50

/53

156

/53

/53

/53

153

/71

171

/71

/71

/71

/71

171

/71

/71

/71

/56

/59

/53

/53

/53

/53

/53

	21-Da	21-Day Release		Release	90-Day Release		
Product		rice Schedule/ age Number	Catalog Pri Number Pa	ice Schedule/ ige Number	Catalog Pri Number Pa	ce Schedule ge Number	
Quinine	K-141	C-21/51	SK-141	C-60/52	NK-141	C-90/53	
Rescinnamine	C-275	B-21/48	SC-275	B-60/49	NC-275	B-90/50	
Reserpine	C-181	C-21/51	SC-181	C-60/52	NC-181	C-90/53	
Retinal	V-131	B-21/48	SV-131	B-60/49	NV-131	B-90/50	
all trans-Retinoic Acid (ATRA)	V-111	B-21/48	SV-111	B-60/49	NV-111	B-90/50	
13-cis-Retinoic Acid	V-115	E-21/57	SV- 115	E-60/58	NV-115	E-90/59	
Retinol	V-121	B-21/48	SV-121	B-60/49	NV-121	B-90/50	
Retinol Acetate	V-141	C-21/51	SV-141	C-60/52	NV-141	C-90/53	
Retinol Palmitate	V-151	C-21/51	SV-151	C-60/52	NV-151	C-90/53	
Rifampicin	B-146	B-21/48	SB-146	B-60/49	NB-146	B-90/50	
Rifamycin	B-147	B-21/48	SB-147	B-60/49	NB-147	B-90/50	
Salbutamol	C-285	E-21/57	SC-285	E-60/58	NC-285	E-90/59	
Scopine	K-142	B-21/48	SK-142	B-60/49	NK-142	B-90/50	
Securinine	K-143	D-21/54	SK-143	D-60/55	NK-143	D-90/56	
D-Serine	Q-431	C-21/51	SQ-431	C-60/52	NQ-431	C-90/53	
È-Serine	Q-441	C-21/51	SQ-441	C-60/52	NQ-441	C-90/53	
Serotonin	C-161	C-21/51	SC-161	C-60/52	NC-161	C-90/53	
Sodium Butyrate	F-125	B-21/48	SF- 125	B-60/49	NF-125	B-90/50	
Sodium Iodide	T-181	C-21/51	ST- 181	C-60/52	NT- 181	C-90/53	
Solasodine	K-144	D-21/54	SK-144	D-60/55	NK-144	D-90/56	
(-)Sparteine	K-145	C-21/51	SK-145	C-60/52	NK-145	C-90/53	
Spermidine	N-301	B-21/48	SN-301	B-60/49	NN-301	B-90/50	
Spermine	N-311	B-21/48	SN-311	B-60/49	NN-311	B-90/50	
Spiramycin	B-148	B-21/48	SB-148	B-60/49	NB-148	B-90/50	
Spironolactone	M-161	B-21/48	SM-161	B-60/49	NM-161	B-90/50	
Stanozolol	A-331	B-21/48	SA-331	B-60/49	NA-331	B-90/50	
Stearic Acid	F-151	C-21/51	SF-151	C-60/52	NF-151	C-90/53	

	21-Day Release Catalog Price Schedule/ Number Page Number		60-Day Release Catalog Price Schedule/ Number Page Number		90-Day Release Catalog Price Schedule, Number Page Number	
Product						
Streptomycin Sulfate	B-149	C-21/51	SB-149	C-60/52	NB-149	C-90/53
Streptozotocin	Z-280	A-21/45	SZ-280	A-60/46	NZ-280	A-90/47
Strychnine (See Controlled Substances Page 8)	K-148	C-21/51	SK-148	C-60/52	NK-148	C-90/53
Sulfabenzamide	B-150	C-21/51	SB-150	C-60/52	NB-150	C-90/53
Sulfinpyrazone	1-118	C-21/51	SI-118	C-60/52	NI-118	C-90/53
Sulindac	I-119	B-21/48	SI-119	B-60/49	NI-119	B-90/50
(-)Sulpiride	S-101	B-21/48	SS-101	B-60/49	NS-101	B-90/50
(±)Sulpiride	S-102	C-21/51	SS-102	C-60/52	NS-102	C-90/53
Tamoxifen Citrate	E-351	A-21/45	SE-351	A-60/46	NE-351	A-90/47
Tamoxifen (Free Base)	E-361	A-21/45	SE-361	A-60/46	NE-361	A-90/47
Testosterone (See Controlled Substances Page 8)	Special	dosing for	mmuno- D	eficient Mic	e. See pag	jes 78-80.
Testosterone (See Controlled Substances Page 8)	A-151	B-21/48	SA-151	B-60/49	NA-151	B-90/50
Testosterone Benzoate (See Controlled Substances Page 8)	A-171	B-21/48	SA-171	B-60/49	NA-171	B-90/50
Testosterone Acetate (See Controlled Substances Page 8)	A-181	B-21/48	SA -181	B-60/49	NA -181	B-90/50
Testosterone Cypionate (See Controlled Substances Page 8)	A-281	B-21/48	SA-281	B-60/49	NA-281	B-90/50
Testosterone Enanthate (See Controlled Substances Page 8)	A-191	B-21/48	SA-191	B-60/49	NA-191	B-90/50
Testosterone 17ß-Hemisuccinate	A-201	A-21/45	SA-201	A-60/46	NA-201	A-90/47
(See Controlled Substances Page 8) Testosterone Propionate (See Controlled Substances Page 8)	A-211	B-21/48	SA-211	B-60/49	NA-211	B-90/50
Tetracycline	B-151	A-21/45	SB-151	A-60/46	NB-151	A-90/47
Theobromine	C-381	C-21/51	SC-381	C-60/52	NC-381	C-90/53
Theophylline	C-211	C-21/51	SC-211	C-60/52	NC-211	C-90/53
Thiabendazole	B-162	C-21/51	SB-162	C-60/52	NB-162	C-90/53
Thiacetazone	B-159	C-21/51	SB-159	C-60/52	NB-159	C-90/53
Thiamphenicol	B-160	B-21/48	SB-160	B-60/49	NB-160	B-90/50
Thiobarbital	T-145	C-21/51	ST-145	C-60/52	NT-145	C-90/53
6-Thioguanine	Z-290	B-21/48	SZ-290	B-60/49	NZ-290	B-90/50
D-Threonine	Q-451	C-21/51	SQ-451	C-60/52	NQ-451	C-90/53

i

ase dule/ nber /53

/47

1/53

/53

1/53

/50

/50

153

147

147

80.

/50

150

/50

/50

/50

147

/50

147

/53

1/53

/53

1/53

/50

1/53

/50

1/53

ALPHABETICAL PRODUCT LISTING

Product	21-Day	Release	60-Day	Release	90-Day Release	
		ice Schedule/ ige Number		ce Schedule/ ge Number	Catalog Prio Number Pag	ce Schedule ge Number
L-Threonine	Q-461	C-21/51	SQ-461	C-60/52	NQ-461	C-90/53
Thymidine	N-321	B-21/48	SN-321	B-60/49	NN-321	B-90/50
Thyroglobulin	T-201	D-21/54	ST-201	D-60/55	NT-201	D-90/56
Thyroid Releasing Hormone	T-211	H-21/60	ST-211	H-60/61	NT-211	H-90/62
Thyroid Stimulating Hormone	T-221	H-21/60	ST-221	H-60/61	NT-221	H-90/62
DL-Thyronine	T-111	B-21/48	ST-111	B-60/49	NT-111	B-90/50
D-Thyroxine	T-121	B-21/48	ST-121	B-60/49	NT-121	B-90/5
L-Thyroxine (T4)	T-131	B-21/48	ST-131	B-60/49	NT-131	B-90/5
Timolol	T-101	D-21/54	ST-101	D-60/55	NT-101	D-90/5
Tolazoline	C-391	C-21/51	SC-391	C-60/52	NC-391	C-90/5
Tomatidine	K-150	D-21/54	SK-150	D-60/55	NK-150	D-90/5
Tomatine	K-151	E-21/57	SK-151	E-60/58	NK-151	E-90/5
Tranylcypromine	C-521	B-21/48	SC-521	B-60/49	NC-521	B-90/5
Triamcinolone	G-251	B-21/48	SG-251	B-60/49	NG-251	B-90/5
Triamcinolone Acetonide	G-261	B-21/48	SG-261	B-60/49	NG-261	B-90/5
Triamcinolone Diacetate	G-271	B-21/48	SG-271	B-60/49	NG-271	B-90/5
Triamterene	D-171	C-21/51	SD-171	C-60/52	ND-171	C-90/5
8.3',5-Triiodo-DL-Thyronine	T-251	A-21/45	ST-251	A-60/46	NT-251	A-90/4
3,3',5-Triiodo-L-Thyronine (T3)	T-261	A-21/45	ST-261	A-60/46	NT-261	A-90/4
Tripelennamine	C-522	C-21/51	SC-522	C-60/52	NC-522	C-90/5
Tropine	K-152	B-21/48	SK-152	B-60/49	NK-152	B-90/5
Tropinone	K-153	B-21/48	SK-153	B-60/49	NK-153	B-90/5
Tryptamine	T-102	C-21/51	ST-102	C-60/52	NT-102	C-90/5
D-Tryptophan	Q-471	C-21/51	SQ-471	C-60/52	NQ-471	C-90/5
L-Tryptophan	Q-481	C-21/51	SQ-481	C-60/52	NQ-481	C-90/5
D-Tyrosine	Q-491	D-21/54	SQ-491	D-60/55	NQ-491	D-90/5
L-Tyrosine	Q-501	C-21/51	SQ-501	C-60/52	NQ-501	C-90/5

I

ALPHABETICAL PRODUCT LISTING

Product	21-Day Release		60-Day Release		90-Day Release	
	Catalog Pr Number P	rice Schedule/ age Number	Catalog Pri Number Pa	ice Schedule/ ige Number	Catalog Pri Number Pa	ce Schedule/ ge Number
Uridine	N-331	C-21/51	SN-331	C-60/52	NN-331	C-90/53
D-Valine	Q-511	C-21/51	SQ-511	C-60/52	NQ-511	C-90/53
L-Valine	Q-521	C-21/51	SQ-521	C-60/52	NQ-521	C-90/53
Vancomycin	B-152	D-21/54	SB-152	D-60/55	NB-152	D-90/56
Verapamil	C-411	B-21/48	SC-411	B-60/49	NC-411	B-90/50
Veratrine	K-154	D-21/54	SK-154	D-60/55	NK-154	D-90/56
Vinblastine	Z-300	H-21/60	SZ-300	H-60/61	NZ-300	H-90/62
Vincamine	K-155	D-21/54	SK-155	D-60/55	NK-155	D-90/56
Vincristine	Z-310	D-21/54	SZ-310	D-60/55	NZ-310	D-90/56
Vitamin B, (Thiamine)	V-161	C-21/51	SV-161	C-60/52	NV-161	C-90/53
Vitamin B ₂ (Riboflavin)	V-171	C-21/51	SV-171	C-60/52	NV-171	C-90/53
Vitamin B ₆ (Pyridoxine)	V-181	C-21/51	SV-181	C-60/52	NV-181	C-90/53
Vitamin B ₁₂ (Cyanocobalamin)	V-191	B-21/48	BV-191	B-60/49	NV-191	B-90/50
Vitamin C (Ascorbic Acid)	V-201	C-21/51	SV-201	C-60/52	NV-201	C-90/53
Vitamin D ₂ (Ergocalciferol)	V-211	C-21/51	SV-211	C-60/52	NV-211	C-90/53
Vitamin D ₃ (Cholecalciferol)	V-221	C-21/51	SV-221	C-60/52	NV-221	C-90/53
Vitamin E (Tocopherol)	V-231	B-21/48	SV-231	B-60/49	NV-231	B-90/50
Vitamin H (d-Biotin)	V-241	B-21/48	SV-241	B-60/49	NV-241	B-90/50
Vitamin K,	V-251	C-21/51	SV-251	C-60/52	NV-251	C-90/53
Vitamin K ₃ (Menadione)	V-261	C-21/51	SV-261	C-60/52	NV-261	C-90/53
Xanthinol Nicotinate	B-153	B-21/48	SB-153	B-60/49	NB-153	B-90/50
Yohimbine	C-401	C-21/51	SC-401	C-60/52	NC-401	C-90/53
α-Zearalenol	Z-101	N-21/69	SZ-101	N-60/70	NZ-101	N-90/71
ß-Zearalenol	Z-102	N-21/69	SZ-102	N-60/70	NZ-102	N-90/71
Zearalenone	Z-103	N-21/69	SZ-103	N-60/70	NZ-103	N-90/71
Zopepirac	I-120	B-21/48	SI-120	B-60/49	NI-120	B-90/50

INNOVATIVE RESEARCH OF AMERICA

dule/ nber

1/53

1/53

1/56

1/50

1/56

1/62

1/56

1/53

1/53

/53 /50

1/53

1/53

/50

150

1/53

1/53


150

1/53

1/71

171

/71 /50



Our pellets have a guaranteed shelf life of 3 years from the time that you receive them.

The Choice Is Evident

ORDERING INFORMATION

Mail

Innovative Research of America, Inc. 2 North Tamiami Trail Suite 404 Sarasota, Florida 34236 USA


· Phone

(941) 365-1406 (941) 365-1506 (800) 421-8171 (USA/Canada)

· Fax

(941) 365-1703 (941) 365-1803 (800) 643-4345 (USA/Canada) (800) 648-6030 (USA/Canada)

THE DIFFERENCE IS CONSISTENCY AND UNIFORMITY.



• Internet / E-Mail

http://www.innovrsrch.com (website) pellets@innovrsrch.com (e-mail)

IRA's website features our company profile, the latest product technology and **on-line ordering**.



AMERICAN EXPRESS, VISA AND MASTERCARD ACCEPTED. Purchase Order Forms are in the back of the catalog.

Custom Pellets Information Form on page 95.

Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank 1800 Second St., Suite 100 Sarasota, Florida 34236 Routing # (ABA) 263191387 Electronic Transfers # 263191387

In favor of: Innovative Research of America 2 North Tamiami Trail Suite 404 Sarasota, FL 34236 Checking Account: #0000147816154 Swift Code: BRBTUS33



Ushering In The Age Of Innovative Research

IRA

ring.

of the


ge 95.

STOCK PELLET PRICE SCHEDULES (PAGES 45-71)

This section of Price Schedules is for our stock products listed on pages 45-71 with our stock doses and releases (21 Day, 60 Day, 90 Day).

If there is a product, dose or release that is of interest not displayed in this catalog, please inquire.

Products are sold in lots of 25, 50, 100 and 200 pellets.



For Immuno-Deficient Mouse Studies:

Special doses and references for Cyproterone Acetate, Flutamide, 17β-Estradiol, Tamoxifen (Free Base), Testosterone and 5α-Dihydrotestosterone (5α-DHT)

Please see pages 73-80.

We Save You Time





PRICE SCHEDULE A-21

The price schedule below applies to all the products that are given the A-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O 50 pellets	OF PELLETS 100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6138
1.5	\$918	\$1752	\$3316	\$6178
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$951	\$1829	\$3409	\$6409
10.0	\$971	\$1859	\$3479	\$6499
15.0	\$989	\$1909	\$3579	\$6649
25.0	\$1019	\$1964	\$3659	\$6869
35.0	\$1049	\$1999	\$3729	\$7009
50.0	\$1089	\$2069	\$3809	\$7195
75.0	\$1119	\$2199	\$3959	\$7299
100.0	\$1209	\$2317	\$4279	\$7629
150.0	\$1329	\$2499	\$4649	\$8449
200.0	\$1449	\$2749	\$4875	\$8799

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

More Time For Creative Research



PRICE SCHEDULE A-60

The price schedule below applies to all the products that are given the A-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER C 50 pellets	OF PELLETS 100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$7275
0.5	\$1030	\$1915	\$3675	\$7285
1.5	\$1035	\$1945	\$3755	\$7295
2.5	\$1040	\$1955	\$3775	\$7300
5.0	\$1045	\$1965	\$3785	\$7350
7.5	\$1056	\$1981	\$3830	\$7400
10.0	\$1066	\$1996	\$3846	\$7500
15.0	\$1170	\$2125	\$4065	\$7999
25.0	\$1175	\$2130	\$4095	\$8005
35.0	\$1180	\$2146	\$4146	\$8010
50.0	\$1200	\$2226	\$4306	\$8015
75.0	\$1249	\$2362	\$4406	\$8260
100.0	\$1349	\$2562	\$4679	\$8460
150.0	\$1479	\$2822	\$4975	\$8910
200.0	\$1649	\$3162	\$5375	\$9249

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Time Release Pellets - The Affordable Solution

PRICE SCHEDULE A-90

The price schedule below applies to all the products that are given the A-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

of

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O 50 pellets	F PELLETS 100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1162	\$2195	\$4090	\$7672
0.5	\$1163	\$2198	\$4092	\$7673
1.5	\$1164	\$2199	\$4095	\$7674
2.5	\$1165	\$2200	\$4100	\$7675
5.0	\$1180	\$2225	\$4140	\$7676
7.5	\$1195	\$2245	\$4180	\$7800
10.0	\$1210	\$2256	\$4220	\$7850
15.0	\$1325	\$2390	\$4475	\$8548
25.0	\$1335	\$2396	\$4495	\$8555
35.0	\$1340	\$2406	\$4501	\$8600
50.0	\$1345	\$2486	\$4661	\$8750
75.0	\$1389	\$2622	\$4933	\$9000
100.0	\$1489	\$2822	\$5333	\$9250
150.0	\$1619	\$3022	\$5533	\$9750
200.0	\$1789	\$3362	\$5713	\$10250

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

The Picture Suddenly Gets Clearer



PRICE SCHEDULE B-21

The price schedule below applies to all the products that are given the B-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose	PRI	CE/NUMBER C	F PELLETS	
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6138
1.5	\$918	\$1752	\$3316	\$6178
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$950	\$1828	\$3408	\$6408
10.0	\$970	\$1858	\$3478	\$6498
15.0	\$979	\$1894	\$3529	\$6579
25.0	\$999	\$1929	\$3579	\$6698
35.0	\$1009	\$1944	\$3609	\$6798
50.0	\$1019	\$1964	\$3629	\$6848
75.0	\$1029	\$1979	\$3679	\$6898
100.0	\$1049	\$1999	\$3729	\$6948
150.0	\$1079	\$2049	\$3879	\$7198
200.0	\$1099	\$2099	\$4075	\$7398

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Pellets Help Put Research In The Proper Perspective

PRICE SCHEDULE B-60

The price schedule below applies to all the products that are given the B-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O	F PELLETS 100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1037	\$1950	\$3761	\$7275
0.5	\$1038	\$1955	\$3775	\$7285
1.5	\$1039	\$1960	\$3795	\$7295
2.5	\$1040	\$1962	\$3810	\$7300
5.0	\$1044	\$1964	\$3814	\$7349
7.5	\$1050	\$1970	\$3825	\$7400
10.0	\$1060	\$1985	\$3835	\$7500
15.0	\$1125	\$2035	\$3866	\$7700
25.0	\$1130	\$2065	\$3945	\$7800
35.0	\$1140	\$2080	\$3975	\$7850
50.0	\$1195	\$2145	\$4015	\$7900
75.0	\$1199	\$2175	\$4045	\$7950
100.0	\$1225	\$2235	\$4075	\$8000
150.0	\$1250	\$2275	\$4205	\$8200
200.0	\$1280	\$2295	\$4435	\$8400

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

The Research Puzzle Need Not Be Unsolved



The price schedule below applies to all the products that are given the B-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER (OF PELLETS 100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1162	\$2195	\$4090	\$7672
0.5	\$1163	\$2198	\$4092	\$7673
1.5	\$1164	\$2199	\$4095	\$7674
2.5	\$1165	\$2200	\$4100	\$7675
5.0	\$1179	\$2224	\$4139	\$7676
7.5	\$1191	\$2241	\$4171	\$7677
10.0	\$1206	\$2255	\$4201	\$7678
15.0	\$1285	\$2365	\$4300	\$8100
25.0	\$1294	\$2370	\$4350	\$8200
35.0	\$1295	\$2375	\$4390	\$8250
50.0	\$1320	\$2380	\$4430	\$8300
75.0	\$1335	\$2395	\$4470	\$8350
100.0	\$1350	\$2445	\$4510	\$8400
150.0	\$1365	\$2475	\$4550	\$8450
200.0	\$1380	\$2515	\$4590	\$8700

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Here Is The Better Alternative

PRICE SCHEDULE C-21

The price schedule below applies to all the products that are given the C-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

of

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O	F PELLETS 100 pellets	200 pellets
0.001	\$875	\$1666	\$3144	\$5792
0.010	\$876	\$1668	\$3148	\$5800
0.025	\$883	\$1682	\$3176	\$5856
0.05	\$888	\$1692	\$3196	\$5896
0.1	\$893	\$1702	\$3216	\$5936
0.25	\$898	\$1712	\$3236	\$5976
0.5	\$908	\$1732	\$3276	\$6056
1.5	\$918	\$1752	\$3316	\$6136
2.5	\$928	\$1772	\$3356	\$6216
5.0	\$940	\$1796	\$3404	\$6312
7.5	\$949	\$1827	\$3407	\$6407
10.0	\$959	\$1842	\$3442	\$6452
15.0	\$969	\$1857	\$3477	\$6497
25.0	\$979	\$1894	\$3529	\$6549
35.0	\$989	\$1912	\$3554	\$6574
50.0	\$999	\$1929	\$3579	\$6598
75.0	\$1009	\$1944	\$3609	\$6679
100.0	\$1019	\$1964	\$3629	\$6749
150.0	\$1029	\$1979	\$3679	\$6799
200.0	\$1049	\$1999	\$3729	\$6899

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Your Research Time Is Under Your Control



PRICE SCHEDULE C-60

The price schedule below applies to all the products that are given the C-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER (50 pellets	OF PELLETS 100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1045	\$1965	\$3785	\$7050
7.5	\$1050	\$1970	\$3795	\$7095
10.0	\$1055	\$1975	\$3805	\$7145
15.0	\$1065	\$1990	\$3835	\$7195
25.0	\$1075	\$2005	\$3865	\$7245
35.0	\$1085	\$2020	\$3885	\$7295
50.0	\$1095	\$2035	\$3915	\$7345
75.0	\$1105	\$2050	\$3945	\$7395
100.0	\$1120	\$2065	\$3975	\$7445
150.0	\$1145	\$2080	\$4005	\$7495
200.0	\$1170	\$2195	\$4035	\$7545

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Reassuring... Eliminates Uncertainties

PRICE SCHEDULE C-90

The price schedule below applies to all the products that are given the C-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

of

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose	PRI	CE/NUMBER O	F PELLETS	
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1180	\$2225	\$4140	\$7450
7.5	\$1185	\$2240	\$4170	\$7485
10.0	\$1200	\$2265	\$4210	\$7535
15.0	\$1215	\$2290	\$4250	\$7585
25.0	\$1230	\$2315	\$4290	\$7635
35.0	\$1245	\$2340	\$4330	\$7685
50.0	\$1260	\$2365	\$4370	\$7735
75.0	\$1275	\$2390	\$4410	\$7785
100.0	\$1290	\$2415	\$4450	\$7835
150.0	\$1305	\$2425	\$4490	\$7885
200.0	\$1320	\$2445	\$4530	\$7935

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Pellets... The Time Machines



PRICE SCHEDULE D-21

The price schedule below applies to all the products that are given the D-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O	F PELLETS 100 pellets	200 pellets
0.001	\$875	\$1671	\$3183	\$5967
0.010	\$876	\$1675	\$3191	\$5979
0.025	\$883	\$1689	\$3218	\$5999
0.05	\$888	\$1699	\$3223	\$6009
0.1	\$893	\$1729	\$3228	\$6019
0.25	\$915	\$1749	\$3308	\$6027
0.5	\$939	\$1795	\$3378	\$6143
1.5	\$975	\$1849	\$3428	\$6247
2.5	\$999	\$1895	\$3498	\$6363
5.0	\$1009	\$1949	\$3608	\$6527
7.5	\$1019	\$1964	\$3629	\$6748
10.0	\$1029	\$1979	\$3729	\$6898
15.0	\$1049	\$1999	\$3749	\$7025
25.0	\$1079	\$2049	\$3779	\$7098
35.0	\$1129	\$2109	\$3879	\$7199
50.0	\$1199	\$2299	\$4179	\$7699
75.0	\$1309	\$2449	\$4429	\$8199
100.0	\$1419	\$2549	\$4779	\$8499
150.0	\$1649	\$3049	\$5579	\$10199
200.0	\$1869	\$3449	\$6079	\$11199

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

It Is Only A Matter Of Time Release Pellets

PRICE SCHEDULE D-60

The price schedule below applies to all the products that are given the D-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRI 25 pellets	CE / NUMBER O 50 pellets	F PELLETS 100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.010	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1125	\$2075	\$3890	\$7050
7.5	\$1135	\$2125	\$3905	\$7345
10.0	\$1145	\$2195	\$3965	\$7445
15.0	\$1175	\$2225	\$4005	\$7545
25.0	\$1200	\$2245	\$4025	\$7645
35.0	\$1245	\$2295	\$4275	\$7995
50.0	\$1295	\$2445	\$4425	\$8195
75.0	\$1445	\$2645	\$4825	\$8695
100.0	\$1545	\$2845	\$5075	\$8995
150.0	\$1845	\$3345	\$5875	\$10695
200.0	\$2245	\$3745	\$6375	\$11695

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Solid Pellets For Better Solutions



PRICE SCHEDULE D-90

The price schedule below applies to all the products that are given the D-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose	PRI	CE/NUMBER O	F PELLETS	4000 000
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.010	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1235	\$2315	\$4240	\$7750
7.5	\$1249	\$2329	\$4280	\$8000
10.0	\$1265	\$2395	\$4405	\$8195
15.0	\$1325	\$2445	\$4505	\$8495
25.0	\$1385	\$2485	\$4575	\$8545
35.0	\$1485	\$2575	\$4725	\$8895
50.0	\$1625	\$2775	\$4875	\$9095
75.0	\$1725	\$2875	\$5275	\$9475
100.0	\$2145	\$3245	\$5575	\$9675
150.0	\$2440	\$3845	\$6175	\$10875
200.0	\$2545	\$4145	\$6775	\$12195

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Timing Is Everything

PRICE SCHEDULE E-21

The price schedule below applies to all the products that are given the E-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on 21.

Products are sold in lots of 25, 50 and 100 pellets.

of

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose mg/pellet	PRICE / NUMBER OF PELLETS 25 pellets 50 pellets 100 pellets			
0.001	\$897	\$1712	\$3228	
0.01	\$905	\$1728	\$3251	
0.05	\$910	\$1731	\$3274	
0.1	\$913	\$1732	\$3280	
0.25	\$933	\$1792	\$3389	
0.5	\$962	\$1825	\$3458	
1.5	\$976	\$1850	\$3481	
2,5	\$991	\$1873	\$3561	
5.0	\$1014	\$1922	\$3619	
7.5	\$1060	\$1939	\$3676	
10.0	\$1106	\$1972	\$3734	
15.0	\$1170	\$2110	\$4079	
25.0	\$1278	\$2483	\$4824	
35.0	\$1439	\$2964	\$5779	
50.0	\$2354	\$4694	\$8254	
75.0	\$3532	\$6827	\$12778	
100.0	\$4444	\$8304	\$16099	

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Consistency Is Important



PRICE SCHEDULE E-60

The price schedule below applies to all the products that are given the E-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose mg/pellet	PRICE / NU 25 pellets	MBER OF PELI 50 pellets	LETS 100 pellets
0.001	\$947	\$1812	\$3428
0.01	\$955	\$1828	\$3451
0.05	\$960	\$1831	\$3474
0.1	\$963	\$1832	\$3480
0.25	\$983	\$1892	\$3589
0.5	\$1012	\$1925	\$3658
1.5	\$1026	\$1950	\$3681
2.5	\$1041	\$1973	\$3761
5.0	\$1064	\$2022	\$3819
7.5	\$1085	\$2114	\$3976
10.0	\$1131	\$2147	\$4034
15.0	\$1195	\$2285	\$4379
25.0	\$1403	\$2658	\$5124
35.0	\$1624	\$3139	\$6079
50.0	\$2479	\$4869	\$8554
75.0	\$3657	\$7002	\$13078
100.0	\$4569	\$8479	\$16199

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Close The Gap With Good Results

PRICE SCHEDULE E-90

The price schedule below applies to all the products that are given the E-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

of

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS				
mg/pellet	25 pellets	50 pellets	100 pellets		
0.001	\$997	\$1912	\$3628		
0.01	\$1005	\$1928	\$3651		
0.05	\$1010	\$1931	\$3674		
0.1	\$1013	\$1932	\$3680		
0.25	\$1033	\$1992	\$3789		
0.5	\$1062	\$2025	\$3858		
1.5	\$1076	\$2050	\$3881		
2.5	\$1091	\$2073	\$3961		
5.0	\$1114	\$2122	\$4019		
7.5	\$1210	\$2289	\$4276		
10.0	\$1256	\$2322	\$4334		
15.0	\$1320	\$2460	\$4679		
25.0	\$1528	\$2833	\$5424		
35.0	\$1689	\$3314	\$6379		
50.0	\$2604	\$5044	\$8854		
75.0	\$3782	\$7177	\$13378		
100.0	\$4694	\$8654	\$16499		

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Discover The Ultimate Time-Saving Device



PRICE SCHEDULE H-21

The price schedule below applies to all the products that are given the H-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose	PRICE/N	UMBER OF PI	ELLETS
mg/pellet	25 pellets	50 pellets	100 pellets
0.001	\$905	\$1735	\$3305
0.005	\$915	\$1750	\$3330
0.01	\$925	\$1765	\$3355
0.025	\$935	\$1780	\$3380
0.05	\$945	\$1795	\$3405
0.1	\$955	\$1810	\$3430
0.25	\$975	\$1845	\$3485
0.5	\$1050	\$1965	\$3610
1.0	\$1225	\$2235	\$4135
2.5	\$1625	\$3135	\$5575
5.0	\$2825	\$5485	\$9575
7.5	\$4150	\$8245	\$13275
10.0	\$4745	\$8445	\$16775

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

An Instrument Of Success

PRICE SCHEDULE H-60

The price schedule below applies to all the products that are given the H-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

of

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS				
mg/pellet	25 pellets	50 pellets	100 pellets		
0.001	\$955	\$1835	\$3505		
0.005	\$965	\$1850	\$3530		
0.01	\$975	\$1865	\$3555		
0.025	\$985	\$1880	\$3580		
0.05	\$995	\$1895	\$3605		
0.1	\$1005	\$1910	\$3630		
0.25	\$1025	\$1945	\$3685		
0.5	\$1100	\$2065	\$3810		
1.0	\$1325	\$2435	\$4535		
2.5	\$1725	\$3335	\$5975		
5.0	\$2925	\$5685	\$9975		
7.5	\$4250	\$8445	\$13675		
10.0	\$4845	\$8645	\$17175		

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

A Tool For Change



PRICE SCHEDULE H-90

The price schedule below applies to all the products that are given the H-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose		NUMBER OF PI	
mg/pellet	25 pellets	50 pellets	100 pellets
0.001	\$1005	\$1935	\$3705
0.005	\$1015	\$1950	\$3730
0.01	\$1025	\$1965	\$3755
0.025	\$1035	\$1980	\$3780
0.05	\$1045	\$1995	\$3805
0.1	\$1055	\$2010	\$3830
0.25	\$1075	\$2045	\$3885
0.5	\$1150	\$2165	\$4010
1.0	\$1425	\$2635	\$4735
2.5	\$1825	\$3535	\$6175
5.0	\$3025	\$5885	\$10175
7.5	\$4350	\$8645	\$13875
10.0	\$4945	\$8845	\$17375

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM



A Tool For Discovery

PRICE SCHEDULE L-21

The price schedule below applies to all the products that are given the L-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

of

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose	PRI	CE/NUMBER O	F PELLETS	
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$875	\$1671	\$3183	\$5967
0.01	\$876	\$1675	\$3191	\$5979
0.025	\$883	\$1689	\$3218	\$5999
0.05	\$888	\$1699	\$3223	\$6009
0.1	\$893	\$1729	\$3228	\$6019
0.25	\$915	\$1749	\$3308	\$6027
0.5	\$939	\$1795	\$3378	\$6143
1.5	\$975	\$1849	\$3428	\$6247
2.5	\$999	\$1895	\$3498	\$6363
5.0	\$1009	\$1949	\$3608	\$6527
7.5	\$1019	\$1964	\$3629	\$6748
10.0	\$1029	\$1979	\$3729	\$6898
15.0	\$1049	\$1999	\$3749	\$7025

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Pellets Capture The Change In Research



PRICE SCHEDULE L-60

The price schedule below applies to all the products that are given the L-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose	PRI	CE/NUMBER O	F PELLETS	Section .
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1000	\$1855	\$3555	\$6550
0.01	\$1005	\$1865	\$3565	\$6600
0.025	\$1010	\$1875	\$3585	\$6650
0.05	\$1015	\$1885	\$3600	\$6700
0.1	\$1020	\$1895	\$3615	\$6750
0.25	\$1025	\$1905	\$3645	\$6800
0.5	\$1030	\$1915	\$3675	\$6850
1.5	\$1035	\$1945	\$3755	\$6950
2.5	\$1040	\$1955	\$3775	\$7000
5.0	\$1125	\$2075	\$3890	\$7050
7.5	\$1135	\$2125	\$3905	\$7345
10.0	\$1145	\$2195	\$3965	\$7445
15.0	\$1175	\$2225	\$4005	\$7545

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

The Perfect Gift Of Time

PRICE SCHEDULE L-90

The price schedule below applies to all the products that are given the L-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, 100 and 200 pellets.

of

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose		CE/NUMBER OF	FPELLETS	Ann. 1914
mg/pellet	25 pellets	50 pellets	100 pellets	200 pellets
0.001	\$1045	\$2000	\$3775	\$6950
0.01	\$1060	\$2025	\$3820	\$7000
0.025	\$1075	\$2050	\$3860	\$7050
0.05	\$1090	\$2075	\$3900	\$7100
0.1	\$1105	\$2100	\$3940	\$7150
0.25	\$1120	\$2125	\$3980	\$7200
0.5	\$1135	\$2150	\$4020	\$7300
1.5	\$1150	\$2175	\$4060	\$7350
2.5	\$1165	\$2200	\$4100	\$7400
5.0	\$1235	\$2315	\$4140	\$7450
7.5	\$1249	\$2329	\$4280	\$8000
10.0	\$1265	\$2395	\$4405	\$8195
15.0	\$1325	\$2445	\$4505	\$8495

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.

FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Options For Excellence



PRICE SCHEDULE M-21

The price schedule below applies to all the products that are given the M-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS						
mg/pellet	25 pellets	50 pellets	100 pellets				
0.05	\$875	\$1649	\$3159				
0.1	\$900	\$1725	\$3259				
0.5	\$952	\$1835	\$3450				
5.0	\$1265	\$2410	\$4579				
15.0	\$1365	\$2549	\$4779				

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM



We Deliver What You Expect With Confidence

PRICE SCHEDULE M-60

The price schedule below applies to all the products that are given the M-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS						
mg/pellet	25 pellets	50 pellets	100 pellets				
0.05	\$925	\$1700	\$3230				
0.1	\$950	\$1775	\$3305				
0.5	\$1002	\$1885	\$3525				
5.0	\$1315	\$2460	\$4755				
15.0	\$1415	\$2600	\$4855				

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

Reduce Experimental Variables



PRICE SCHEDULE M-90

The price schedule below applies to all the products that are given the M-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.


Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS						
mg/pellet	25 pellets	50 pellets	100 pellets				
0.05	\$975	\$1775	\$3305				
0.1	\$1000	\$1825	\$3380				
0.5	\$1052	\$1935	\$3575				
5.0	\$1365	\$2510	\$4805				
15.0	\$1465	\$2650	\$4905				

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.





FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM



Increase Data Reproducibility

PRICE SCHEDULE N-21

The price schedule below applies to all the products that are given the N-21 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.


Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 21 days.

TWENTY-ONE DAY RELEASE

Total Dose	PRICE/N	UMBER OF PEI	LETS
mg/pellet	25 pellets	50 pellets	100 pellets
0.001	\$905	\$1735	\$3305
0.005	\$915	\$1750	\$3330
0.01	\$925	\$1765	\$3355
0.025	\$935	\$1780	\$3380
0.05	\$945	\$1795	\$3405
0.1	\$955	\$1810	\$3430
0.25	\$1129	\$2146	\$3986
0.5	\$1345	\$2555	\$4775
1.0	\$1755	\$3345	\$6030

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.



FOR ADDED CONVENIENCE PLACE YOUR ORDER ON LINE AT WWW.INNOVRSRCH.COM

More Time For Creative Research



PRICE SCHEDULE N-60

The price schedule below applies to all the products that are given the N-60 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 60 days.

SIXTY DAY RELEASE

Total Dose	PRICE/NUMBER OF PELLETS						
mg/pellet	25 pellets	50 pellets	100 pellets				
0.001	\$955	\$1835	\$3505 -				
0.005	\$965	\$1850	\$3530				
0.01	\$975	\$1865	\$3555				
0.025	\$985	\$1880	\$3580				
0.05	\$995	\$1895	\$3605				
0.1	\$1005	\$1910	\$3630				
0.25	\$1179	\$2246	\$4135				
0.5	\$1395	\$2655	\$4925				
1.0	\$1805	\$3445	\$6180				

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.





We Put Management In Time

PRICE SCHEDULE N-90

The price schedule below applies to all the products that are given the N-90 price code.

Catalog items with their assigned price codes appear in the Alphabetical Listing of Products beginning on Page 21.

Products are sold in lots of 25, 50, and 100 pellets.

Doses of pellets reflect the total amount of net active product released over 90 days.

NINETY DAY RELEASE

Total Dose	PRICE/N	UMBER OF PEI	THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TW
mg/pellet	25 pellets	50 pellets	100 pellets
0.001	\$1005	\$1935	\$3705
0.005	\$1015	\$1950	\$3730
0.01	\$1025	\$1965	\$3755
0.025	\$1035	\$1980	\$3780
0.05	\$1045	\$1995	\$3805
0.1	\$1055	\$2010	\$3830
0.25	\$1229	\$2346	\$4285
0.5	\$1445	\$2755	\$5075
1.0	\$1855	\$3545	\$6330

A combination of multiple dosages in one lot, for any specified product, is also available. PLEASE INQUIRE.




We Help Manage Time



PRECISION TROCHAR

Please view pages 81 and 123 for trochar and pellet implantation information.



(Trochar can also be used for tissue transplantation.)



Pellets Capture The Change In Research

What



Special Dose Pellets for Tumor Growth and Regression in Immuno-Deficient Mice

It has been established that the growth and regression of estrogen-dependent and androgen-dependent tumor tissue in mice is dependent upon three factors:

- 1. The tumor tissue itself
- 2. A healthy and untraumatized mouse
- 3. Exogenous estrogen/androgen or anti-estrogen/anti-androgen ready-to-implant pellets from Innovative Research of America

NOTE: In this section, the pricing for the most commonly used 60 Day Release and 90 Day Release pellets in mice are listed for the below products. You may also view the selected references for these specific pellets on pages 74-80 and additional references citing the use of these products on pages 109-122.

Available Special C for 60 Days or		Pellet Size in Diameter
li de Lemanimi 1716-te matini 1716-testracion 1716-testracion 1716-testracion Batacolon (Gene Basa) Planola	Lingpeiler 6. ingspeiler 6. ingspeiler 6. ingspeiler sungspeiler	(Samo (Samo) (Lacuti Literati (Lacuti

Available Special C for 60 Days or		Pellet Size in Diameter
Theoresterrope Societies Moreoneste Copendones in decidad Papada	Etheropolise Etheropolise Etheropolise Etheropolise	Francis Francis Francis



*Please inquire directly with us if further assistance is required regarding a product of interest.

What You Get Out Of Your Research Is Only As Good As What You Put Into It



No. 1 These No. 1

NE NE

NE

NE

ME Mul Cs.

Thes No. 1 throu

SC

SE

∃S ∃S

Ca Nu SE

17B-ESTRADIOL AND TAMOXIFEN PELLETS FOR TUMOR GROWTH & REGRESSION IN IMMUNO-DEFICIENT MICE.

It has been established that the growth and regression of estrogen-dependent tumor tissue in mice is dependent upon three factors:

- 1. The tumor tissue itself.
- 2. A healthy and untraumatized mouse.
- Exogenous estrogen or anti-estrogen ready-to-implant pellets from Innovative Research of America.

The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:

60-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
SE-121	17 ß-Estradiol	1.7	3.0mm	\$1036	\$1949	\$3760	\$7270
SE-121	17 ß-Estradiol	0.72	3.0mm	\$1035	\$1948	\$3759	\$7269
SE-121	17 ß-Estradiol	0.36	3.0mm	\$1034	\$1947	\$3758	\$7268
SE-121	17 ß-Estradiol	0.18	3.0mm	\$1033	\$1946	\$3757	\$7267
SE-361	Tamoxifen (free base)	5.0	3.0mm	\$1045	\$1965	\$3815	\$7350
SC-111	Placebo	N/A	3.0mm	\$781	\$1518	\$2951	\$5374

These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog No. MP-182 - \$240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

90-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
NE-121	17 ß-Estradiol	1.7	3.0mm	\$1161	\$2194	\$4085	\$7670
NE-121	17 ß-Estradiol	0.72	3.0mm	\$1160	\$2193	\$4084	\$7669
NE-121	17 ß-Estradiol	0.36	3.0mm	\$1159	\$2192	\$4083	\$7668
NE-121	17 ß-Estradiol	0.18	3.0mm	\$1158	\$2191	\$4082	\$7667
NE-361	Tamoxifen (free base)	5.0	3.0mm	\$1180	\$2225	\$4140	\$7750
NC-111	Placebo	N/A	3.0mm	\$814	\$1574	\$3049	\$5528

These pellets are designed for simple subcutaneous implantation in mice with a 10 Gauge Precision Trochar (Catalog No. MP-182-\$240.00 each). NOTE: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

73

17B-ESTRADIOL

ACTA Neurochiurgica, 140 (1): 82-86, 1998

Acta Physiologica Scandinavica, 176 (3): 177-184, 2002

American Association for Cancer Research (AACR), 2003

American Journal of Obstetrics and Gynecology, 184 (3): 303-308, 2001

American Journal of Pathology, 153 (6): 1993-2006, 1998

American Journal of Pathology, 158 (2): 639-646, 2001

American Journal of Pathology, 161 (3): 909-918, 2002

American Journal of Pathology, 163 (5): 1713-1719, 2003

American Journal of Pathology, 163 (6): 2531-2541, 2003

American Journal of Physiology: Endocrinology and Metabolism, 282 (1): E139-E146, 2002

American Journal of Physiology: Endocrinology and Metabolism, 283 (4): E623-E630, 2002

American Journal of Physiology: Gastrointestinal and Liver Physiology, 290 (2): G269-G276, 2006

American Journal of Physiology: Heart and Circulatory Physiology, 284 (5): H1560-H1569, 2003

American Journal of Physiology: Heart and Circulatory Physiology, 290. (5): H2043-H2050, 2006

American Journal of Physiology: Renal Physiology, 283 (5): F934-F943,

American Journal of Physiological Society, 102: 1387-1393, 2007

American Society for Nutritional Sciences, 134: 1929-1934, 2004

Anti-Cancer Drugs, 15 (10): 991-996, 2004

Anticancer Research, 8 (6): 1233-1240, 1988

Applied Spectroscopy, 58 (1): 1-9, 2004

Arteriosclerosis, Thrombosis, and Vascular Biology, 25: 1910-1916,

Biochemical and Biophysical Research Communications, 297 (1): 83-90, 2002

Biochemical and Biophysical Research Communications, 329 (3): 888-897, 2005

Biochemical Pharmacology, 57 (3): 309-312, 1999

Biochemical Pharmacology, 57 (9): 1047-1058, 1999

Biochimica et Biophysica Acta (BBA): Molecular Cell Research, 1591 (1-3): 109-118, 2002

Biological Procedures Online, 5 (1): 211-221, 2003

Brain Research, 1022 (1-2): 148-156, 2004

Brain Research, 1052 (1): 105-111, 2005

Brain Research, 912 (1): 79-88, 2001

Breast Cancer Research and Treatment, 45 (2): 99-107, 1997

Breast Cancer Research and Treatment, 60 (1): 15-28, 2000

Breast Cancer Research and Treatment, 78 (1): 1-6, 2003

Breast Cancer Research and Treatment, 78 (2): 205-216, 2003

Breast Cancer Research and Treatment, 79 (3): 287-299, 2003

Breast Cancer Research and Treatment, 85 (3): 229-238, 2004

Breast Cancer Research and Treatment, 92 (2): 141-149, 2005

Breast Cancer Research and Treatment, 92 (3): 251-263, 2005

Breast Cancer Research, 2 (2): 139-148

Breast Cancer Research, 7 (6): R940-R952, 2005

British Journal of Cancer, 64 (6): 1019-1024, 1999

British Journal of Cancer, 80 (7): 1005-1011, 1999

British Journal of Cancer, 86 (1): 136-142, 2002

British Journal of Cancer, 88 (3): 470-471, 2003

British Journal of Cancer, 89 (2): 385-390, 2003

British Journal of Cancer, 90 (11): 2232-2242, 2004

British Journal of Cancer, 90 (2): 430-435, 2004

British Journal of Pharmacology, 140 (1): 195-201, 2003

176-ESTRADIOL (cont.)

Cancer Letters, 109 (1-2): 223-230, 1996

Cancer Letters, 132 (1-2): 107-112, 1998

Cancer Letters, 179 (1): 43-49, 2002

Cancer Letters, 189 (1): 49-57, 2003

Cancer Research, 48 (4): 1143-1147, 1988

Cancer Research, 53 (14): 3229-3232, 1993

Cancer Research, 53 (2): 283-290, 1993

Cancer Research, 53 (9): 2168-2177, 1993

Cancer Research, 53 (9): 2178-2187, 1993

Cancer Research, 54 (21): 5511-5514, 1994

Cancer Research, 55 (18): 4146-4150, 1995

Cancer Research, 56 (19): 4328-4331, 1996

Cancer Research, 56 (9): 1965-1969, 1996.

Cancer Research, 57 (22): 5155-5161, 1997

Cancer Research, 58 (2): 352-361, 1998

Cancer Research, 58 (21): 4851-4857, 1998

Cancer Research, 59 (15): 3646-3651, 1999

Cancer Research, 59 (19): 5023-5029, 1999

Cancer Research, 59 (6): 1347-1355, 1999

Cancer Research, 60 (1): 42-46, 2000

Cancer Research, 60 (11): 3081-3087, 2000

Cancer Research, 60 (12): 3254-3261, 2000

Cancer Research, 60 (17): 4804-4811, 2000

Cancer Research, 60 (2): 213-218, 2000

Cancer Research, 60 (24): 7094-7098, 2000

Cancer Research, 61 (10): 4229-4237, 2001

Cancer Research, 61 (2): 532-537, 2001

Cancer Research, 61 (24); 8887-8895, 2001

Cancer Research, 61 (5): 1786-1790, 2001

Cancer Research, 61 (6): 2547-2551, 2001

Cancer Research, 61 (7): 2857-2861, 2001 Cancer Research, 61 (7): 2917-2922, 2001

Cancer Research, 61 (8): 3443-3449, 2001

Cancer Research, 62 (13): 3868-3875, 2002

Cancer Research, 62 (5): 1439-1442, 2002

Cancer Research, 62 (6): 1904-1909, 2002 Cancer Research, 62 (7): 1948-1951, 2002

Cancer Research, 62 (7): 2141-2150, 2002

Cancer Research, 63 (10): 2425-2435, 2003

Cancer Research, 63 (19): 6516-6522, 2003

Cancer Research, 63 (24): 8742-8748, 2003

Cancer Research, 63 (24): 8912-8921, 2003

Cancer Research, 63 (9): 2139-2144, 2003

Cancer Research, 64 (1): 415-422, 2004

Cancer Research, 64 (11): 3958-3965, 2004

Cancer Research, 64 (12): 4302-4308, 2004 Cancer Research, 64 (13): 4539-4546, 2004

Cancer Research, 64 (14): 4875-4886, 2004

Cancer Research, 64 (17): 6127-6136, 2004

Cancer Research, 64 (17): 6200-6206, 2004

Cancer Research, 64 (3): 977-984, 2004

Cancer Research, 64 (4): 1419-1424, 2004

Cancer Research, 64 (5): 1737-1743, 2004

Cancer Research, 65 (1): 18-25, 2005

Cancer Research, 65 (1): 317-324, 2005 Cancer Research, 65 (21): 9962-9970. 2005

Cancer Research, 65 (3): 681-685, 2005

Cancer Research, 65 (4): 1459-1470, 2005

Additional references for 17B-Estradiol on pages 112-117

17B-ESTRADIOL (cont.)

Cancer Research, 65 (9): 3815-3822, 2005 Cancer Research, 66 (6): 3271-3277, 2006 Cancer Research, 66 (7): 3667-3672, 2006 Cancer Research, 66 (9): 4789-4794, 2006 Cancer Research, 66 (12): 6063 -6071, 2006 Cancer Research, 61 (21): 10230-10240, 2007 Cancer Research, 67 (18): 8439-8443, 2007 Cancer Research, 67 (11): 5505-5512, 2007 Cancer Research, 67 (9): 4254-4263, 2007 Cancer Research, 67: 5865-5871, 2007 Cancer Research, 67 (24): 11732-11741, 2007 Cancer Research, 67 (7): 3412-3421, 2007 Cancer Research, 67: 2062-2071, 2007 Cancer Research, 67 (20): 9929-9936, 2007 Cancer Research, 67 (23): 11463-11469, 2007 Cancer Research, 67 (17): 8032-8042, 2007 Cancer Science, 94 (6): 501-507, 2003 Cancer Therapy: Preclinical, 13 (6): 1892-1902, 2007 Cancer, Chemotherapy, and Pharmacology, 43 (3): 183-197, 1999

Cancer, Immunology, and Immunotherapy, 51 (10): 557-564, 2002

Carcinogenesis, 19 (11): 1895-1900, 1998 Carcinogenesis, 26 (3): 587-595, 2005

Carcinogenesis, 26 (4): 771-778, 2005

Carcinogenesis, 26 (9): 1527-1535, 2005

Cell, 130: 811-823, 2007

Cell and Tissue Research, 304: 51-58, 2001

Cell Growth and Differentiation, 4 (3): 193-201, 1993

Cell Proliferation, 34 (4): 223-233, 2001 Chemistry and Biology, 11 (6): 787-797, 2004

Circulation Research, 93 (2): 170-177, 2003 Circulation, 102 (24): 2983-2989, 2000

Circulation, 103 (3): 435-441, 2001

Circulation, 107 (24): 3059-3065, 2003

Circulation, 108 (25): 3115-3121, 2003

Circulation, 111 (12): 1492-1498, 2005

Circulation, 97 (22): 2197-2201, 1998

Clinical and Experimental Metastasis, 17 (4): 323-330, 1999

Clinical and Experimental Metastasis, 21 (1): 65-74, 2004

Clinical Cancer Research, 10 (12): 4038-4047, 2004

Clinical Cancer Research, 10 (18): 6058-6065, 2004

Clinical Cancer Research, 10 (22): 7703-7711, 2004

Clinical Cancer Research, 10 (23): 8059-8067, 2004

Clinical Cancer Research, 10 (4): 1530-1534, 2004 Clinical Cancer Research, 11 (12): 4601-4609, 2005

Clinical Cancer Research, 11 (15): 5390-5395, 2005

Clinical Cancer Research, 11 (2): 931-936, 2005 Clinical Cancer Research, 11 (22): 8195-8200, 2005

Clinical Cancer Research, 11 (4): 1483-1489, 2005

Clinical Cancer Research, 11 (5): 1983-1989, 2005

Clinical Cancer Research, 11 (9): 3392-3401, 2005

Clinical Cancer Research, 12 (1): 281-288, 2006

Clinical Cancer Research, 12 (11): 3280-3287, 2006

Clinical Cancer Research, 4 (9): 2245-2251, 1998

Clinical Cancer Research, 5 (11): 3632-3638, 1999

Clinical Cancer Research, 6 (11): 4373-4380, 2000

Clinical Cancer Research, 6 (9): 3621-3628, 2000

Clinical Cancer Research, 7 (10): 3166-3177, 2001

Clinical Cancer Research, 7 (11): 3544-3550, 2001

17B-ESTRADIOL (cont.)

Clinical Cancer Research, 7 (11): 3613-3624, 2001 Clinical Cancer Research, 7 (4): 1061-1072, 2001 Clinical Cancer Research, 7 (7): 2050-2056, 2001 Clinical Cancer Research, 8 (4): 1008-1013, 2002 Clinical Cancer Research, 8 (5): 1003-1007, 2002 Clinical Cancer Research, 8 (5): 1008-1013, 2002 Clinical Cancer Research, 8 (6): 1932-1939, 2002 Clinical Cancer Research, 9 (15): 5514-5520, 2003 Clinical Cancer Research, 9 (5): 1877-1884, 2003 Clinical Cancer Research, 9 (6): 2350-2356, 2003 Clinical Cancer Research, 9 (8): 2933-2939, 2003 Clinical Cancer Research, 12 (11): 3280 - 3287, 2006 Clinical Cancer Research, 13 (16): 4909-4919, 2007 Clinical Cancer Research, 13: 5020-5027, 2007 Clinical Cancer Research, 13 (3): 1061-1067, 2007 Cytokine, 25 (2): 45-51, 2004 Department of Neurology Series of Reports, 60: 2002

Development, 132 (17): 3923-3933, 2005

Developmental Brain Research, 122 (2): 149-155, 2000

Diabetes, 51 (7): 2158-2169, 2002

Endocrinology, 135 (6): 2615-2622, 1994

Endocrinology, 136 (11): 4996-5003, 1995

Endocrinology, 141 (2): 809-820, 2000

Endocrinology, 142 (4): 1497-1505, 2001

Endocrinology, 143 (2): 636-646, 2002 Endocrinology, 148 (3): 1131-1143, 2007

Endocrinology, 148 (8): 3618-3624, 2007

Estrogen, Social Recognition Memory, and HPA Axis, 2002

Estrogen, Social Recognition Memory, and HPA Axis, 2003

European Journal of Cancer, 34 (3): 384-388, 1998

European Journal of Cancer, 37 (12): 1545-1553, 2001

European Journal of Endocrinology, 142 (4): 307-314, 2000

European Journal of Heart Failure, 7 (7): 1079-1084, 2005

Experimental Eye Research, 80 (3): 413-423, 2005

Experimental Neurology, 197 (1): 197-205, 2006 FASEB Journal Express, 18 (3): 565-567, 2004

FASEB Journal, 16 (6): 555-564, 2002

Federation of European Biochemical Societies (FEBS) Letters, 440 (3): 403-408, 1998

Fertility and Sterility, 78 (5): 973-978, 2002

Fertility and Sterility, 80 (Supplement 2): 832-838, 2003

Fertility and Sterility, 82 (3): 673-678, 2004

Gastroenterology, 127 (1): 239-249, 2004

Gene Therapy, 5 (2): 240-246, 1998

Gene Therapy, 7 (3): 241-248, 2000

Genes Chromosomes and Cancer, 1 (1): 48-58, 1989

Genome Biology, 7 (4): 2006

Hormones and Behavior, 47 (3): 350-357, 2005

Hypertension, 36 (5): 774-779, 2000

Hypertension, 42 (6): 1157-1163, 2003

International Journal of Cancer, 107 (2): 177-182, 2003

International Journal of Cancer, 107 (4): 535-540, 2003

International Journal of Cancer, 108 (1): 8-14, 2003

International Journal of Cancer, 108 (6): 922-929, 2004 International Journal of Cancer, 110 (5): 767-774, 2004

International Journal of Cancer, 113 (2): 316-328, 2005

International Journal of Cancer, 116 (6): 847-852, 2005

International Journal of Cancer, 118 (5): 1316-1320, 2006

Additional references for 17ß-Estradiol on pages 112-117

17B-ESTRADIOL (cont.)

International Journal of Cancer, 66 (5): 669-677, 1996 International Journal of Cancer, 81 (3): 309-313, 1999 International Journal of Cancer, 87 (5): 716-723, 2000 International Journal of Gynecological Cancer, 13 (2): 103-110, 2003 International Journal of Oncology, 20 (4): 813-818, 2002 International Journal of Oncology, 21 (1): 73-80, 2002 International Journal of Oncology, 22 (4): 835-841, 2003 Investigative Opthalmology and Visual Science, 44 (3): 1221-1229, 2003 Investigative Opthalmology and Visual Science, 44 (4): 1740-1746, 2003 JNCI, 99 (9): 694-705, 2007 Journal of Applied Physiology, 97 (2): 756-763, 2004 Journal of Applied Physiology, 97 (4): 1234-1244, 2004 Journal of Applied Physiology, 102 (5): 1387-1393, 2007 Journal of Biological Chemistry, 227 (42): 39858-39866, 2002 Journal of Biological Chemistry, 269 (42): 26449-26455, 1994 Journal of Biological Chemistry, 276 (26): 23763-23768, 2001 Journal of Biological Chemistry, 276 (45): 42259-42267, 2001 Journal of Biological Chemistry, 277 (42): 39858-39866, 2002 Journal of Biological Chemistry, 278 (9): 7580-7590, 2003 Journal of Biological Chemistry, 279 (10): 8602-8607, 2004 Journal of Biological Chemistry, 280 (29): 27022-27028, 2005 Journal of Biological Chemistry, 282 (19): 14328-14336, 2007 Journal of Cardiovascular Electropsysiology, 13 (3): 276-280, 2002 Journal of Cardiovascular Pharmacology, 43 (5): 607-615, 2004 Journal of Cell Biology, 148 (4): 779-790, 2000 Journal of Clinical Endocrinology and Metabolism, 89 (3): 1089-1095, Journal of Clinical Investigation, 106 (11): 1373-1379, 2000 Journal of Clinical Investigation, 106 (6): 763-771, 2000 Journal of Clinical Investigation, 107 (3): 333-340, 2001 Journal of Clinical Investigation, 109 (12): 1625-1633, 2002 Journal of Clinical Investigation, 109 (4): 541-548, 2002. Journal of Clinical Investigation, 110 (4): 453-462, 2002 Journal of Clinical Investigation, 116 (1): 209-216, 2006 Journal of Clinical Investigation, 117 (1): 218-228, 2007 Journal of Immunological Methods, 272 (1-2): 177-187, 2003 Journal of Immunology, 152 (5): 2377-2384, 1994 Journal of Immunology, 160 (10): 5098-5104, 1998 Journal of Immunology, 166 (3): 2080-2089, 2001 Journal of Immunology, 167 (4): 1886-1890, 2001 Journal of Immunology, 174 (10): 6023-6029, 2005 Journal of Immunology, 175 (3): 1415-1423, 2005 Journal of Immunology, 176 (5): 2703-2710, 2006 Journal of Inorganic Biochemistry, 77 (1): 117-120, 1999 Journal of Lipid Research, 47 (4): 778-786, 2006 Journal of Magnetic Resonance Imaging (JMRI), 6 (1): 195-202, 1996 Journal of Neurochemistry, 79 (4): 796-803, 2001 Journal of Neurochemistry, 80 (1): 191-196, 2002 Journal of Neurochemistry, 87 (4): 1052-1055, 2003 Journal of Neuro-Oncology, 34: 221-231, 1997 Journal of Neuroscience Research, 77 (1): 119-126, 2004 Journal of Neuroscience Research, 79 (3): 279-286, 2005 Journal of Neuroscience, 22 (10): 4095-4102, 2002

Journal of Nuclear Medicine, 44 (9): 1469-1478, 2003

Journal of Nutrition, 131 (9): 2351-2357, 2001

Journal of Nutrition, 132 (8): 2246-2250, 2002

Journal of Nuclear Medicine, 46 (10): 1719-1726, 2005

17B-ESTRADIOL (cont.)

Journal of Steroid Biochemistry and Molecular Biology, 84 (2-3): 361-367, 2003 Journal of Steroid Biochemistry and Molecular Biology, 94 (5): 489-498, 2005 Journal of Steroid Biochemistry, 27 (1-3): 493-498, 1987 Journal of the American College of Cardiology, 41 (11): 2084-2092, Journal of the National Cancer Institute, 96 (10): 739-749, 2004 Journal of the National Cancer Institute, 96 (11): 875-878, 2004 Journal of the National Cancer Institute, 96 (3): 210-218, 2004 Journal of Virology, 73 (6): 5144-5148, 1999 Laboratory Animal Science, 47 (1): 82-85, 1997 Long-Term Estrogen Replacement and Social Memory, 2004 Luminescence, 18 (4): 218-223, 2003 Magnetic Resonance in Medicine, 46 (1): 31-38, 2001 Metabolism, 52 (6): 659-661, 2003 Molecular and Cellular Biology, 23 (19): 6887-6900, 2003 Molecular Cancer, 65 (6): 2007 Molecular Cancer Therapeutics, 1 (4): 239-246, 2002 Molecular Cancer Therapeutics, 1 (6): 377-384, 2002 Molecular Cancer Therapeutics, 2 (8): 729-737, 2003 Molecular Cancer Therapeutics, 3 (12): 1565-1575, 2004 Molecular Cancer Therapeutics, 3 (3): 233-244, 2004 Molecular Cancer Therapeutics, 4 (12): 1837-1849, 2005 Molecular Cancer Therapeutics, 5 (1): 1-7, 2006 Molecular Cancer Therapeutics, 5 (2): 317-328, 2006 Molecular Cancer Therapeutics, 5 (3): 685-692, 2006 Molecular Cancer Therapeutics, 6 (9): 2458-2467, 2007 Molecular Carcinogenesis, 19 (1): 54-66, 1997 Molecular Endocrinology, 20 (1): 14-34, 2006 Molecular Endocrinology, 20 (5): 996-1008, 2006 Molecular Human Reproduction, 3 (4): 333-342, 1997 Molecular Human Reproduction, 5 (12): 1141-1149, 1999 Molecular Pharmacology, 65 (3): 730-743, 2004 Molecular Therapy, 9 (4): 540-547, 2004 Nature Biotechnology, 22 (3): 313-320, 2004 Nature Biotechnology, 22 (6): 701-706, 2004 Nature Medicine, 6 (4): 443-446, 2000 Nature Medicine, 9 (8): 1026-1032, 2003 Nature, 406 (6797): 742-747, 2000 Neoplasia, 3 (2): 143-153, 2001 Neoplasia, 9 (6): 487-494, 2007 Neurobiology, 24 (7): 977-983, 2003 Neuroendocrinology, 78 (3): 147-158, 2003 Neuroreport, 10 (6): 1369-1372, 1999 Neuroreport, 15 (1): 89-93, 2004 Neuroscience, 121 (3): 659-666, 2003 NMR in Biomedicine, 15 (2): 114-119, 2002 NMR in Biomedicine, 17 (4): 170-180, 2004 Nuclear Medicine and Biology, 28 (4): 397-399, 2001 Nuclear Medicine and Biology, 31 (6): 761-770, 2004 Nuclear Medicine and Biology, 32 (1): 51-58, 2005 Obesity Research, 12 (4): 716-724, 2004 Oncogene, 15 (17): 2093-2108, 1997 Oncogene, 17 (18): 2235-2249, 1998 Oncogene, 18 (13): 2241-2251, 1999

Additional references for 17B-Estradiol on pages 112-117

Oncogene, 18 (39): 5435-5447, 1999

17ß-ESTRADIOL (cont.)

Oncogene, 19 (38): 4337-4345, 2000 Oncogene, 19 (8): 1605-1612, 2000 Oncogene, 21 (18): 2805-2814, 2002 Oncogene, 21 (25): 4000-4008, 2002 Oncogene, 21 (8): 1159-1166, 2002 Oncogene, 23 (57): 9295-9302, 2004 Oncogene, 24 (16): 2677-2683, 2005 Oncogene, 24 (19): 3166-3176, 2005 Oncogene, 24 (5): 746-760, 2005

Otolaryngology - Head and Neck Surgery, 120 (2): 262-264, 1999

Physiology and Behavior, 74 (4-5): 653-658, 2001

PNAS, 87 (6): 2314-2318, 1990 PNAS, 93 (13): 6247-6251, 1996 PNAS, 95 (5): 2648-2652, 1998 PNAS, 95 (8): 4579-4583, 1998

PNAS, 96 (23); 13023-13028, 1999 PNAS, 96 (26): 15133-15136, 1999

PNAS, 97 (4): 1754-1759, 2000 PNAS, 97 (6): 2703-2708, 2000

PNAS, 98 (23): 13391-13395, 2001

Proceedings of the American Association of Cancer Research (AACR), 28: 235, 1987

Proteomics, 4 (7): 2175-2183, 2004 Regulatory Peptides, 124 (1): 7-17, 2005

Society for Experimental Biology & Medicine: 754-761, 2007

The Journal of Nuclear Medicine, 46 (11): 1866-1871, 2005

Toxicological Sciences, 54 (2): 493-499, 2000 Toxicological Sciences, 68 (2); 295-303, 2002



TAMOXIFEN

American Journal of Pathology, 15+B446:B5303 (6): 1993-2006, 1998 American Journal of Physiology: Endocrinology and Metabolism, 283 (4): E623-E630, 2002

American Journal of Physiology: Gastrointestinal and Liver Physiology, 283 (1): G27-G36, 2002

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 282 (3): R904-R907, 2001

Breast Cancer Research and Treatment, 41 (1): 71-79, 1996

Calcified Tissue International, 43 (6): 1988 Cancer Letters, 62 (2): 107-114, 1992

Cancer Research, 49 (15): 4090-4093, 1989

Cancer Research, 49 (17): 4765-4769, 1989

Cancer Research, 50 (11): 3189-3192, 1990

Cancer Research, 53 (9): 2168-2177, 1993

Cancer Research, 54 (21): 5511-5514, 1994

Cancer Research, 54 (24): 6334-6337, 1994

Cancer Research, 56 (19): 4328-4331, 1996

Cancer Research, 57 (22): 5155-5161, 1997

Cancer Research, 58 (2): 352-361, 1998

Cancer Research, 60 (24): 7094-7098, 2000

Cancer Research, 62 (7): 1948-1951, 2002

Cancer Research, 63 (10): 2425-2434, 2003

Cancer Research, 64 (5): 1737-1743, 2004

Cancer Research, 65 (1): 18-25, 2005

Cancer Research, 65 (3): 879-886, 2005

Carcinogenesis, 8 (5): 699-703, 1987

Cell Proliferation, 34 (4): 223-232, 2001

Clinical Cancer Research, 4 (3): 697-711, 1998

Clinical Cancer Research, 9 (8): 2933-2939, 2003

Endocrinology, 136 (11): 4996-5003, 1995

European Journal of Pharmacology, 483 (2-3): 155-162, 2004

Hormone and Metabolic Research, 35 (11/12): 836-842, 2003

Hormones and Behavior, 45 (4): 270-277, 2004

International Journal of Cancer, 92 (3): 342-347, 2001

Journal of Immunology, 175 (3): 1415-1423, 2005

Journal of Magnetic Resonance Imaging (JMRI), 6 (1): 195-202, 1996

Journal of Neuroendocrinology, 11 (10): 801-803, 1999

Journal of Neuroendocrinology, 13 (7): 618-624, 2001

Journal of Nutrition, 132 (8): 2246-2251, 2002

Journal of Steroid Biochemistry, 27 (1-3): 493-498, 1987

Journal of the Society for Gynecologic Investigation, 7 (4): 249-256.

Microbes and Infection, 7 (3): 485-493, 2005

Molecular Brain Research, 108 (1-2): 121-128, 2002

Molecular Endocrinology, 11 (7): 917-927, 1997

Molecular Endocrinology, 20 (5): 996-1008, 2006

Nature Immunology, 2 (1): 64-68, 2001

Nature, 416 (6878): 334-338, 2002

Neuroscience, 103 (2): 385-394, 2001

Oncogene, 10 (12): 2435-2446, 1995

Oncogene, 21 (25): 4000-4008, 2002

Oncogene, 24 (19): 3166-3176, 2005

PNAS, 93 (13): 6247-6251, 1996

Proceedings of the American Association of Cancer Research (AACR), 28: 235, 1987

Additional references for 17B-Estradiol on pages 112-117 Additional references for Tamoxifen on page 121

TESTOSTERONE, 5α-DIHYDROTESTOSTERONE, FLUTAMIDE AND CYPROTERONE ACETATE PELLETS FOR TUMOR GROWTH AND REGRESSION IN IMMUNO-DEFICIENT MICE

SEE PAGE 8 FOR ORDERING INFORMATION OF ANABOLIC STEROIDS

It has been established that the growth and regression of androgen-dependent tumor tissue in mice is dependent upon three factors.

- 1. The tumor tissue itself.
- 2. A healthy and untraumatized mouse.
- Exogenous androgen or anti-hormone ready-to-implant pellets from Innovative Research of America.

The most commonly used 60-day and 90-day pellets in mice are listed below in these charts:

60-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
SA-151	Testosterone (See Controlled Substances Page 8)	12.5	3.0mm	\$1120	\$2025	\$3865	\$7699
SA-161	5α -Dihydrotestosterone (See Controlled Substances Page 8)	12.5	3.0mm	\$1169	\$2124	\$4064	\$7998
SA-152	Flutamide	25.0	4.5mm	\$1130	\$2065	\$3945	\$7800
SC-114	Cyproterone Acetate	25.0	4.5mm	\$1403	\$2658	\$5124	N/A
SC-111	Placebo	N/A	3.0mm	\$794	\$1554	\$3004	\$5463

90-Day Release Pellets

Catalog Number	Product Description	Total Dose mg/p	Pellet Size	25 Pellets	50 Pellets	100 Pellets	200 Pellets
NA-151	Testosterone (See Controlled Substances Page 8)	12.5	3.0mm	\$1275	\$2290	\$4260	\$8099
NA-161	5α-Dihydrotestosterone (See Controlled Substances Page 8)	12.5	3.0mm	\$1324	\$2389	\$4459	\$8498
NA-152	Flutamide	25.0	4.5mm	\$1294	\$2370	\$4350	\$8200
NC-114	Cyproterone Acetate	25.0	4.5mm	\$1528	\$2833	\$5424	N/A
NC-111	Placebo	N/A	3.0mm	\$832	\$1622	\$3123	\$5650

Note: Other products and dosages that can also be used in mouse studies are found throughout this catalog.

5α-DIHYDROTESTOSTERONE (5α-DHT)

American Journal of Physiology: Cell Physiology, 274 (6): C1530-C1536, 1998

American Journal of Physiology: Cell Physiology, 277 (1): C35-C42, 1999

American Journal of Physiology: Endocrinology and Metabolism, 285 (1): 189-196, 2003

American Journal of Physiology: Endocrinology and Metabolism, 285 (4): E812-E818, 2003

American Journal of Physiology: Renal Physiology, 288 (3): F513-F520, 2005

Biochimica et Biophysica Acta (BBA): Gene Structure and Expression, 1518 (1-2): 73-78, 2001

Blood, 102 (2): 480-488, 2003

Bone, 26 (1): 27-32, 2000

Cancer Research, 50 (23): 7677-7681, 1990

Cancer Research, 52 (19): 5171-5177, 1992

Cancer Research, 59 (19): 5030-5036, 1999

Cancer Research, 60 (21): 6134-6141, 2000

Cardiovascular Research, 53 (3): 752-762, 2002

Cerebral Cortex, 13 (3): 282-296, 2003

Developmental Brain Research, 125 (1-2): 83-88, 2000

Endocrinology, 130 (6): 703-714, 1992

Endocrinology, 135 (4): 1605-1610, 1994

Endocrinology, 135 (6): 2615-2622, 1994

Endocrinology, 139 (2): 688-695, 1998

Endocrinology, 140 (10): 4509-4515, 1999

Endocrinology, 141 (12): 4698-4710, 2000

Endocrinology, 141 (8): 2923-2929, 2000

Endocrinology, 142 (11): 4652-4662, 2001

Endocrinology, 142 (3): 1278-1283, 2001

Endocrinology, 144 (10): 4478-4484, 2003

Endocrinology, 144 (5): 2311-2318, 2003

Endocrinology, 145 (1): 330-336, 2004

Endocrinology, 145 (7): 3507-3522, 2004

Endocrinology, 146 (2): 564-578, 2004

Experimental Parasitology, 100 (4): 209-216, 2002

Journal of Biological Chemistry, 268 (18): 13556-13564, 1993

Journal of Biological Chemistry, 275 (22): 16536-16542, 2000

Journal of Clinical Investigation, 108 (11): 1697-1704, 2001

Journal of Clinical Investigation, 111 (9): 1319-1327, 2003

Journal of Endocrinology, 189 (3): 519-528, 2006

Journal of Experimental Medicine, 175 (5): 1409-1412, 1992

Journal of Immunology, 159 (1): 1-6, 1997

Journal of Immunology, 167 (4): 2060-2067, 2001

Journal of Molecular Endocrinology, 21 (2): 217-223, 1998

Journal of Neurobiology, 52 (4): 312-321, 2002

5α-DIHYDROTESTOSTERONE (5α-DHT) (cont.)

Journal of Neurochemistry, 87 (4): 1052-1055, 2003

Journal of Neuroimmunology, 146 (1-2): 144-152, 2004

Journal of Orthopedic Research, 8 (4): 612-617, 1990

Journal of Steroid Biochemistry and Molecular Biology, 52 (6): 575-580, 1995

Journal of the National Cancer Institute, 67 (1): 51-56, 1981

Liver, 20 (3): 228-233, 2000

Molecular and Cellular Endocrinology, 120 (2): 133-138, 1996

Molecular Endocrinology, 11 (7): 917-927, 1997

Molecular Endocrinology, 13 (9): 1449-1459, 1999

Molecular Endocrinology, 7 (7): 898-906, 1993

Molecular Pharmacology, 65 (3): 730-743, 2004

Neurology and Neuroscience, 2 (2): 277-286, 2002

Neuroscience, 122 (3): 573-578, 2003

Oncogene, 18 (39): 5435-5447, 1999

PNAS, 100 (16): 9416-9421, 2003

PNAS, 101 (6): 1673-1678, 2004

PNAS, 91 (12): 5382-5386, 1994

PNAS, 98 (9): 5211-5216, 2001

Science, 298 (5594): 843-846, 2002

Toxicological Sciences, 76 (1): 171-181, 2003

American Journal of Kidney Diseases, 29 (2): 265-272, 1997

American Journal of Obstetrics and Gynecology, 173 (5): 1491-1498,

American Journal of Obstetrics and Gynecology, 184 (3): 303-308, 2001 American Journal of Physiology: Heart and Circulatory Physiology, 290

(4): H1610-H1616, 2006
Biochemical and Biophysical Research Communications, 300 (1): 167-171, 2003

Biochemical and Biophysical Research Communications, 326 (1): 181-187, 2005

Bone, 19 (2): 107-114, 1996

British Journal of Urology International, 96 (7): 1126-1130, 2005

Cardiovascular Research, 57 (1): 28-36, 2003

Cardiovascular Research, 65 (1): 148-157, 2005

Cytokine, 25 (3): 110-118, 2004

Diabetes, 54 (6): 1717-1728, 2005

Drug Metabolism and Disposition, 34 (3): 377-482, 2006

Experimental Neurology, 181 (2): 301-312, 2003

Immunological Investigations, 32 (4): 259-273, 2003

International Journal of Andrology, 25 (4): 210-214, 2002

Journal of Trauma, Injury, Infection, and Critical Care, 44 (1): 78-85,

Molecular Carcinogenesis, 41 (3): 150-163, 2004

Neuroscience, 116 (1): 213-222, 2003

Pharmacology, Biochemistry, and Behavior, 78 (3): 513-522, 2004

Shock, 24 (4): 318-323, 2005

Additional references for 5α-DHT are on page 111

TESTOSTERONE

AAPS Journal, 3 (2): 2001

American Journal of Pathology, 159 (2): 753-764, 2001

American Journal of Pathology, 159 (3): 855-860, 2001

American Journal of Pathology, 160 (1): 219-226, 2002

American Journal of Pathology, 162 (2): 655-663, 2003

American Journal of Physiology: Heart and Circulatory Physiology, 284

(5): H1560-H1569, 2003 American Journal of Physiology: Heart and Circulatory Physiology, 290

(5): H2043-H2050, 2006 British Journal of Cancer, 81 (2): 242-251, 1999

Cancer Cell, 2 (2): 127-137, 2002

Cancer Cell, 5 (6): 565-574, 2004

Cancer Cell, 6 (5): 517-527, 2004

Cancer Research, 54 (23): 6049-6052, 1994

Cancer Research, 56 (13): 3042-3046, 1996

Cancer Research, 58 (14): 3009-3014, 1998

Cancer Research, 58 (24): 5718-5724, 1998

Cancer Research, 59 (19): 4761-4764, 1999

Cancer Research, 60 (15): 4033-4036, 2000

Cancer Research, 60 (18): 5165-5170, 2000

Cancer Research, 61 (7): 2892-2898, 2001

Cancer Research, 61 (8): 3256-3261, 2001

Cancer Research, 62 (18): 5254-5259, 2002

Cancer Research, 63 (10): 2470-2476, 2003

Cancer Research, 64 (14): 4774-4782, 2004

Cancer Research, 64 (24): 8867-8875, 2004

Cancer Research, 64 (5): 1712-1721, 2004

Cancer Research, 66 (1): 175-183, 2006

Cancer Research, 66 (11): 5723-5728, 2006

Clinical Cancer Research, 12 (8): 3870-3876, 2002

Clinical Cancer Research, 7 (4): 962-970, 2001 Clinical Cancer Research, 8 (12): 3870-3876, 2002

Clinical Cancer Research, 8 (4): 986-993, 2002

Clinical Cancer Research, 8 (5): 986-993, 2002

Clinical Cancer Research, 9 (12): 4529-4536, 2003

Cytometry, 35 (1): 2-10, 1999

Endocrinology, 140 (5): 2372-2381, 1999

TESTOSTERONE (cont.)

Endocrinology, 142 (1): 139-146, 2001

Endocrinology, 148 (7): 3089-3101, 2007

Endocrinology, 148 (7): 3383-3390, 2007

European Urology, 45 (3): 382-389, 2004

Experimental and Molecular Pathology, 79 (1): 23-32, 2005

International Journal of Cancer, 82 (3): 424-429, 1999

Journal of Andrology, 22 (4): 537-548, 2001

Journal of Biological Chemistry, 278 (1): 1-45, 2003

Journal of Biological Chemistry, 279 (8): 7119-7130, 2004

Journal of Cellular Physiology, 178 (3): 371-378, 1999

Journal of Clinical Investigation, 114 (12): 1774-1781, 2004

Journal of Clinical Investigation, 116 (1): 209-216, 2006

Journal of Nuclear Medicine, 45 (3): 519-525, 2004

Journal of Nuclear Medicine, 48 (3): 420-428, 2007

Journal of the National Cancer Institute, 85 (5): 394-398, 1993

Journal of the National Cancer Institute, 91 (21): 1869-1876, 1999

Journal of Urology, 161 (3): 945-949, 1999

Journal of Urology, 170 (2): 615-618, 2003

Molecular and Cellular Biology, 26 (3): 965-975, 2006

Molecular Endocrinology, 11 (4): 450-459, 1997

Nuclear Medicine and Biology, 29 (8): 783-790, 2002

Oncogene, 21 (33): 5069-5080, 2002

PNAS, 100 (1): 11896-11903, 2003

PNAS, 103 (6): 1888-1893, 2006

PNAS, 98 (6): 3589-3593, 2001

PNAS, 99 (3): 1527-1531, 2002

Prostate, 51 (2): 73-83, 2002

Prostate, 51 (4): 247-255, 2002

Prostate, 57 (1): 1-7, 2003

Prostate, 57 (1): 24-31, 2003

Prostate, 60 (2): 77-90, 2004

Prostate, 60 (2): 91-97, 2004

Prostate, 62 (4): 322-338, 2005 Prostate, 63 (1): 91-103, 2005

Additional references for Testosterone are on pages 121-122



IMPLANTATION


Implantation of our Time Release Pellets

Implantation of our time release pellets can be done with and without using our Precision Trochar. The following section contains information about our Trochar as well as offers two detailed recommended implantation procedures to fit your experimental needs.

For pellets ranging in size from 0.001 mg/pellet up to 5mg/pellet (3mm in diameter) our MP-182 10 Gauge Precision Trochar is suitable. Please view page 81 for further information regarding the use of our Trochar. Our Trochar is also suitable for tissue implantation.

For implantation of pellets larger than 5mg/pellet (3mm in diameter) in size, please view page 123 for our detailed recommended implantation procedure with and without using a Trochar.

NOTE: In order to ensure reliable and continued performance the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.



*Please inquire directly with us if further assistance is required regarding your pellet implantation needs.

Pellets Capture The Change In Research







TROCHAR INFORMATION

Stainless steel reusable precision trochar with regular point needle and rounded stylet protruding 1/8" from needle point for easy implantation of small pellets up to 3mm in diameter (usually 0.001 mg up to 5 mg/pellet).


MP - 182 10 Gauge \$ 240.00

MP - 181 12 Gauge (Please Inquire)

NOTE: Physical restrictions on the pellet could alter the release rate. An injury to the muscle will cause local inflammation. The most ideal place to implant the pellet is where there is maximal space between the skin and the muscle such as the lateral side of the neck between the ear and the shoulder.

A. HOW TO USE TROCHAR FOR SMALL PELLET IMPLANTATION

- Put pellet in a standing position on needle of trochar, away from sharp edge and press gently.
- 2. Pellet should be stable in that position so that if trochar is pointed downward pellet will not fall.
- Put obturator half way in trochar and hold with stronger hand. With other hand lift skin on the lateral side of the neck of the animal and insert trochar. When the pellet in the trochar contacts the skin, twist the trochar sideways and insert pellet. Then, push with obturator all the way. Total distance from incision is about 2 cm.



When either technique is properly executed no antibiotics or stitches are needed and the animal should not bleed.

IMPORTANT: In order to ensure reliable and continued performance, the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.

*Please inquire directly with us if further assistance is required regarding a product of interest.



THE STORY OF THE S

ATTENTION

The three parameters in successful estrogen-dependent tumor heterotransplantation in immuno-deficient mice are:

- The tumor cells have to be mycoplasma-free, be grown to full monolayer (preferably with domes), and harvested with a rubber policeman (not with trypsin-EDTA) because these are epithelial cells and fare better as a clump. Metastasis depends on the metastatic potential of the cell sub-line.
- The mouse should be healthy and always checked for staph infection and/or mouse pox.
 - Signs of mouse pox are dry skin and body weight loss.
 - Signs of staph infection are red rashes on one or more of the following sites:
 - (a) Nostrils
 - (b) Lips
 - (c) Vagina
 - (d) Anal Cavity
 - * Staph infection potentiates an immune buildup which hinders the tumor growth and metastasis and can lead to bladder stones.
- 3) The 17ß-Estradiol pellet for estrogen dependent tumor growth and metastasis. We offer four doses (1.7mg/pellet, 0.72 mg/pellet, 0.36mg/pellet, and 0.18mg/pellet). All four doses support tumor growth, but at a different rate.

The highest dose is supposed to give the best and fastest results when the mouse and the cells are in the best condition. If the mouse and/or cells are not in the best condition, then the lower doses are options, however, it could take a little longer to achieve the results.



SAMPLE OF TESTIMONIALS

Major University School of Medicine, from Researcher

"I am writing to tell you of my experiences using your pellets. They are more reliable and more easily manipulated than other methods of drug delivery. They are less time consuming than injections and superior to silastic tubing. Our preliminary results with these pellets have been impressive..."

Veterans Administration, from Professor

"I was pleased to learn of the worldwide interest in our work which has been directed to you. Dr. X and I are appreciative of the excellent quality of the pellets that you have provided which gave uniform and predictable growth factor release both in this study and the earlier one reported in..."

National Institutes of Health, from Senior Scientist

"We purchased pellets from your company containing epidermal growth factor (EGF), insulin-like growth factor 1 (IGF), and transforming growth factor beta (TGFB). Our results have been great, far beyond our expectations...I want to congratulate you and your staff for doing fast, reliable and excellent work."

Research Center, Major Medical School, from Professor

"We wish to let you know that, thanks to custom pellets made by your company, we are now able to ask questions about the formation of new blood vessels that were unapproachable until now. We have had great success using your pellets in the past, and anticipate using them extensively in the future. I have recommended your company to a number of associates, and I will continue to do so."

Major Pharmaceutical Company, from Director

"As we discussed over the telephone, I am sending you the rat data with subcutaneous pellets and rabbit data with oral pellets. We are very happy with your subcutaneous pellets. During the second and third weeks after implantation, we achieved the designated plasma levels (10 to 20ng/ml) with 20 or 40mg pellets. I would like to congratulate you and your associates for a job well done."



ORDERING INFORMATION

REQUIRED INFORMATION

Orders may be placed by telephone, fax, mail, online or e-mail. For your convenience, order forms can be found in the back of this catalog.

For the processing of each order, the following information is required:

- ... Purchase Order Number or Credit Card (see below)
- ... Ship-to address
- ... Bill-to address
- ... Catalog number and name of product
- ... Quantity, unit, dose, and release time

TO ORDER

Mail

Innovative Research of America, Inc. 2 North Tamiami Trail Suite 404 Sarasota, Florida 34236 USA

· Phone

(941) 365-1406

(941) 365-1506

(800) 421-8171 (USA/Canada)

• Fax

(941) 365-1703

(941) 365-1803

(800) 643-4345 (USA/Canada)

(800) 648-6030 (USA/Canada)

· Internet / E-mail

http://www.innovrsrch.com (website) pellets@innovrsrch.com (e-mail)

IRA's website features our company profile, the latest product technology and **on-line ordering**.



AMERICAN EXPRESS, VISA & MASTERCARD ACCEPTED.
Purchase Order Forms - See back of Catalog.



Custom Pellets Information Form on page 95.

Bank Wire Payment Information

Payment via bank wire should be directed as follows:

BB&T Bank

1800 Second St., Suite 100 Sarasota, Florida 34236 Routing # (ABA), 263191387

Electronic Transfers # 263191387

In favor of: Innovative Research of America 2 North Tamiami Trail

Suite 404

Sarasota, FL 34236...

Checking Account: #0000147816154

Swift Code: BRBTUS33

TECHNICAL INQUIRIES

To receive technical assistance or request information about our product line, we encourage you to contact us via mail, phone, fax or e-mail.



It Is An Easier Way With IRA

IRA

DOXYCYCLINE & TETRACYCLINE IN MICE

Special Common Doses in a 21 Day, 60 Day and 90 Day Release Pellet



ALLOWS YOU TO CONTROL

TIME IN A PELLET CONSTANT PRODUCT RELEASE FOR A SUCCESSFUL EXPERIMENT.

On the following pages are the most commonly used 21 Day, 60 Day and 90 Day Release pellets for the products Doxycycline and Tetracycline in Mice.

Also available are a list of sample references citing the use of these common doses. Further publications may be viewed at our website: www.innovrsrch.com


*Please inquire directly with us if further assistance is required regarding a product of interest.

Variables Vanish While Saving You Time



DOXYCYCLINE & TETRACYCLINE IN MICE

Please see the following page for information on Doxycycline and Tetracycline in mice and for specific references.



Time Release Pellets . . . Always On Time



DOXYCYCLINE AND TETRACYCLINE IN MICE

Listed below are the most commonly used 21-day, 60-day and 90-day release pellets in mice:

21-DAY RELEASE

Catalog Number	PRODUCT DESCRIPTION	Total Dose	Pellet	PRICE/NUMBER OF PELLETS					
	TRODUCT DESCRIPTION	mg/pellet	Size	25	50	100	200		
B-168	Doxycycline	15.0	3.0mm	\$989	\$1909	\$3579	\$6649		
B-151	Tetracycline	15.0	3.0mm	\$989	\$1909	\$3579	\$6649		
C-111	Placebo	N/A	3.0mm	\$752	\$1529	\$2974	\$5258		

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

60-DAY RELEASE

Catalog	PRODUCT DESCRIPTION	Total Dose Pellet PRICE/No.				UMBER OF PELLETS			
Number		ing/pener	Size	45	50	100	200		
SB-168	Doxycycline	42.0	4.5mm	\$1231	\$2276	\$4356	\$7699		
SB-151	Tetracycline	42.0	4.5mm	\$1231	\$2276	\$4356	\$7699		
SC-111	Placebo	N/A	4.5mm	\$858	\$1624	\$3084	\$5564		

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

90-DAY RELEASE

Catalog Number		Total Dose mg/pellet	Pellet Size	PR 25	ICE/NUME 50	SER OF PEI 100	LETS 200
NB-168	Doxycycline	63.0	6.0mm	\$1439	\$2672	\$4983	\$8545
NB-151	Tetracycline	63.0	6.0mm	\$1439	\$2672	\$4983	\$8545
NC-111	Placebo	N/A	6.0mm	\$899	\$1698	\$3213	\$5766

Note: Other Doxycycline and Tetracycline dosages may also be used and are found on pages 28 & 40.

SAMPLES OF REFERENCES / DOXYCYCLINE & TETRACYCLINE IN MICE

DOXYCYCLINE

Cancer Research, 62:1588-1591 (2002)

Diabetes, 55 (12): 3520-3528 (2006)

Gene, 369: 80-89 (2006)

Human Molecular Genetics, 10 (19): 2039-2047 (2001)

Journal of Clinical Investigation, 108 (2): 319-329 (2001)

Journal of Gene Medicine, 7 (6): 817-828 (2004)

Oncogene, 21: 4435-4447 (2002)

PNAS, 95 (12): 580-585 (1998)

PNAS, 97 (16): 9209-9214 (2000)

PNAS, 99 (10): 6973-6978 (2002)

Transgenic Research, 2 (12): 171-178 (2003)

TETRACYCLINE

Blood, 96 (6): 2108-2115 (2000)

Cancer Research, 62 (5): 2749-2752 (2002)

Cancer Research, 61 (7): 3110-3118 (2001)

Development, 128: 1531-1538 (2001)

TETRACYCLINE (cont.)

European Molecular Biology Organization Journal, 16 (10): 2814-2825 (1997)

Gene Therapy, 12 (5): 452-460, (2005)

Gene Therapy, 12 (4): 80-89 (2006)

Journal of Biological Chemistry, 272 (47): 29482-29486 (1997)

Journal of Biological Chemistry, 276 (17): 13989-13994 (2001)

Journal of Cellular Biochemistry, 59: 463-472 (1995)

Journal of Immunology, 163: 4721-4727 (1999)

Journal of National Cancer Institute, 19 (90): 1451-1460 (1998)

Molecular and Cellular Biology, 21 (17): 5958-5969 (2001)

Nature Biotechnology, 14: 499-503 (1996)

Nature Biotechnology, 16: 757-761 (1998)

Nucleic Acids Research, 24 (19): 3875-3877 (1996)

Oncogene, 15 (7): 851-856 (1997)

Oncogene, 18 (46): 6343-6356 (1999)


PNAS, 91 (20): 9302-9306 (1994)

PNAS, 92 (8): 3576-3580 (1995)

Science, 273: 1384-1386 (1996)

PRECISION TROCHAR

Please see page 81 for information on the 10-Gauge Precision Trochar.




More Time For Creative Research



Alphabetical stock product listings can be found on pages 21-42

Stock Pellet prices can be found on pages 45-71

Stock Pellet doses and prices for tumor studies in mice can be found on pages 73-80




ALLOWS YOU TO CONTROL

TIME IN A PELLET CONSTANT PRODUCT RELEASE FOR A SUCCESSFUL EXPERIMENT.

Custom Pellet information can be found on pages 93-108.





(Two to three hormones in one pellet)

The following price schedules are for 17\(\mathbb{B}\)-Estradiol + Progesterone combined in one pellet. These pellets are offered in several Estradiol/Progesterone ratios in 21 Day, 60 Day and 90 Day Release forms. For other hormone combinations please view pages 90-92.

Available Stock Combinations							
17ß-Estradiol + Progesterone	17ß-Estradiol + Progesterone + Hydrocortisone	17α-Ethynyl Estradiol + Norethindrone					
17ß-Estradiol + Hydrocortisone	Hydrocortisone + Progesterone	Mestranol + Norethindrone					

NOTE: In order to ensure reliable and continued performance the pellet should not come in contact at the time of implantation with any organic solvent or exogenous fluid.

*Please inquire directly with us if further assistance is required regarding a product of interest.

Pellets Capture The Change In Research



HORMONE + HORMONE PELLETS

(Two or three hormones in one pellet)

Following are price schedules for 17ß-Estradiol + Progesterone combined in one pellet. The pellets are offered in several Estradiol/Progesterone ratios and in 21-day, 60-day or 90-day release forms. Other hormone combinations are on pages 90-92.

21-DAY RELEASE

Catalog	PRODUCT DESCRIPTION	Total Dose	PRICE/NUMBER OF PELLETS				
Number	PRODUCT DESCRIPTION	mg/pellet	25	50	100	200	
HH-111	17ß-Estradiol (0.1) + Progesterone (10.0)	10.1	\$1113	\$2110	\$3803	\$6883	
HH-112	17ß-Estradiol (0.5) + Progesterone (10.0)	10.5	\$1128	\$2140	\$3848	\$6958	
HH-113	17ß-Estradiol (0.1) + Progesterone (32.5)	32.6	\$1152	\$2196	\$3928	\$7094	
HH-114	17/3-Estradiol (0.5) + Progesterone (32.5)	33.0	\$1167	\$2226	\$3973	\$7169	
HH-115	17ß-Estradiol (any size) + Progesterone (any size)	-	\$1192	\$2251	\$4023	\$7244	

60-DAY RELEASE

Catalog	PRODUCE DESCRIPTION	Total Dose	PRICE/NUMBER OF PELLETS				
Number	PRODUCT DESCRIPTION	mg/pellet	25	50	100	200	
SHH-111	17ß-Estradiol (0.1) + Progesterone (10.0)	10.1	\$1203	\$2237	\$4020	\$7227	
SHH-112	17ß-Estradiol (0.5) + Progesterone (10.0)	10.5	\$1218	\$2267	\$4065	\$7302	
SHH-113	17ß-Estradiol (0.1) + Progesterone (32.5)	32.6	\$1233	\$2282	\$4095	\$7347	
SHH-114	17ß-Estradiol (0.5) + Progesterone (32.5)	33.0	\$1248	\$2312	\$4140	\$7422	
SHH-115	17ß-Estradiol (any size) + Progesterone (any size)	-	\$1298	\$2362	\$4240	\$7572	

90-DAY RELEASE

Catalog	PROPERT PERCENTAN	Total Dose	PRICE/NUMBER OF PELLETS				
Number	PRODUCT DESCRIPTION	mg/pellet	25	50	100	200	
NHH-111	17ß-Estradiol(0.1) + Progesterone (10.0)	10.1	\$1249	\$2274	\$4245	\$7585	
NHH-112	17ß-Estradiol(0.5) + Progesterone (10.0)	10.5	\$1264	\$2290	\$4279	\$7599	
NHH-113	17ß-Estradiol(0.1) + Progesterone (32.5)	32.6	\$1279	\$2326	\$4355	\$7725	
NHH-114	17ß-Estradiol(0.5) + Progesterone (32.5)	33.0	\$1294	\$2373	\$4379	\$7799	
NHH-115	17ß-Estradiol(any size) + Progesterone (any size)	-	\$1344	\$2415	\$4425	\$7825	

17ß-Estradiol + Hydrocortisone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRIC 25	CE/NUMB 50	ER OF PE 100	LLETS 200
HH-121	17ß-Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1113	\$2110	\$3803	\$6883
HH-122	17ß-Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1152	\$2196	\$3928	\$7094
HH-125	17ß-Estradiol (any size) + Hydrocortisone (any size)		\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLE 25 50 100 2			
SHH-121	17ß-Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1203	\$2237	\$4020	\$7227
SHH-122	17ß-Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1233	\$2282	\$4090	\$7347
SHH-125	17ß-Estradiol (any size) + Hydrocortisone (any size)	-	\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRIC 25	E/NUMB 50	ER OF PE 100	LLETS 200
NHH-121	17ß-Estradiol (2.5) + Hydrocortisone (2.5)	5.0	\$1249	\$2274	\$4245	\$7585
NHH-122	17ß-Estradiol (7.5) + Hydrocortisone (7.5)	15.0	\$1279	\$2326	\$4355	\$7725
NHH-125	17ß-Estradiol (any size) + Hydrocortisone (any size)	_	\$1344	\$2415	\$4425	\$7825

17ß-Estradiol + Progesterone + Hydrocortisone

Catalog	PRODUCT DESCRIPTION	Total Dose	PRICE/NUMBER OF PELLETS				
Number	21-DAY RELEASE	mg/pellet	25	50	100	200	
HH-141	17/3-Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1113	\$2140	\$3803	\$6883	
HH-142	17ß-Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1152	\$2196	\$3928	\$7094	
HH-145	17ß-Estradiol (any size) + Progesterone (any size) +Hydrocortisone (any size)	-	\$1192	\$2251	\$4023	\$7244	
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRIC 25	CE/NUMB 50	ER OF PE	LLETS 200	
SHH-141	17ß-Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1203	\$2237	\$4020	\$7227	
SHH-142	17ß-Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1233	\$2282	\$4090	\$7347	
SHH-145	7ß-Estradiol (any size) + Progesterone (any size) +Hydrocortisone (any size)	-	\$1298	\$2362	\$4240	\$7572	
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRIC 25	CE/NUMB 50	ER OF PE 100	LLETS 200	
NHH-141	17ß-Estradiol (0.1) + Progesterone (10.0) + Hydrocortisone (1.0)	11.1	\$1249	\$2274	\$4245	\$7585	
NHH-142	17ß-Estradiol (0.3) + Progesterone (30.0) + Hydrocortisone (3.0)	33.3	\$1279	\$2326	\$4355	\$7725	
NHH-145	17/6-Estradiol (any size) + Progesterone (any size) + Hydrocortisone (any size)	-	\$1344	\$2415	\$4425	\$7825	

Hydrocortisone + Progesterone


Catalog	PRODUCT DESCRIPTION	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS 25 50 100 200				
Number	21-DAY RELEASE	mg/penet	25	50	100	200	
HH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1113	\$2110	\$3803	\$6883	
HH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1152	\$2196	\$3928	\$7094	
HH-165	Hydrocortisone (any size) + Progesterone (any size)		\$1192	\$2251	\$4023	\$7244	
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRIC 25	E/NUMBI 50	ER OF PEI 100	LLETS 200	
SHH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1203	\$2237	\$4020	\$7227	
SHH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1233	\$2282	\$4090	\$7347	
SHH-165	Hydrocortisone (any size) + Progesterone (any size)		\$1298	\$2362	\$4240	\$7572	
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRIC 25	E/NUMBE 50	ER OF PEI 100	LETS 200	
NHH-161	Hydrocortisone (1.0) + Progesterone (10.0)	11.0	\$1249	\$2274	\$4245	\$7585	
NHH-162	Hydrocortisone (3.0) + Progesterone (30.0)	33.0	\$1279	\$2326	\$4355	\$7725	
NHH-165	Hydrocortisone (any size) + Progesterone (any size)	_	\$1344	\$2415	\$4425	\$7825	

17α-Ethynyl Estradiol + Norethindrone

Catalog	PRODUCT DESCRIPTION	Total Dose	PRIC	CE/NUMB	ER OF PE	LLETS
Number	21-DAY RELEASE	mg/pellet	25	50	100	200
HH-171	17α-Ethynyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1113	\$2110	\$3803	\$6883
HH-172	17α-Ethynyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1113	\$2111	\$3804	\$6884
HH-173	17α-Ethynyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1113	\$2112	\$3805	\$6885
HH-174	17α-Ethynyl Estradiol (0.2) + Norethindrone (30.0)	30,20	\$1152	\$2196	\$3928	\$7094
HH-175	17α-Ethynyl Estradiol (any size) + Norethindrone (any size)		\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRIC 25	E/NUMBI 50	ER OF PEI	LLETS 200
SHH-171	17α-Ethynyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1203	\$2237	\$4020	\$7227
SHH-172	17α-Ethynyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1233	\$2237	\$4020	\$7227
SHH-173	17α-Ethynyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1233	\$2237	\$4020	\$7227
SHH-174	17α-Ethynyl Estradiol (0.2) + Norethindrone (30.0)	30.20	\$1233	\$2282	\$4290	\$7347
SHH-175	17α-Ethynyl Estradiol (any size) + Norethindrone (any size)	-	\$1298	\$2362	\$4450	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRIC 25	E/NUMB 50	ER OF PE 100	LLETS 200
NHH-171	17α-Ethynyl Estradiol (0.02) + Norethindrone (1.0)	1.02	\$1249	\$2274	\$4245	\$7585
VHH-172	17α-Ethynyl Estradiol (0.03) + Norethindrone (1.5)	1.53	\$1249	\$2274	\$4245	\$7585
VHH-173	17α-Ethynyl Estradiol (0.2) + Norethindrone (10.0)	10.20	\$1249	\$2274	\$4245	\$7585
NHH-174	17α-Ethynyl Estradiol (0.2) + Norethindrone (30.0)	30.20	\$1279	\$2326	\$4355	\$7725
NHH-175	17α-Ethynyl Estradiol (any size) + Norethindrone (any size)	-	\$1344	\$2415	\$4425	\$7825

Mestranol + Norethindrone

Catalog Number	PRODUCT DESCRIPTION 21-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS 25 50 100 200			
HH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1113	\$2110	\$3803	\$6883
HH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1113	\$2110	\$3803	\$6883
HH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1152	\$2196	\$3928	\$7094
HH-185	Mestranol (any size) + Norethindrone (any size)		\$1192	\$2251	\$4023	\$7244
Catalog Number	60-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS 25 50 100 200			
SHH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1203	\$2237	\$4020	\$7227
SHH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1203	\$2237	\$4020	\$7227
SHH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1233	\$2282	\$4095	\$7347
SHH-185	Mestranol (any size) + Norethindrone (any size)		\$1298	\$2362	\$4240	\$7572
Catalog Number	90-DAY RELEASE	Total Dose mg/pellet	PRICE/NUMBER OF PELLETS 25 50 100 200			
NHH-181	Mestranol (0.03) + Norethindrone (1.0)	1.03	\$1249	\$2274	\$4245	\$7585
NHH-182	Mestranol (0.1) + Norethindrone (4.0)	4.10	\$1249	\$2274	\$4245	\$7585
NHH-183	Mestranol (0.5) + Norethindrone (20.0)	20.50	\$1279	\$2326	\$4355	\$7725
NHH-185	Mestranol (any size) + Norethindrone (any size)		\$1344	\$2415	\$4425	\$7825



CUSTOM PELLETS

The Closest Thing Yet To An Ideal Drug Delivery Method

In addition to the listed stock items on pages 21-42, Innovative Research of America provides scientists with an efficient and innovative Custom Pellets Department for products and sizes that are not carried in stock.

Our innovative process, tailored for any specific product, gives scientists time release pellets that consistently deliver the active product in vivo.

Custom pellets minimize the experimental variables, extend the product shelf life, and help avoid the "peak and valley" effects produced by conventional delivery methods.

The Alternative Solution

Whether the custom product is a small peptide or a large protein, a lymphokine or a cytokine, a growth factor or an antibody, an anti-hormone or an inhibitor, we have the proper technology that produces ready-to-implant custom pellets.

When supplied with your product and the required information on page 95, we will design the proper matrix with regard to dosage and release rate to provide you with the finished product in a ready-to-implant pellet form.

Each Custom order will include (25 Placebo Pellets) FREE of charge for each individual choice of dose.

We can also design time-release pellets in a variety of sizes, shapes and doses. Please inquire.

Use Time Release Pellets Or Take Your Chances





CUSTOM PELLETS PRICE LIST


RELEASE RATES

Number of Pellets	Up to 21 days Cat. No. X-999	Up to 60 days Cat. No. SX-999	Up to 90 days Cat. No. NX-999
25	\$1250	\$1425	\$1550
50	\$2125	\$2425	\$2600
100	\$3800	\$4200	\$4500
200	\$7100	\$7800	\$8400

^{*}Each Custom Order will include 25 Placebo Pellets Free of Charge.

These prices do not apply to 1/16" diameter, 3/32" diameter, rod shaped or special shaped pellets. See page 94 for small size custom pellets.

We can also design tools to make time-release pellets in any size, shape or dose. PLEASE INQUIRE.



We Put More Than Time In Our Pellets



Above Prices are for one product in one dose.

Prices for additional Placebo Pellets can be found on Pages 17-19.

SMALL SIZE CUSTOM PELLETS

1/16" (1.5 mm) diameter and 3/32" (2.25 mm) diameter.


In keeping with the innovative standards of our company, Innovative Research of America provides the scientific community with small size pellet services. These pellets are designed especially for experiments that have pellet size restrictions.

Small size pellets are available in two different sizes, 1/16" (1.5 mm) diameter and 3/32" (2.25 mm) diameter and can be prepared into any thickness and varying lengths of release time up to 90 days.

When ordering small size pellets, please indicate the size.

The minimum order of the small size preparation is 25 pellets.

Quantity	Cat. No.	Description	Release Rate	Price		
25 Y-999		One product in one dose	Up to 21 days	\$1300		
25	CY-999	Placebo for one product in one dose	Up to 21 days	\$1050		
25	SY-999	One product in one dose	Up to 60 days	\$1475		
25	SCY-999	Placebo for one product in one dose	Up to 60 days	\$1225		
25 NY-999 O		One product in one dose	Up to 90 days	\$1625		
25	NCY-999	Placebo for one product in one dose	Up to 90 days	\$1325		



We can also design tools to make time-release pellets in any size, shape or dose, *PLEASE INQUIRE*.



Go With The Pellet That Delivers

CUSTOM PELLETS INFORMATION FORM

In order to help us prepare the highest quality Custom Pellets that *precisely* meet your needs and specifications we require that you complete and submit a copy of this form with each order.

Please Attach Purchase Order Along With Shipping and Billing Addresses. Allow 4-6 weeks for delivery. PURCHASE ORDER NUMBER: INSTITUTION: INVESTIGATOR'S NAME: E-MAIL ADDRESS: FAX NUMBER: TELEPHONE NUMBER: COMPOUND NAME OR CODE NAME (no controlled substances accepted and should be clearly labeled for research purpose only) IS THE ABOVE COMPOUND A CONTROLLED SUBSTANCE? □NO ☐ YES □ NO IS THE ABOVE COMPOUND LABELED FOR RESEARCH PURPOSE ONLY? AMOUNT OF COMPOUND SHIPPED: CHEMICAL IDENTITY/MOLECULAR WEIGHT: INTRINSIC SOLUBILITY: WATER, ALCOHOL, LIPID:_____ HEAT, COLD, LIGHT SENSITIVITY:____ HALF-LIFE OF COMPOUND IN ANIMAL: DESIRED BLOOD LEVELS :____ REQUIRED PELLET RELEASE TIME & DOSE PER PELLET: NUMBER OF PELLETS REQUESTED: ANIMAL: GENDER, AVERAGE WEIGHT, AGE: TOXICITY: It is the responsibility of the investigator to provide all proteins, growth factors and peptides in a crystalline, powder or lyophilized form. IRA will be happy to provide, if necessary, a matrix stabilizer to increase the mass of the product. Due to residual loss in our multi-stage process, supply at least 50% more product than you request in pellet form. Please include your completed order

INNOVATIVE RESEARCH OF AMERICA CONTACT INFORMATION: 2 NORTH TAMIAMI TRAIL, SUITE 404

SARASOTA, FLORIDA 34236 USA

PHONE:

FAX:

INTERNET / E-MAIL:

(941) 365-1406

(941) 365-1703

http://www.innovrsrch.com pellets@innovrsrch.com

(941) 365-1506

(941) 365-1803

(800) 643-4345 (USA/Canada)

(800) 648-6030 (USA/Canada)

(800) 421-8171 (USA/Canada)

form with Custom Pellet information form.

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Acetyl-(LYSO, NLE3)-Y2-MSH AMIDE

Journal of Endocrinology, 191: 677-686 (2006)

Acetylsalicyclic Acid (ASA)

Cancer, 71 (2): 486-492 (1993)

Comparative Medicine, 55 (5): 452-458 (2001)

Adenine

Proceedings of the National Academy of Sciences (PNAS), 97 (12): 6716-6721 (1997)

Aldactone

Hypertension, 41 (2): 201-206 (2003)

Allodihydrocortisone

Molecular Endocrinology, 11 (7): 917-927 (1997)

Allopregnanolone

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 278 (3): R684-R691 (2000)

Amifostine

International Journal of Radiation Biology, 78 (6): 535-543 (2002)

Amphiregulin

Development, 132 (17): 3923-3933 (2005)

Anastrozole

Experimental Physiology, 98 (1): 161-171 (2013)

5\alpha-Androstan-3\alpha, 17\beta-diol

Molecular Endocrinology, 10 (4): 380-392 (1996)

Molecular Endocrinology, 11 (7): 917-927 (1997)

2, (5a)-Androsten-17B-ol

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

Angiotensin II

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 278 (3): R640-R645 (2000)

American Journal of Physiology: Renal Physiology, 277 (1): F41-F47 (1999)

Arteriosclerosis, Thrombosis and Vascular Biology, 25 (2): 365-371 (2005)

Circulation, 104 (3): 346-351 (2001)

EMBO Journal, 22 (24): 6471-6482 (2003)

Public Library of Science (PLoS ONE), 7 (4): e35632 (2012)

Anti-Viral

American Journal of Physiology: Endocrinology and Metabolism, 292 (1): E40-E48 (2007) (Indinavir)

Cancer Research, 65 (18): 8256-8265 (2005) (Nelfinavir)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (Amprenavir)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (Indinavir)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (Nelfinavir)

Journal of Nutrition, 130 (9): 2361-2366 (2000) (Saquinavir)

Seventh European Conference on Clinical Aspects and Treatment of HIV Infection, 31-34 (1999) (Indinavir)

Seventh European Conference on Clinical Aspects and Treatment of HIV Infection, 31-34 (1999) (Nelfinavir)

Arimidex

Molecular Endocrinology, 11 (7): 917-927 (1997)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Asoprisnil

Steroids, 74 (13-14): 1015-1024 (2009)

Atrazin

Basic and Clinical Pharmacology and Toxicology, 102: 139-145 (2008) Toxicology and Applied Pharmacology, 214 (1): 69-77 (2006)

Bazedoxifene

Clinical Cancer Research, 19 (9): 2420-2431 (2013)

Bisphenol A (BPA)

Biology of Reproduction, 85 (3): 490-497 (2011) Cancer Causes and Control, 20 (7): 1029-1037 (2009) Dissertation, 1-214 (2008) International Journal of Andrology, 33 (2): 385-393 (2010)

Molecular Cancer Therapeutics, 5 (12): 3181-3190 (2006) Public Library of Science (PLoS) Genetics, 3 (1): e5 (2007)

Reproductive Toxicology, 24 (2): 240-252 (2007)

Brilliant Blue G (BBG)

Journal of Neuroscience, 27 (35): 9525-9535 (2007)

Calimycin

Prostate, 13 (1): 103-117 (1988)

Camostat Mesilate (CM)

American Journal of Physiology; Renal Physiology, 303 (8): F1126-F1135 (2012) American Journal of Physiology; Renal Physiology, 305 (2): F174-F181 (2013)

Carvedilol

American Journal of Physiology: Heart and Circulatory Physiology, 287 (3): H1003-H1012 (2004)

Casodex (Bicalutamide)

Endocrinology, 154 (9): 3168-3177 (2013)

Proceedings of the National Academy of Sciences (PNAS), 108 (12): 4938-4943 (2011)

CDB-4124

Cancer Prevention Research, 4 (3): 414-424 (2011)

Cholera Toxin

Carcinogenesis, 9 (7): 1113-1119 (1988)

Clordecone

Environmental Health Perspectives, 113: 323-328 (2005) Toxicology, 218 (2): 81-89 (2006)

Compound A (CpdA)

Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012)

Cortisol Hemisuccinate

Placenta, 31: 1064-1069 (2010)

CP-113,818

Chembiochem, 10 (8): 1344-1347 (2009) Neuron, 44 (2): 227-238 (2004)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

CRE (CRE-decoy)

Proceedings of the National Academy of Sciences (PNAS), 99 (24): 15626-15631 (2002)

Cyclosporin A

Behavioural Brain Research, 104 (1-2): 179-187 (1999)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

3, 5-Diiodothyropropionic Acid (DITPA)

American Journal of Physiology: Heart and Circulatory Physiology, 296: H1551-H1557 (2007)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 294: R1504-R1509 (2008)

Canadian Journal of Physiology and Pharmacology, 85 (3-4): 311-318 (2007)

Journal of Physiology and Pharmacology, 85: 311-318 (2004)

Dihydroprogesterone

Brain Research, 766 (1-2): 19-28 (1997)

European Journal of Neuroscience, 16 (9): 1731-1740 (2002)

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

Molecular Endocrinology, 11 (7): 917-927 (1997)

5ß-Dihydroprogesterone (5ß-DHP)

American Journal of Obstetrics and Gynccology, 192 (4): 1304-1315 (2005)

Dizolcipine Maleate (MK-801)

Journal of Pharmacology and Experimental Therapeutics, 311 (1): 8-13 (2004)

DPN

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011) Biology of Sex Differences, 3 (1): 24 (2012) Clinical Cancer Research, 18 (16): 4385-4396 (2012) FASEB Journal, 26 (10): 3993-4002 (2012)

Epiandrosterone

Molecular Endocrinology, 11 (7): 917-927 (1997)

ERB-041

Steroids, 74 (13-14): 1015-1024 (2009)

178-Estradiol 3-Sulfate

Anticancer Research, 32 (7): 2769-2782 (2012)

4-Estren-30, 17B-diol

Endocrinology, 147 (4): 1986-1996 (2006)

Journal of Clinical Investigation, 111 (11): 1651-1664 (2003)

Journal of Clinical Investigation, 116 (9): 2500-2509 (2006)

Journal of Immunology, 171 (12): 6936-6940 (2003)

Journal of Neuroimmunology, 149 (1): 84-89 (2004)

Journal of Neuroscience Research, 77 (1): 119-126 (2004)

Neurology, 52 (6): 1230-1238 (1999)

Proceedings of the National Academy of Sciences (PNAS), 91 (12): 5382-5386 (1994)

Science, 298 (5594): 843-846 (2002)

ETA Receptor Antagonist

Circulation, 95 (7): 1918-1929 (1997)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Fadrozole

International Journal of Parasitology, 32 (11): 1379-1387 (2002) Journal of Comparative Neurology, 475 (1): 83-94 (2004) Journal of Neurobiology, 54 (2): 370-379 (2003)

Fluorescein Isothiocyanate (FITC) - Inulin

Kidney International, 71 (3): 266-271 (2007)

Fluoxetine

Biological Psychiatry, 64 (8): 691-700 (2008)

Dissertation, 1-264 (2013)

European Journal of Neuroscience, 37 (2): 242-250 (2013)

Journal of Clinical Endocrinology and Metabolism, 95 (2): 1-10 (2010)

Journal of Endocrinology, 209 (1): 45-54 (2011)

Journal of Neuroscience, 29 (37): 11451-11460 (2009)

Molecular Brain, 4: 10 (2011)

Nature Neuroscience, 13 (6): 745-754 (2010)

Neuropsychopharmacology, 38 (6): 909-920 (2013)

G-1

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011)
Journal of Molecular Endocrinology, 51 (1): 191-202 (2013)

Public Library of Science (PLoS ONE), 7 (9): e43215 (2012)

GABA (Aminobutyric Acid)

Journal of Immunology, 173 (8): 5298-5304 (2004) Journal of Neuroimmunology, 96 (1): 21-28 (1999)

Gangliosides

Circulatory Shock, 44 (1): 57-62 (1995)

Galardin

Molecular Cancer Therapeutics, 7 (9): 2758-2767 (2008)

Glucosamine

Biology of Reproduction, 89 (1): 16 (2013)

Glucose

Journal of Perinatal Medicine, 29 (6): 476-485 (2001)

Growth Factors and Peptides

Aging: Immunology and Infectious Disease, 3 (1): 19-26 (1991) (Ovine GH)

American Journal of Physiology: Endocrinology and Metabolism, 279 (2): E314-E322 (2000) (Ovine GH)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 298: R824-R832 (2010) (VEGF)

American Journal of Physiology: Renal Physiology, 283 (6): F1296-F1303 (2002) (S3226)

American Journal of Clinical Nutrition, 83 (Supplement): S470-S474 (2006) (IL-1B)

American Society for Nutritional Sciences, 130 (9): 2361-2366 (2000) (Protease Inhibitor)

Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, (Chapter 2): 1-160 (2000) (Neuropeptide Y (NPY))

Annals of New York Academy of Sciences, 638: 306-315 (1991) (bFGF)

Annals of Surgery, 2: 1-9 (1995) (TGF-61)

Annals of Surgery, 222 (2): 146-154 (1995) (TGF-B1)

Anticancer Research, 8: 1233-1240 (1988) (IL-18)

Aquaculture Research, 35: 278-288 (2004) (GnRH)

Arteriosclerosis, Thrombosis and Vascular Biology, 23: 1204-1210 (2003) (Neuropeptide Y (NPY))

Arteriosclerosis, Thrombosis and Vascular Biology, 25 (10): e20275-e2080 (2005) (Neuropeptide Y (NPY))

Brain Research, 933: 130-138 (2002) (VIP)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

```
Growth Factors and Peptides (cont.)
Cancer Cell, 9 (1): 23-32 (2006) (Prolactin)
Cancer Letters, 187 (1): 129-133 (2002) (VEGF)
Cancer Medicine, 1 (2): 275-288 (2012) (IGF-1)
Cancer Research, 56: 3540-3545 (1996) (VEGF)
Cancer Research, 57: 765-772 (1997) (VEGF).
Cancer Research, 65 (5): 1719-1728 (2005) (Neuropeptide Y (NPY))
Carcinogenesis, 21: 113-116 (2000) (FTI-276)
Cardiovascular Research, 3 (52): 468-476 (2001) (Endothelin-1)
Cell Tissue Research, 300: 89-95 (2000) (TGF-83)
Circulation, 95: 1918-1929 (1997) (Endothelin-1) (ETA Receptor Antagonist)
Dissertation, 1-138 (2010) (IGF-1)
Endocrinology, 131 (4): 1657-1664 (1992) (TGFα)
Endocrinology, 147 (11): 5400-5411 (2006) (Prolactin)
Endocrine Reviews, 11 (4): 578-610 (1990) (Rat GH)
European Molecular Biology Organization, 18: 363-374 (1999) (VEGF)
Experimental Biology and Medicine, 235 (10): 1179-1184 (2010) (Neuropeptide Y (NPY))
Experimental Lung Research, 8 (26): 773-790 (2000) (FTI-276)
Experimental Neurology, 163: 388-391 (2000) (IL-1B)
FASEB Journal, 13 (2): 325-329 (1999) (bFGF)
FASEB Journal, 27 (6): 2244-2255 (2013) (Neuropeptide Y (NPY))
General and Comparative Endocrinology, 113: 146-154 (1999) (VIP)
Human Reproduction, 17 (2): 457-462 (2002) (IGF-1)
International Journal of Oncology, 20: 813-818 (2002) (hPRL-G129R - Prolactin)
Investigative Ophthalmology and Visual Sciences, 53 (1): 68-75 (2012) (IGF-1)
In Vitro Cellular and Developmental Biology - Animal, 36 (10): 657-666 (2000) (FSH)
In Vivo, 19: 667-674 (2005) (IGF-1)
Journal of American Association for Pediatric Ophthalmology and Strabismus, 10 (5): 424-429 (2006) (IGF-1)
Journal of Applied Physiology, 85 (2): 716-722 (1998) (BMP)
Journal of Bone and Mineral Research, 26 (12): 2886-2898 (2011) (rCart Peptide (55-102))
Journal of Clinical Investigation, 99 (11): 2625-2634 (1997) (VEGF)
Journal of Clinical Investigation, 103 (2): 271-279 (1999) (TRH)
Journal of Clinical Investigation, 110 (4): 453-462 (2002) (IgG)
Journal of Clinical Investigation, 111 (12): 1853-1862 (2003) (Neuropeptide Y (NPY))
Journal of Endocrinology, 160: 217-222 (1999) (GHRH)
Journal of Endocrinology, 161: 77-87 (1999) (Rat GH)
Journal of Endocrinology, 169: 389-396 (2001) (GHRH)
Journal of Medicinal Chemistry, 51 (15): 4632-4640 (2008) (VEGF)
Journal of Neurobiology, 34: 164-178 (1998) (NGF)
Journal of Neuroinflammation, 8: 175 (2011) (IL-1B)
Journal of Neuroscience, 20 (1): 149-155 (2000) (IL-18)
Journal of Neuroscience, 21 (2): 363-371 (2001) (NGF)
Journal of Neurosurgery, 80: 484-490 (1994) (IL-18)
Journal of Nutrition, 134 (9): 2482-2486 (2004) (IGF-1)
Journal of Pediatric Surgery, 30 (2): 198-203 (1995) (TGF-61)
Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012) (Rat GH)
Journal of Surgical Research, 43: 322-328 (1987) (EGF)
Laboratory Investigation, 61 (5): 571-575 (1989) (bFGF) (IgG) (Anti-FGF)
Molecular and Cellular Biochemistry, 333 (1-2): 27-32 (2010) (Neuropeptide Y (NPY))
Molecular Cancer Therapy, 2: 1243-1255 (2003) (GIP)
Nature, 13: 803-811 (2007) (Neuropeptide Y (NPY))
Neurobiology of Aging, 32 (8): 1420-1434 (2011) (Peptide 6)
Neurochemistry International, 39 (5-6): 341-348 (2001) (IL-1B)
Oncogene, 22 (40): 6257-6265 (2003) (FTI -276)
Opthalmic Research, 19: 82-94 (1987) (Prolactin)
Pancreas, 26 (4): 392-397 (2003) (NGF) (VEGF)
```

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Growth Factors and Peptides (cont.)

Peptides, 24 (1): 99-106 (2003) (Neuropeptide Y (NPY))

Peptides, 28 (2): 435-440 (2007) (Neuropeptide Y (NPY))

Pharmacology and Toxicology, 84: 34-40 (1999) (FGF) (VEGF)

Physiological Research, 52: 743-748 (2003) (VEGF)

Plastic Reconstructive Surgery, 123 (2): 486-492 (2009) (Neuropeptide Y (NPY))

Proceedings of the National Academy of Sciences (PNAS), 82 (21): 7340-7344 (1985) (EGF)

Proceedings of the National Academy of Sciences (PNAS), 88 (1): 21-25 (1991) (EGF)

Proceedings of the National Academy of Sciences (PNAS), 89 (10): 4658-4662 (1992) (EGF)

Proceedings of the National Academy of Sciences (PNAS), 93 (22): 12626-12630 (1996) (EGF)

Proceedings of the National Academy of Sciences (PNAS), 95 (12); 7727-7730 (1998) (LIF)

Proceedings of the National Academy of Sciences (PNAS), 97 (23): 12782-12787 (2000) (bFGF)

Transplantation Proceedings, 22 (2): 824-829 (1990) (EGF)

Transplantation Proceedings, 36 (4): 1178-1180 (2004) (VEGF)

Transplantation Proceedings, 40 (2): 452-454 (2008) (VEGF) (NGF)

Wound Repair and Regeneration, 5 (1): 77-88 (1997) (bFGF)

GW7604

Steroids, 74 (13-14): 1015-1024 (2009)

Heparin

American Journal of Pathology, 127 (3): 592-604 (1987)

Angiogenesis, 61: 381-385 (1992)

Comparative Medicine, 55 (5): 452-458 (1988)

Journal of Burn Care and Research, 19 (2): 95-101 (1998)

Science, 221 (4612): 719-726 (1983)

Transplantation Proceedings, 22 (2): 824-829 (1990)

Hexarelin

Growth Hormone and IGF Research, 20 (1): 49-54 (2009)

HS-142-1

Journal of Clinical Investigation, 94 (5): 1938-1946 (1994)

4-Hydroxyandrostene-3,17-dione (4-OHA)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 280 (3): R904-R907 (2001)

4-Hydroxyandrostenedione

Molecular Endocrinology, 11 (7): 917-927 (1997)

16α-Hydroxyestrone (16α-OHE1)

Bone, 33 (1): 124-131 (2003)

Journal of Endocrinology, 170 (1): 165-174 (2001)

4-Hydroxytamoxifen

Blood, 108 (7): 2416-2419 (2006)

Cancer Research, 56: 4315-4319 (1996)

Cancer Research, 58: 1779-1784 (1998)

Cancer Research, 60: 5803-5814 (2000)

Cancer Research, 60: 7094-7098 (2000)

Cell, 148 (4): 651-663 (2012)

Cell Proliferation, 4 (34): 223 (2001)

Journal of Cellular and Molecular Medicine, 17 (8): 936-957 (2013)

Journal of Steroid Biochemistry, 30 (16): 311-314 (1988)

Korean Journal of Laboratory Medicine, 24: 339-346 (2004)

Korean Journal of Laboratory Medicine, 25: 205-211 (2005)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

4-Hydroxytamoxifen (cont.)

Nature, 469: 102-106 (2011)

Open Cancer Journal, 3: 89-100 (2010)

Proceedings of the National Academy of Sciences (PNAS), 103 (24); 9232-9237 (2006)

ICI-182,780

American Journal of Obstetrics and Gynecology, 184 (3): 303-308 (2001)

Dissertation, 1-77 (2010)

Endocrinology, 144 (3): 785-795 (2003)

Molecular and Cellular Endocrinology, 292 (1-2): 50-62 (2008)

Molecular Endocrinology, 22 (3): 665-675 (2008)

Nature Medicine, 9 (8): 1081-1084 (2003)

Nature Medicine, 11 (2): 153-159 (2005)

Oncogene, 21 (25): 4000-4008 (2002)

Insulin

Biochemical Pharmacology, 36 (7): 1011-1016 (1987)

Canadian Journal of Physiology and Pharmacology, 80: 180-192 (2002)

Journal of Biological Chemistry, 268 (17): 12952-12957 (1993)

Journal of Neuroendocrinology, 9 (4): 307-316 (1997)

Journal of Experimental Medicine, 182 (3): 897-902 (1995)

IN-1130

American Journal of Physiology: Renal Physiology, 304 (5): F481-F490 (2013)

Isradipine

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812 (12): 1584-1590 (2011)

Biological Psychiatry, 65 (6): 518-526 (2009)

Disease Models and Mechanisms, 4 (5): 634-648 (2011)

Movement Disorders, 25 (1): s63-s70 (2010)

Nature, 447: 1081-1086 (2007)

Neurobiology of Disease, 41 (1): 67-70 (2010)

Keoxifene

Cancer Research, 50 (11): 3189-3192 (1990)

11-Ketotestosterone

Hormones and Behavior, 25 (3): 410-423 (1991)

Lactitol

Cellular Microbiology, 8 (7): 1086-1095 (2006)

Lazaroid

Laryngoscope, 110 (5): 727-738 (2000)

16α-LE2

Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)

Leptin

Cancer Research, 72 (6): 1416-1427 (2012)

Neuroendocrinology, 67: 29-36 (1998)

Public Library of Science (PLoS ONE), 4 (2): e4602 (2009)

Public Library of Science (PLoS ONE), 7 (3): e34090 (2012)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Letrozole

Dissertation, 1-191 (2011)

Fertility and Sterility, 99 (3): 889-896 (2013)

Frontiers in Zoology, 10 (1): 8 (2013)

Leuprolide Acetate

Brain Research, 1466: 137-145 (2012)

Lipopolysaccharide (LPS)

Bone, 38 (3): 378-386 (2006)

Cardiovascular Pathology, 18 (1): 1-10 (2009)

Current Eye Research, 34 (6): 476-484 (2009)

Dissertation, 1-98 (2012)

Dissertation, 1-109 (2012)

Inflammation Research, 60 (7): 665-672 (2011)

Journal of Biomedical Materials Research (Part A), 100 (4): 918-928 (2012)

Journal of Immunology, 186: 5367-5375 (2011)

Journal of Nutritional Biochemistry, 21: 968-974 (2010)

Nutrition Research, 29 (7): 437-456 (2009)

Osteoporosis International, 21: 1841-1852 (2010)

Luteinizing Hormone (LH)

Neuroendocrinology, 94 (4): 313-322 (2011)

LY3201

Molecular Psychiatry, 18 (6): 674-680 (2013)

Proceedings of the National Academy of Sciences (PNAS), 109 (5): 1708-1712 (2012)

Proceedings of the National Academy of Sciences (PNAS), 110 (9): 3543-3548 (2013)

Manumycin

Biochemical Journal, 391 (1): 59-67 (2005)

Journal of Clinical Endocrinology and Metabolism, 86 (4): 1769-1777 (2000)

2-Methoxyestradiol

Clinical Immunology, 140 (1): 37-46 (2011)

Dissertation, 1-42 (2010)

Endocrine Journal, 54 (6): 1027-1031 (2007)

1-Methyl-DL-Tryptophan (I-MT)

Allergy, 64: 488-492 (2009)

American Journal of Respiratory Cell and Molecular Biology, 30 (3): 311-318 (2004)

American Journal of Transplantation, 12 (3): 610-619 (2012)

Arthritis and Rheumatism, 60 (5): 1342-1351 (2009)

Arthritis Research and Therapy, 9 (3): R50 (2007)

Blood, 106 (7): 2382-2390 (2005)

Blood, 110 (3): 1064-1072 (2007)

Cancer Research, 67 (2): 792-801 (2007)

Cellular and Molecular Immunology, 8: 31-40 (2011)

Cytokine, 34: 233-242 (2006)

Diabetes, 56: 1686-1693 (2007)

Dissertation, 1-140 (2011)

European Journal of Immunology, 35 (11): 3111-3118 (2005)

European Journal of Immunology, 36 (3): 690-700 (2006)

European Journal of Immunology, 39 (6): 1552-1563 (2009)

Gastroenterology, 125 (6): 1762-1773 (2003)

Gut, 59 (5): 595-604 (2010)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

1-Methyl-DL-Tryptophan (1-MT) (cont.) International Journal of Cancer, 101 (2): 151-155 (2002) Journal of Alzheimer's Disease, 28 (4): 905-915 (2012)

Journal of Clinical Investigation, 114 (2): 270-279 (2004)

Journal of Experimental Therapeutics and Oncology, 3 (6): 336-345 (2003)

Journal of Immunology, 171 (4): 1652-1655 (2003)

Journal of Immunology, 176: 6752-6761 (2006)

Journal of Immunology, 182: 3202-3212 (2009)

Journal of Immunology, 183: 6303-6312 (2009)

Journal of Immunology, 189 (1): 72-79 (2012)

Journal of Immunology, 191 (4): 1965-1975 (2013)

Journal of Infectious Diseases, 193 (2): 214-222 (2006) Journal of Neuroimmunology, 129 (1): 186-196 (2002)

Journal of Reproductive Immunology, 61 (2): 67-77 (2004)

Journal of Virology, 80 (1): 270-280 (2006)

Nature Immunology, 2 (1): 64-68 (2001) Nature Immunology, 3 (11): 1097-1101 (2002)

Nature Immunology, 4 (12): 1206-1212 (2003)

Nature Medicine, 10 (10): 1088-1094 (2004)

Nature Medicine, 11 (4): 312-319 (2005)

Nature Medicine, 13 (5): 579-586 (2007)

Oncogene, 27 (20): 2851-2857 (2008)

Science, 281 (5380): 1191-1193 (1998)

Transplant Immunology, 17 (1): 58-60 (2006)

Transplant Immunology, 22 (3-4): 172-178 (2010)

Transplantation, 83 (5): 663-667 (2007)

1-Methyl-D-Tryptophan

Immunity, 22: 633-642 (2005)

Journal of Clinical Investigation, 117 (9): 2570-2582 (2007)

Journal of Immunology, 183: 2475-2483 (2009)

1-Methyl-L-Tryptophan

Gastroenterology, 145 (2): 416-425 (2013)

Mifepristone (RU-486)

Alzheimer's and Dementia, 6 (4): S565 (2010)

American Journal of Physiology: Endocrinology and Metabolism, 256 (5): E682-E685 (1989)

American Journal of Physiology: Lung Cellular and Molecular Physiology, 281 (5): L1150-L1156 (2001)

American Journal of Physiology: Lung Cellular and Molecular Physiology, 284 (1): L197-L204 (2003)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 270 (1): R199-R206 (1996) American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 296 (5): R1445-R1454 (2009)

Audiology and Neurotology, 14 (6): 423-431 (2009)

Brain, Behavior and Immunity, 19 (5): 413-422 (2005)

Brain, Behavior and Immunity, 25 (2): 340-348 (2011)

Cancer Prevention Research, 5 (5): 754-764 (2012)

Cancer Research, 67 (20): 9929-9936 (2007)

Clinical Cancer Research, 12: 4062-4071 (2006)

Contraception, 58 (1): 45-50 (1998)

Endocrine-Related Cancer, 19 (3): R35-R50 (2012)

Endocrinology, 141 (12): 4698-4710 (2000)

Endocrinology, 146 (10): 4340-4348 (2005)

Endocrinology, 151 (6): 2433-2442 (2010)

Fertility and Sterility, 82 (2): 430-436 (2004)

Genesis, 48 (10): 585-595 (2010)

International Immunology, 9 (1): 105-115 (1997)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Mifepristone (RU-486) (cont.)

Journal of Biological Chemistry, 273 (43): 27904-27910 (1998)

Journal of Experimental Medicine, 171 (4): 979-996 (1990)

Journal of Experimental Medicine, 181 (3): 901-914 (1995)

Journal of Molecular and Cellular Cardiology, 38 (4): 685-691 (2005)

Journal of Molecular Medicine, 87 (7): 703-712 (2009)

Journal of Neuroscience, 32 (22): 7563-7571 (2012)

Journal of Orthopaedic Research, 30 (2): 288-295 (2012)

Journal of the American College of Cardiology, 44 (11): 2221-2230 (2004)

Molecular and Cellular Biology, 30 (12): 3111-3125 (2010)

Molecular Endocrinology, 14 (7): 1075-1085 (2000)

Molecular Endocrinology, 18 (9): 2196-2207 (2004)

Neurobiology of Disease, 45 (1): 539-546 (2012)

Proceedings of the National Academy of Sciences (PNAS), 98 (10): 5898-5903 (2001)

Proceedings of the National Academy of Sciences (PNAS), 99 (17): 11187-11192 (2002)

Proceedings of the National Academy of Sciences (PNAS), 100 (5): 2951-2956 (2003)

Proceedings of the National Academy of Sciences (PNAS), 102 (39): 13789-13794 (2005)

Science, 314: 1467 (2006)

Steroids, 74 (13-14): 1015-1024 (2009)

Surgery, 125 (6): 594-601 (1999)

Surgery, 127 (6): 687-695 (2000)

MK-434

American Journal of Physiology: Endocrinology and Metabolism, 293: 507-514 (2007)

MNTDE

Journal of Immunology, 178: 908-917 (1997)

NBI-27914

Proceedings of the National Academy of Sciences (PNAS), 103 (9): 3462-3467 (2006)

Nedocromil Sodium

American Journal of Physiology: Heart and Circulatory Physiology, 287 (5): H2295-H2299 (2004)

American Journal of Physiology: Heart and Circulatory Physiology, 302 (3): H811-H817 (2012)

Hypertension, 53 (6): 1041-1047 (2009)

Inflammation Research, 55 (10): 408-415 (2006)

Journal of Cardiac Failure, 11 (7): 548-556 (2005)

Journal of Molecular and Cellular Cardiology, 49 (2): 245-250 (2010)

Public Library of Science (PLoS ONE), 8 (3): e60827 (2013)

Nimodipine

Acta Neurochirurgica Supplementum, 104 (4): 103-107 (2008)

American Journal of Physiology: Heart and Circulatory Physiology, 258 (5): H1395-H1401 (1990)

Archives of Facial Plastic Surgery, 12 (1): 49-52 (2010)

Behavioral Brain Research, 98 (1): 95-101 (1998)

Brain Research Bulletin, 39 (5): 311-316 (1996)

European Journal of Neuroscience, 31 (3): 478-490 (2010)

Experimental Brain Research, 117 (1): 111-119 (1997)

Hearing Research, 121 (1-2): 139-146 (1998)

Journal of Neuroscience Methods, 68 (2): 297-301 (1996)

Military Medicine, 166 (12): 74-75 (2001)

Molecular Brain Research, 110 (2): 193-202 (2003)

Nature Neuroscience, 9 (2): 251-259 (2006)

Neurobiology of Aging, 17 (3): 453-457 (1996)

Neurological Research, 24 (8): 775-780 (2002)

Neuroradiology, 49 (2): 129-137 (2007)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Nimodipine (cont.)

Pharmacology, Biochemistry and Behavior, 39 (3): 781-786 (1991) Pharmacology, Biochemistry and Behavior, 44: 827-835 (1993)

Nitrosobis-(2oxopropyl)-amine (BOP)

Chemico-Biological Interactions, 66 (1-2): 111-119 (1988)

Nomegesterol

Fertility and Sterility, 78 (5): 973-978 (2002)

Noradrenaline (NA)

International Journal of Neuroscience, 62 (1-2): 123-140 (1992)

Norethisterone Acetate

Dissertation, I-121 (2005)

Journal of Bone and Mineral Research, 8 (2): 219-230 (1993)

NS-398

Microbes and Infection, 8 (2): 478-486 (2006)

Oxandrolone

Experimental Eye Research, 51 (6): 659-666 (1995)

Journal of Steroid Biochemistry and Molecular Biology, 60 (3-4): 237-245 (1997)

PD123319

Public Library of Science (PLoS ONE), 7 (4): e35632 (2012)

PDFG-BB

FASEB Journal, 13: 325-329 (2003)

Pesticides and Related Products

United States Geological Society (USGS), The Society of Environmental Toxicology and Chemistry (SETAC) meeting, November, (2002) (DDE) (Dieldin)

United States Geological Society (USGS), Superfund Basic Research Program Annual Conference, November, (2002) (DDE) (Dieldin)

Phosphoramidon

Inflammation Research, 57 (7): 300-305 (2008)

PHTPP

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011)

PJ34

Cardiovascular Research, 78: 158-166 (1989)

Ponasterone A

American Journal of Physiology: Heart and Circulatory Physiology, 295: H543-H554 (2008)

Cancer Research, 68: 4588-4596 (2008)

FASEB Journal, 14: 877-884 (2004)

Molecular and Cellular Biology, 26 (14): 5449-5469 (2006)

Molecular and Cellular Biology, 26 (19): 7116-7129 (2006)

Proceedings of the National Academy of Sciences (PNAS), 104 (41): 16170-16175 (2007)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

PPT

American Journal of Respiratory and Critical Care Medicine, 184 (6): 715-723 (2011) Biology of Sex Differences, 3 (1): 24 (2012)

D-Propranolol

Canadian Journal of Physiology and Pharmacology, 90 (9): 1257-1268 (2012)

Ouercetin

Journal of Steroid Biochemistry and Molecular Biology, 46 (4): 489-495 (1993)

Raloxifene

Cancer Research, 63 (15): 4426-4433 (2003)
Carcinogenesis, 26 (6): 1109-1116 (2005)
Journal of Clinical Investigation, 111 (11): 1651-1664 (2003)
Medical Principles and Practices, 13: 220-226 (2004)
Molecular Endocrinology, 24 (4): 735-744 (2010)
Neuroscience, 121 (3): 659-666 (2003)
Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)
Steroids, 74 (13-14): 1015-1024 (2009)
Urology, 69 (6): 1221-1226 (2007)

Ranolazine

Circulation, 126 (18): 2208-2219 (2012)

Rapamycin

Aging, 5 (2): 111-119 (2013) American Journal of Pathology, 181 (1): 278-293 (2012) Cancer Prevention Research, 3 (12): 1542-1551 (2010) Journal of Cellular Physiology, 221 (3): 579-585 (2009) Kidney International, 76: 178-182 (2009)

50. Reductase Inhibitor (4MA)

Prostate, 10: 189-197 (1987)

Resveratrol

Journal of Nutrition, 136: 2542-2546 (2006) Journal of Surgical Research, 179 (1): E141-E148 (2013)

S3226

American Journal of Physiology: Renal Physiology, 283 (6): F1296-F1303 (2002)

Sildenafil Citrate

Experimental Biology and Medicine, 229: 920-925 (2004) International Journal of Impotence Research, 11 (1): S9-S14 (1999)

Synthroid

Cells, Tissues, and Organs, 173: 162-171 (2003)

Tacrolimus

Experimental Neurology, 248: 85-99 (2013)

Tamoxifen Methiodide

Dissertation, 1-89 (2003)

Innovative Research of America has provided customized pellets for many influential biomedical researchers and institutions worldwide. Following are samples of publications and testimonials which acknowledge the contributions of the MDDTM Pellet System.

PRODUCT/JOURNAL

Tamoxifen (N-Desmethyl)

Journal of Steroid Biochemistry, 30 (16): 311-314 (1988)

Tetrodotoxin (TTX)

Journal of Cell Biology, 127 (5): 1435-1445 (1994)

Thalidomide

Molecular and Cellular Biochemistry, 129: 195-200 (1993)

Thrombin Inhibitor

Clinical Explanation Metastasis, 4 (3): 205-220 (1996)

Thyrotropin-Releasing Hormone (TRH)

Alcohol, 13 (6): 559-567 (1996)

Journal of Biological Chemistry, 281 (8): 5000-5007 (2006)

Journal of Clinical Investigation, 103 (2): 271-279 (1999)

Toremifene Citrate

Cancer Research, 62: 1370-1376 (2002)

Vitamin D3 Analog (EB1089)

Endocrinology, 139 (4): 2102-2110 (1998)

Journal of Dairy Science, 73 (2): 406-412 (1990)

Journal of Steroid Biochemistry and Molecular Biology, 84 (2): 181-192 (2003)

ZK-810630

Immunology Letters, 76 (3): 193-201 (2001)

Journal of Clinical Investigation, 114 (2): 270-279 (2004)

Journal of Experimental Therapeutics and Oncology, 3 (6): 336-345 (2003)

Journal of Immunology, 171 (4): 1652-1655 (2003)

Journal of Neuroimmunology, 129 (1): 186-196 (2002)

Journal of Reproductive Immunology, 61 (2): 67-77 (2004)

Journal of Virology, 80 (1): 270-280 (2006)

Nature Immunology, 2 (1): 64-68 (2001)

Nature Immunology, 3 (11): 1097-1101 (2002)


Nature Immunology, 4 (12): 1206-1212 (2003)

Nature Medicine, 10 (10): 1088-1094 (2004)

Nature Medicine, 11 (4): 312-319 (2005)

Science, 281 (5380): 1191-1193 (1998)

CONSISTENCY IS IMPORTANT



TIMING IS EVERYTHING

In this section are references found in the years 2012 through 2013 citing the use of our innovative technology. To view all references and new entries on a daily basis, a complete list of publications can be found at our website: www.innovrsrch.com



REFERENCES



With Reliable Results, We Deliver.





PRODUCT / JOURNALS

CURRENT AVAILABILITY

2-Acetamidofluorene (2-AAF) STOCK

Experimental and Molecular Pathology, 93 (1): 40-49 (2012) Public Library of Science (PLoS ONE), 7 (12): e51878 (2012)

STOCK d-Aldosterone

Journal of the Renin-Angiotensin-Aldosterone System, 13 (3): 353-359 (2012)

CUSTOM Anastrozole

Experimental Physiology, 98 (1): 161-171 (2013)

STOCK Androstenedione

Breast Cancer Research, 14 (5): R132 (2012)

CUSTOM Asoprisnil Steroids, 74 (13-14): 1015-1024 (2009)

STOCK 5-Azacytidine

Molecular and Cellular Biology, 33 (19): 3920-3935 (2013)

CUSTOM Bazedoxifene Clinical Cancer Research, 19 (9): 2420-2431 (2013)

STOCK Bromocriptine Mesylate

Diabetes, 62 (5): 1646-1655 (2013)

5-Bromo-2'-Deoxyuridine (BrDU) STOCK

Experimental Gerontology, 48 (9): 973-984 (2013) Journal of Clinical Investigation, 123 (8): 3409-3419 (2013)

Camostat Mesilate (CM) CUSTOM

American Journal of Physiology: Renal Physiology, 303 (8): F1126-F1135 (2012) American Journal of Physiology: Renal Physiology, 305 (2): F173-F181 (2013)

rCart Peptide (55-102) CUSTOM Journal of Bone and Mineral Research, 26 (12): 2886-2898 (2011)

Casodex (Bicalutamide) CUSTOM Endocrinology, 154 (9): 3168-3177 (2013)

CUSTOM Compound A (CpdA) Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012)

Corticosterone STOCK

American Journal of Hypertension, 16 (8): 685-688 (2003) Behavioral and Neural Biology, 60 (2): 103-109 (1993)

Behavioural Brain Research, 238: 170-177 (2013)

Brain Research Bulletin, 98: 10-22 (2013) British Journal of Pharmacology, 166 (8): 2417-2429 (2012)

Conservation Physiology, 1 (1): 1-12 (2013)

Dissertation, 1-223 (2001) Dissertation, 1-78 (2009)

Dissertation, 1-108 (2011) Dissertation, 1-79 (2013) Endocrinology, 154 (8): 2807-2820 (2013)

European Journal of Applied Physiology, 104 (5): 847-858 (2008)

Evolutionary Biology, 39 (3): 348-358 (2012)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Corticosterone (cont.)

General and Comparative Endocrinology, 178 (1): 139-144 (2012)

Hormones and Behavior, 64 (1): 161-171 (2013)

Journal of Applied Physiology, 108 (2): 298-305 (2010)

Journal of Avian Biology, 44 (4): 359-368 (2013)

Journal of Chemical Neuroanatomy, 48-49: 23-28 (2013)

Journal of Endocrinology, 219: 79-88 (2013)

Journal of Neuroimmunology, 100 (1-2): 243-251 (1999)

Neuropharmacology, 59 (6): 375-379 (2010)

Neuroscience, 190: 166-176 (2011)

Neuroscience, 222: 269-280 (2012)

Neuroscience Research, 51 (3): 319-327 (2005)

Neurotoxicology, 30 (6): 965-976 (2009)

Physiological and Biochemical Zoology, 81 (5): 641-650 (2008)

Physiology and Behavior, 75 (1): 207-215 (2002)

Prostate, 71 (3): 289-297 (2011)

Deoxycorticosterone Acetate (DOCA)

ACS Chemical Neuroscience, 4 (1): 141-148 (2013)

American Journal of Hypertension, 25 (4): 421-429 (2012)

American Journal of Hypertension, 25 (4): 479-486 (2012)

American Journal of Physiology: Heart and Circulatory Physiology, 302 (11): H2243-H2249 (2012)

American Journal of Physiology: Heart and Circulatory Physiology, 302 (11): H2428-H2438 (2012)

American Journal of Physiology: Renal Physiology, 303 (8): F1207-F1215 (2012)

Arteriosclerosis, Thrombosis, and Vascular Biology, 33 (7): 1568-1579 (2013)

Cardiovascular Research, 94 (3): 510-518 (2012)

Cardiovascular Research, 96 (1): 120-129 (2012)

Cardiovascular Research, 98 (1): 37-46 (2013)

Current Cardiology Reviews, 6 (4): 291-297 (2010)

Dissertation, 1-115 (2012)

Dissertation, 1-151 (2012)

European Journal of Anaesthesiology: Neurosciences, 30: 103-103 (2013)

European Journal of Clinical Investigation, 39 (2): 116-125 (2009)

European Journal of Physiology, 456 (6): 1207-1216 (2008)

Hypertension, 59 (1): 167-172 (2012)

Hypertension, 60 (5): 1184-1191 (2012)

Hypertension, 60 (5): 1207-1212 (2012)

Hypertension, 61 (2): 270-277 (2013)

Hypertension, 61 (3): 716-722 (2013)

Hypertension, 61 (3): 730-736 (2013)

Hypertension, 62 (2): 302-309 (2013)

Journal of Cerebral Blood Flow and Metabolism, 32 (2): 368-375 (2012)

Journal of Cerebral Blood Flow and Metabolism, 33 (4): 483-489 (2013)

Journal of Clinical Investigation, 123 (7): 2803-2815 (2013)

Journal of Hypertension, 27 (2): 376-385 (2009)

Journal of Molecular and Cellular Cardiology, 56: 44-54 (2013)

Journal of the American Society of Hypertension, 7 (1): 14-23 (2013)

Kidney International, 80 (1): 51-60 (2011)

Life Sciences, 91 (13-14): 587-592 (2012)

Molecular Medicine, 17 (11-12): 1204-1212 (2011)

Public Library of Science (PLoS ONE), 7 (10): e48150 (2012)

Public Library of Science (PLoS ONE), 8 (8): e72857 (2013)

Dexamethasone

Molecular Cancer Therapeutics, 11 (12): 2621-2632 (2012)

STOCK

STOCK

STOCK

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Diethylstilbestrol (DES)

Clinical Science, 123 (8): 509-518 (2012)

Proceedings of the National Academy of Sciences (PNAS), 109 (31): 12491-12496 (2012)

5α-Dihydrotestosterone (5α-DHT)

STOCK

STOCK

Acta Physiologica Hungarica, 99 (3): 279-288 (2012)

American Journal of Physiology: Heart and Circulatory Physiology, 301 (5): H1882-H1890 (2011)

American Journal of Physiology: Renal Physiology, 302 (9): F1203-F1209 (2012) American Journal of Physiology: Renal Physiology, 305 (5): F753-F763 (2013)

Arthritis & Rheumatism, 65 (9): 2392-2402 (2013) Behavioral Neuroscience, 127 (3): 400-414 (2013) Biological Psychiatry, 71 (7): 642-651 (2012) Biology of Sex Differences, 2 (1): 14 (2011)

Biomed Research International, Volume 2013 (Article ID 320249): 1-12 (2013)

Brain Research, 1429: 43-51 (2012)

Dissertation, 1-123 (2012) Dissertation, 1-265 (2012) Dissertation, 1-116 (2013) Endocrine, 6 (1): 39-45 (1997)

Experimental Eye Research, 96 (1): 88-97 (2012) Experimental Lung Research, 38 (4): 165-172 (2012)

Experimental Neurology, 181 (2): 301-312 (2003)

Experimental Physiology, 97 (5): 651-662 (2012)

Evidence-Based Complementary and Alternative Medicine, Volume 2013 (Article ID 964070): 1-13 (2013)

Fertility and Sterility, 99 (2): 573-578 (2012) Frontiers in Endocrinology, 2 (82): 1-15 (2011)

Hormone and Metabolic Research, 41 (5): 356-362 (2009)

International Journal of Andrology, 32 (4): 399-410 (2008)

Journal of Biological Chemistry, 288 (29): 20843-20855 (2013)

Journal of Cellular Biochemistry, 112 (12): 3638-3647 (2011)

Journal of Cerebral Blood Flow and Metabolism, 33: 1549-1555 (2013)

Journal of Endocrinology, 218 (2): 205-213 (2013) Journal of Neurobiology, 52 (3): 203-220 (2002)

Journal of Neuroscience, 32 (36): 12312-12324 (2012)

Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)

Journal of Steroid Biochemistry and Molecular Biology, 138: 100-106 (2013)

Journal of the American Heart Association, 2 (4): e271 (2013)

Life Sciences, 93 (4): 133-138 (2013) Menopause, 16 (3): 582-588 (2009)

Molecular Endocrinology, 27 (1): 25-37 (2013)

Molecular Therapy, 19 (11): 1999-2011 (2011)

Neuroendocrinology, 97 (3): 271-282 (2013)

Neuroscience, 122 (3): 573-578 (2003)

Pharmaceutical Reports, 65 (2): 476-483 (2013)

Public Library of Science (PLoS ONE), 8 (1): e54357 (2013)

Public Library of Science (PLoS ONE), 8 (3): e55589 (2013)

Translational Stroke Research, 4 (4): 447-461 (2013)

Doxycycline

DPN

STOCK

CUSTOM

Journal of Surgical Research, 158 (2): 300 (2010)

Biology of Sex Differences, 3 (1): 24 (2012)

Clinical Cancer Research, 18 (16): 4385-4396 (2012)

FASEB Journal, 26 (10): 3993-4002 (2012)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

ERB-041

CUSTOM

Steroids, 74 (13-14): 1015-1024 (2009)

17B-Estradiol

STOCK

ACS Nano, 5 (11): 9113-9121 (2011)

ACS Nano, 6 (5): 4530-4539 (2012)

Acta Medica Iranica, 50 (12): 789-797 (2012)

Acta Pharmacologica Sinica, 32 (11): 1402-1410 (2011)

Adipocyte, 2 (3): 165-169 (2013)

Age, 34 (4): 895-904 (2012)

American Journal of Obstetrics and Gynecology, 209 (1): 24.e1-24.e12 (2013)

American Journal of Pathology, 178 (6): 2450-2460 (2011)

American Journal of Pathology, 180 (3): 1189-1201 (2012)

American Journal of Pathology, 180 (6): 2536-2547 (2012)

American Journal of Pathology, 183 (1): 304-312 (2013)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (1): R159-R165 (2012)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (3): R331-R339 (2012)

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 303 (6): R651-R657 (2012)

American Journal of Respiratory Cell and Molecular Biology, 49 (1): 135-142 (2013)

Anti-Cancer Agents in Medicinal Chemistry, 13 (8): 1178-1187 (2013)

Asian Pacific Journal of Cancer Prevention, 14 (1): 63-68 (2013)

Asian Pacific Journal of Cancer Prevention, 14 (4): 2185-2190 (2013)

Autoimmunity, 45 (5): 364-376 (2012)

Autonomic Neuroscience, 153 (102): 84-89 (2010)

Basic Research in Cardiology, 105 (4): 479-486 (2010)

Basic Research in Cardiology, 106 (4): 563-575 (2011)

Biochemical and Biophysical Research Communications, 434 (4): 740-745 (2013)

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1501 (2): 125-137 (2000)

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1591 (13): 109-118 (2002)

Bioconjugate Chemistry, 12 (2): 213-219 (2001)

Bioconjugate Chemistry, 22 (11): 2304-2316 (2011)

Biological Research, 38 (2-3): 213-223 (2005)

Biological Trace Element Research, 93 (1): 155-169 (2003)

Biology of Reproduction, 86 (3): 68 (2012)

Biology of Sex Differences, 2 (1): 14 (2011)

Biology of Sex Differences, 3 (1): 24 (2012)

Blood, 120 (8): 1703-1712 (2012)

Brain Research, 937 (1-2): 58-65 (2002)

Brain Research, 1443: 64-74 (2012)

Brain Research, 1461: 76-86 (2012)

Brain Research, 1493: 90-98 (2013)

Brain Research, 1514: 107-122 (2013)

Brain Pathology, 23 (4): 462-475 (2013)

Breast Cancer Research, 15 (2): R21 (2013)

Breast Cancer Research, 15 (4): R55 (2013)

Breast Cancer Research, 15 (5): R87 (2013)

Breast Cancer Research and Treatment, 135 (3): 771-780 (2012)

British Journal of Cancer, 106 (6): 1117-1122 (2012)

British Journal of Cancer, 107 (1): 43-52 (2012)

British Journal of Cancer, 108 (11): 2291-2298 (2013)

Canadian Journal of Physiology and Pharmacology, 91 (10): 823-829 (2013)

Cancer Biology and Therapy, 6 (6): 936-941 (2007)

Cancer Biology and Therapy, 13 (11): 1026-1033 (2012)

Cancer Cell, 20 (3): 341-356 (2011)

Cancer Cell, 21 (3): 430-446 (2012)

Cancer Cell, 23 (6): 753-767 (2013)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

176-Estradiol (cont.)

Cancer Gene Therapy, 20 (5): 282-289 (2013)

Cancer Gene Therapy, 20 (8): 461-468 (2013)

Cancer Letters, 332 (1): 102-109 (2013)

Cancer Letters, 339 (2): 175-184 (2013)

Cancer Letters, 339 (2): 214-225 (2013)

Cancer Medicine, 1 (2): 105-113 (2012)

Cancer Prevention Research, 5 (8): 1053-1060 (2012)

Cancer Research, 72 (19): 5048-5059 (2012)

Cancer Research, 73 (4): 1420-1433 (2013)

Cancer Research, 73 (7): 2070-2081 (2013)

Cancer Research, 73 (13): 1-11 (2013)

Cancer Research, 73 (13): 5449-5458 (2013)

Cancer Research, 73 (15): 4697-4710 (2013)

Cancer Research, 73 (15): 4885-4897 (2013)

Cancer Science, 102 (11): 2038-2042 (2011)

Cancer Science, 103 (6): 1000-1009 (2012)

Carcinogenesis, 30 (9): 1581-1590 (2009)

Carcinogenesis, 34 (10): 2271-2280 (2013)

Cell Cycle, 8 (4): 2266-2280 (2009)

Cell Death and Disease, 4 (8): e757 (2013)

Cell Death and Disease, 4 (8): e758 (2013)

Cell Metabolism, 17 (1): 49-60 (2013)

Cell Reports, 3 (2): 342-349 (2013)

Cell Reports, 4 (6): 1116-1130 (2013)

Cell Stem Cell, 1 (5): 555-567 (2007)

Cerebral Cortex, 22 (8): 1799-1812 (2012)

Circulation, 126 (16): 1993-2004 (2012)

Clinical and Cellular Immunology, 4 (3): 143 (2013)

Clinical and Experimental Metastasis, 11 (1): 15-26 (1993)

Clinical and Experimental Metastasis, 29 (5): 493-509 (2012)

Clinical Cancer Research, 18 (15): 4059-4069 (2012)

Clinical Cancer Research, 18 (20): 5816-5828 (2012)

Clinical Cancer Research, 18 (21): 5911-5923 (2012)

Clinical Cancer Research, 19 (7): 1760-1772 (2013)

Clinical Cancer Research, 19 (9): 2420-2431 (2013)

Clinical Cancer Research, 19 (14): 3881-3893 (2013)

Clinical Cancer Research, 19 (19): 5390-5401 (2013)

Clinical Cancer Research, 19 (19): 5413-5422 (2013)

Clinical Immunology, 140 (1): 37-46 (2011)

Clinical Science, 123 (8): 509-518 (2012)

Development, 140 (5): 1079-1089 (2013)

Diabetes, 62 (2): 424-434 (2013)

Dissertation, 1-120 (2006)

Dissertation, 1-272 (2010)

Dissertation, 1-42 (2012)

Dissertation, 1-52 (2012)

Dissertation, 1-180 (2012)

Dissertation, 2-253 (2012)

Dissertation, 1-83 (2013)

Drug Development Research, 69 (8): 526-534 (2008)

Drug Metabolism and Disposition, 40 (9): 1785-1796 (2012)

Elife, 2: e00358 (2013)

EMBO Molecular Medicine, 5 (9): 1335-1350 (2013)

Endocrine - Related Cancer, 20 (4): 515-525 (2013)

Endocrinology, 153 (9): 4412-4421 (2012)

STOCK

PRODUCT / JOURNALS

CURRENT AVAILABILITY

STOCK

176-Estradiol (cont.)

Endocrinology, 153 (9): 4470-4479 (2012)

Endocrinology, 153 (9): 4480-4490 (2012)

Endocrinology, 153 (10): 5011-5022 (2012)

Endocrinology, 153 (10): 5325-5333 (2012)

Endocrinology, 153 (11): 5467-5479 (2012)

Endocrinology, 154 (3): 1021-1028 (2013)

Endocrinology, 154 (6): 2222-2233 (2013)

European Journal of Neuroscience, 34 (5): 745-754 (2011)

European Journal of Nuclear Medicine and Molecular Imaging, 38 (11): 1967-1976 (2011)

European Journal of Nutrition, 51 (7): 861-870 (2012)

Experimental Cell Research, 317 (18): 2573-2581 (2011)

Experimental Clinical Cardiology, 17 (3): 95-100 (2012)

Experimental Eye Research, 96 (1): 88-97 (2012)

Experimental Lung Research, 38 (4): 165-172 (2012)

Experimental Neurology, 237 (1): 1-7 (2012)

FASEB Journal, 27 (1): 63-75 (2013)

FASEB Journal, 27 (9): 3711-3719 (2013)

Female Pelvic Medicine and Reconstructive Surgery, 18 (3): 148-152 (2012)

Food and Chemical Toxicology, 49 (9): 2279-2284 (2011)

Frontiers in Endocrinology, 2 (82): 1-15 (2011)

Frontiers in Neuroscience, 7 (13): 1-8 (2013)

Gastroenterology, 142 (4): 989-998 (2012)

General and Comparative Endocrinology, 176 (2): 144-150 (2012)

Genes and Cancer, 4 (1): 3-14 (2013)

Haematologica, 97 (8): 1131-1135 (2012)

Histology and Histopathology, 27 (8): 1047-1054 (2012)

Hypertension, 59 (3): 552-554 (2012)

Hypertension, 59 (3): 694-704 (2012)

Hormone and Metabolic Research, 41 (5): 356-362 (2009)

Hormone and Metabolic Research, 45 (7): 490-494 (2013)

Human Reproduction, 28 (8): 2253-2264 (2013)

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011)

In Vivo, 24 (4): 553-560 (2010)

Infection and Immunity, 81 (3): 733-739 (2013)

International Journal of Andrology, 32 (4): 399-410 (2008)

International Journal of Cancer, 121 (5): 1055-1058 (2007)

International Journal of Cancer, 132 (12): 2787-2798 (2013)

International Journal of Oncology, 39 (6): 1443-1453 (2011)

International Journal of Oncology, 42 (1): 179-187 (2013)

Japanese Journal of Cancer Research, 86 (8): 770-775 (1995)

Journal of Alzheimer's Disease, 18 (2): 429-445 (2009)

Journal of Applied Physiology, 112 (9): 1564-1575 (2012)

Journal of Applied Physiology, 113 (1): 149-158 (2012)

Journal of Autoimmunity, 37 (2): 95-103 (2011)

Journal of Autoimmunity, 38 (1): 1-9 (2012)

Journal of Autoimmunity, 38 (2-3): J135-J143 (2012)

Journal of Autoimmunity, 38 (2-3): J245-J253 (2012)

Journal of Biological Chemistry, 279 (32): 33696-33701 (2004)

Journal of Biological Chemistry, 287 (44): 37195-37205 (2012)

Journal of Biological Chemistry, 288 (5): 18022-18034 (2013)

Journal of Biological Chemistry, 288 (34): 24590-24599 (2013)

Journal of Biomedical Optics, 17 (11): 116017 (2012)

Journal of Cancer Therapy, 4: 32-40 (2013)

Journal of Cell Biology, 198 (3): 281-293 (2012)

Journal of Cellular Physiology, 219 (2): 477-484 (2009)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

STOCK

17B-Estradiol (cont.)

Journal of Clinical Investigation, 122 (8): 2857-2870 (2012)

Journal of Clinical Investigation, 123 (6): 2551-2563 (2013)

Journal of Clinical Investigation, 123 (9): 3861-3875 (2013)

Journal of Clinical Investigation, 123 (10): 4324-4343 (2013)

Journal of Drug Targeting, 16 (7-8): 605-610 (2008)

Journal of Experimental Therapeutics and Oncology, 3 (1): 27-35 (2003)

Journal of Headache and Pain, 1 (1): P29 (2013)

Journal of Hypertension, 27 (6): 1284-1292 (2009)

Journal of Hypertension, 27 (8): 1602-1608 (2009)

Journal of Immunology, 190 (8): 4420-4430 (2013)

Journal of Inflammation Research, 6: 99-108 (2013)

Journal of Investigative Dermatology, 132 (12): 2838-2848 (2012)

Journal of Labelled Compounds and Radiopharmaceuticals, 55 (9): 346-353 (2012)

Journal of Laboratory and Clinical Medicine, 153 (6): 275-282 (2009)

Journal of Magnetic Resonance Imaging, 29 (5): 1071-1079 (2009)

Journal of Materials Chemistry B, 39 (1): 5288-5297 (2013)

Journal of Molecular and Cellular Cardiology, 53 (2): 268-276 (2012)

Journal of Neurobiology, 65 (2): 192-204 (2005)

Journal of Neuroendocrinology, 22 (10): 1082-1092 (2010)

Journal of Nuclear Medicine, 53 (4): 629-637 (2012)

Journal of Nuclear Medicine, 53 (12): 1943-1950 (2012)

Journal of Nuclear Medicine, 54 (9): 1630-1636 (2013)

Journal of Nutritional Biochemistry, 23 (6): 532-538 (2012)

Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)

Journal of Steroid Biochemistry and Molecular Biology, 114 (3): 186-194 (2009)

Journal of the National Cancer Institute, 104 (17): 1320-1334 (2012)

Journal of the National Cancer Institute, 104 (19): 1485-1502 (2012)

Kidney International, 79 (4): 404-413 (2011)

Magnetic Resonance in Medicine, 69 (6): 1721-1734 (2013)

Magnetic Resonance Materials in Biology, Physics and Medicine, 6 (1): 44-52 (1998)

Menopause, 16 (3): 545-554 (2009)

Menopause, 19 (6): 680-690 (2012)

Menopause, 19 (8): 942-947 (2012)

Menopause, 20 (5): 504-510 (2013)

Menopause, 20 (8): 860-868 (2013)

Methods in Molecular Biology, 946 (Chapter 12): 181-204 (2013)

Molecular and Cellular Endocrinology, 375 (1-2): 149-156 (2013)

Molecular Biosystems, 7 (11): 3006-3020 (2011)

Molecular Cancer, 12 (59): 1-18 (2013)

Molecular Cancer Therapeutics, 12 (4): 542-552 (2013)

Molecular Cancer Therapeutics, 12 (5): 675-684 (2013)

Molecular Cancer Therapeutics, 12 (10): 2078-2087 (2013)

Molecular Carcinogenesis, 52 (7): 514-525 (2013)

Molecular Endocrinology, 27 (9): 1403-1414 (2013)

Molecular Endocrinology, 27 (9): 1415-1428 (2013)

Molecular Endocrinology, 27 (10): 1762-1775 (2013)

Molecular Human Reproduction, 19 (3): 169-176 (2013)

Molecular Imaging and Biology, 13 (6): 1183-1195 (2011)

Molecular Medicine, 18 (9): 913-929 (2012)

Molecular Metabolism, 2 (3): 227-242 (2013)

Molecular Pharmaceutics, 6 (2): 543-556 (2009)

Molecular Pharmaceutics, 10 (1): 69-76 (2013)

Molecular Pharmaceutics, 10 (1): 152-160 (2013)

Molecular Pharmaceutics, 10 (7): 2558-2567 (2013)

Molecular Pharmacology, 82 (6): 1241-1249 (2012)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

17B-Estradiol (cont.)

Molecular Psychiatry, 18 (6): 674-680 (2013)

Molecular Therapy - Nucleic Acids, 2 (9): e121 (2013)

Nanomedicine: Nanotechnology, Biology and Medicine, 9 (1): 122-129 (2012)

Nature Biotechnology, 31 (6): 539-544 (2013)

Nature Medicine, 18 (7): 1102-1111 (2012)

Nature Medicine, 18 (12): 1847-1856 (2012)

Neurobiology of Disease, 45 (1): 479-487 (2012)

Neurobiology of Learning and Memory, 94 (3): 422-433 (2010)

Neurobiology of Learning and Memory, 99: 50-58 (2013)

Nuclear Medicine and Biology, 40 (1): 52-59 (2013)

Oncogene, 29 (22): 3228-3240 (2010)

Oncogene, 31 (34): 3889-3900 (2012)

Oncology Reports, 30 (4): 1762-1772 (2013)

Oncotarget, 3 (8): 869-881 (2012)

Osteoporosis International, 22 (11): 2887-2893 (2011)

Physiological Genomics, 44 (6): 362-373 (2012)

Proceedings of the National Academy of Sciences (PNAS), 109 (33): 13331-13336 (2012)

Proceedings of the National Academy of Sciences (PNAS), 109 (45): 3119-3127 (2012)

Proceedings of the National Academy of Sciences (PNAS), 109 (48): 19822-19827 (2012)

Proceedings of the National Academy of Sciences (PNAS), 110 (5): E407-E414 (2013)

Proceedings of the National Academy of Sciences (PNAS), 110 (6): 2294-2299 (2013)

Proceedings of the National Academy of Sciences (PNAS), 110 (29): 11851-11856 (2013)

Proceedings of the National Academy of Sciences (PNAS), 110 (36): E3445-E3454 (2013)

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89 (2): 81-88 (2013)

Proteomics, 9 (10): 2750-2763 (2009)

Public Library of Science (PLoS ONE), 7 (11): e48220 (2012)

Public Library of Science (PLoS ONE), 7 (11): e48564 (2012)

Public Library of Science (PLoS ONE), 7 (11): e48601 (2012)

Public Library of Science (PLoS ONE), 7 (11): e50301 (2012)

Public Library of Science (PLoS ONE), 7 (12): e50749 (2012)

Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)

Public Library of Science (PLoS ONE), 7 (12): e52692 (2012)

Public Library of Science (PLoS ONE), 8 (1): e54022 (2013)

Public Library of Science (PLoS ONE), 8 (4): e61515 (2013)

Public Library of Science (PLoS ONE), 8 (5): e63146 (2013)

Public Library of Science (PLoS ONE), 8 (5): e64049 (2013) Public Library of Science (PLoS ONE), 8 (5): e64069 (2013)

Public Library of Science (PLoS ONE), 8 (5): e65163 (2013)

Public Library of Science (PLoS ONE), 8 (6): e68637 (2013)

Public Library of Science (PLoS ONE), 8 (7): e68815 (2013)

Public Library of Science (PLoS ONE), 8 (8): e69291 (2013)

Public Library of Science (PLoS ONE), 8 (8): e70719 (2013)

Public Library of Science (PLoS ONE), 8 (8): e72210 (2013)

Public Library of Science (PLoS ONE), 8 (8): e72397 (2013) Public Library of Science (PLoS ONE), 8 (9): e75288 (2013)

Public Library of Science (PLoS ONE), 9 (3): e1003311 (2013)

Public Library of Science (PLoS) Pathogens, 9 (4): e1003292 (2013)

Reproduction, 142 (5): 745-755 (2011)

Research Quarterly for Exercise and Sport, 82 (4): 693-701 (2011)

Scandinavian Journal of Clinical and Laboratory Investigation, 71 (7): 583-592 (2011).

Science Translational Medicine, 5 (169): ra12 (2013)

Stem Cells, 27 (5): 993-1005 (2009)

Stem Cells, 31 (4): 808-822 (2013)

Steroids, 74 (7): 555-561 (2009)

Steroids, 74 (13-14): 1015-1024 (2009)

STOCK

PRODUCT / JOURNALS

CURRENT AVAILABILITY

STOCK

STOCK

STOCK

17B-Estradiol (cont.)

Thrombosis Research, 126 (6): 504-510 (2010)

Toxicology and Applied Pharmacology, 247 (2): 83-90 (2010)

Vaccine, 28 (45): 7279-7287 (2010)

Virology, 447 (1): 155-165 (2013)

B-Estradiol 3-Benzoate

American Journal of Physiology: Endocrinology and Metabolism, 302 (8): E979-E986 (2012)

Biological Psychiatry, 71 (7): 642-651 (2012)

176-Estradiol + Progesterone

Journal of Pathology, 225 (4): 565-573 (2011)

Neuroscience, 184: 172-182 (2011)

Estriol

Dissertation, 1-180 (2012)

Fluoxetine

Dissertation, 1-264 (2013)

European Journal of Neuroscience, 37 (2): 242-250 (2013)

Nature Neuroscience, 13 (6): 745-754 (2010)

Neuropsychopharmacology, 38 (6): 909-920 (2013)

Flutamide

American Journal of Pathology, 182 (2): 1-14 (2013)

Behavioral Neuroscience, 127 (3): 400-414 (2013)

Dissertation, 1-191 (2011)

Dissertation, 1-15 (2013)

Frontiers in Zoology, 10 (1): 8 (2013)

Journal of Comparative Neurology, 431 (4): 444-459 (2001)

Public Library of Science (PLoS ONE), 7 (12): e52009 (2012)

Science, 339 (6123): 1084-1088 (2013)

G-1 CUSTOM

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 11 (4): 262-274 (2011)

Journal of Molecular Endocrinology, 51 (1): 191-202 (2013)

Public Library of Science (PLoS ONE), 7 (9); e43215 (2012)

Glucosamine

Biology of Reproduction, 89 (1): 16 (2013)

GW7604 CUSTOM

Steroids, 74 (13-14): 1015-1024 (2009)

Haloperidol STOCK

Journal of Clinical Investigation, 123 (9): 3902-3913 (2013)

Pharmacogenomics Journal, 12 (2): 147-155 (2012)

Hexarelin

Growth Hormone and IGF Research, 20 (1): 49-54 (2009)

4-Hydroxytamoxifen CUSTOM

Journal of Cellular and Molecular Medicine, 17 (8): 936-957 (2013)

IN-1130 CUSTOM

American Journal of Physiology: Renal Physiology, 304 (5): F481-F490 (2013)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Insulin-Like Growth Factor-1 (IGF-1)

Cancer Medicine, 1 (2): 275-288 (2012)

CUSTOM

CUSTOM

Isradipine
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812 (12): 1584-1590 (2011)

biochimica et biophysica Acta (BBA) - Molecular Basis of Disease, 1812 (12): 1384-1390 (2011)

CUSTOM

Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)

Letrozole CUSTOM

Dissertation, 1-191 (2011)

Fertility and Sterility, 99 (3): 889-896 (2013)

Frontiers in Zoology, 10 (1): 8 (2013)

Lipopolysaccharide (LPS) CUSTOM

Cardiovascular Pathology, 18 (1): 1-10 (2009)

Dissertation, 1-98 (2012)

Inflammation Research, 60 (7): 665-672 (2011)

Journal of Biomedical Materials Research (Part A), 100 (4): 918-928 (2012)

Luteinizing Hormone (LH) CUSTOM

Neuroendocrinology, 94 (4): 313-322 (2011)

LY3201 CUSTOM

Molecular Psychiatry, 18 (6): 674-680 (2013)

Proceedings of the National Academy of Sciences (PNAS), 110 (9); 3543-3548 (2013)

Medroxyprogesterone Acetate (MPA) STOCK

Endocrinology, 153 (10): 4874-4882 (2012)

International Journal of Oncology, 42 (1): 179-187 (2013)

Journal of Cellular Physiology, 219 (2): 477-484 (2009)

Journal of Immunology, 189 (7): 3449-3461 (2012)

Menopause, 19 (7): 804-811 (2012)

1-Methyl-DL-Tryptophan (1-MT) CUSTOM

Journal of Immunology, 189 (1): 72-79 (2012)

Journal of Immunology, 191 (4): 1965-1975 (2013)

Oncogene, 27 (20): 2851-2857 (2008)

1-Methyl-L-Tryptophan CUSTOM

Gastroenterology, 145 (2): 416-425 (2013)

Mifepristone (RU-486) CUSTOM

Journal of Neuroscience, 32 (22): 7563-7571 (2012)

Journal of Orthopaedic Research, 30 (2): 288-295 (2012)

Neurobiology of Disease, 45 (1): 539-546 (2012)

Steroids, 74 (13-14): 1015-1024 (2009)

Nedocromil CUSTOM

American Journal of Physiology: Heart and Circulatory Physiology, 302 (3): H811-H817 (2012)

Public Library of Science (PLoS ONE), 8 (3): e60827 (2013)

Neuropeptide Y (NPY) CUSTOM

Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, (Chapter 2): 1-160 (2000)

FASEB Journal, 27 (6): 2244-2255 (2013)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Nicotine

Biological Trace Element Research, 46 (1-2): 67-78 (1994) Experimental Lung Research, 35 (2): 119-135 (2009)

Norethindrone STOCK

Menopause, 20 (5): 504-510 (2013)

Ouabain STOCK

Journal of Cardiovascular Pharmacology, 62 (2): 174-183 (2013)

Peptide 6 CUSTOM

Neurobiology of Aging, 32 (8): 1420-1434 (2011)

PPT CUSTOM

Biology of Sex Differences, 3 (1): 24 (2012)

Prednisolone STOCK

Annals of the New York Academy of Sciences, 1192 (1): 81-83 (2010)

Arthritis and Rheumatism, 64 (11): 3649-3659 (2012)

FASEB Journal, 25 (10): 3366-3376 (2011)

Human Gene Therapy, 23 (3): 262-273 (2012)

Joint Bone Spine, 80 (1): 77-81 (2013)

Journal of Bone and Mineral Metabolism, 30 (5): 509-516 (2012)

Journal of Bone and Mineral Research, 27 (11): 2242-2250 (2012)

Vitamins and Hormones, 90: 163-186 (2012)

Prednisone STOCK

Journal of Bone and Mineral Metabolism, 28 (5): 532-539 (2010)

Muscle and Nerve, 44 (1): 8-19 (2011)

Pregnenolone STOCK

Experimental Neurology, 233 (2): 677-685 (2012)

Progesterone STOCK

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 302 (3): R331-R339 (2012)

Biochemical and Biophysical Research Communications, 434 (4): 740-745 (2013)

Biology of Reproduction, 86 (3): 68 (2012)

Biology of Sex Differences, 2 (1): 14 (2011)

Brain Research, 1361: 124-132 (2010)

Cancer Research, 73 (15): 4697-4710 (2013)

Carcinogenesis, 30 (9): 1581-1590 (2009)

Development, 140 (17): 1397-1401 (2013)

Disease Models and Mechanisms, 6 (5): 1198-1204 (2013)

Endocrinology, 153 (10): 4874-4882 (2012)

Endocrinology, 153 (11): 5467-5479 (2012)

FASEB Journal, 27 (9): 3711-3719 (2013)

General and Comparative Endocrinology, 176 (2): 144-150 (2012)

Hormone and Metabolic Research, 45 (7): 490-494 (2013)

Human Reproduction, 28 (8): 2253-2264 (2013)

Journal of Neurochemistry, 122 (1): 185-195 (2012)

Journal of Neuroendocrinology, 25 (3): 235-243 (2013)

Journal of Neuroscience, 32 (42): 14664-14669 (2012)

Journal of Sports Medicine and Physical Fitness, 42 (4): 481-487 (2002)

Journal of Steroid Biochemistry and Molecular Biology, 83 (1): 199-209 (2002)

Molecular Endocrinology, 27 (9): 1403-1414 (2013)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

STOCK

STOCK

CUSTOM

STOCK

CUSTOM

Progesterone (cont.)

Molecular Genetics and Genomics, 288 (5-6): 207-229 (2013)

Nature Medicine, 19 (8): 1061-1066 (2013)

Neurobiology of Disease, 45 (1): 479-487 (2012)

Neuropathology and Applied Neurobiology, 30 (1): 80-89 (2004)

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89 (2-3): 81-88 (2013)

Public Library of Science (PLoS ONE), 7 (12): e50749 (2012)

Public Library of Science (PLoS ONE), 8 (6): e68637 (2013)

Public Library of Science (PLoS) Pathogens, 9 (4): e1003292 (2013)

Research Quarterly for Exercise and Sport, 82 (4): 693-701 (2011)

Stem Cells, 31 (4): 808-822 (2013)

Steroids, 74 (13-14): 1015-1024 (2009)

Propranolol

FASEB Journal, 27 (9): 3871-3878 (2013)

D-Propranolol Canadian Journal of Physiology and Pharmacology, 90 (9): 1257-1268 (2012)

Prostaglandin D2

Calcified Tissue International, 52 (6): 442-446 (1993)

Public Library of Science (PLoS ONE), 7 (12): e50802 (2012)

Steroids, 74 (13-14): 1015-1024 (2009)

CUSTOM

Circulation, 126 (18): 2208-2219 (2012)

Rapamycin CUSTOM

Aging, 5 (2): 111-119 (2013)

American Journal of Pathology, 181 (1): 278-293 (2012)

Rat Growth Hormone (GH) CUSTOM

Journal of Pharmacology and Experimental Therapeutics, 342 (3): 688-695 (2012)

CUSTOM Resveratrol

Journal of Surgical Research, 179 (1): E141-E148 (2013)

STOCK all trans-Retinoic Acid (ATRA)

Haematologica, 98 (3): 424-427 (2013)

Journal of Experimental Medicine, 210 (4): 647-653 (2013)

Journal of Immunotherapy, 32 (6): 552-564 (2009)

Leukemia, 26 (7): 1630-1637 (2012)

Leukemia, 26 (11): 2432-2435 (2012)

STOCK Sodium Butyrate

Molecular and Cellular Biology, 33 (19): 3920-3935 (2013)

Spironolactone STOCK

American Journal of Nephrology, 35 (1): 90-100 (2012)

Journal of Human Hypertension, 27 (1): 1-6 (2013)

Journal of the American Heart Association, 2 (1); e18 (2013)

STOCK Streptozotocin

American Journal of Obstetrics and Gynecology, 209 (1): 24.e1-24.e12 (2013)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Tacrolimus

Experimental Neurology, 248: 85-99 (2013)

CUSTOM

STOCK

Tamoxifen

American Journal of Pathology, 183 (1): 304-312 (2013)

Angiogenesis, 6 (1): 65-71 (2003)

Anti-Cancer Agents in Medicinal Chemistry, 13 (8): 1178-1187 (2013)

Cell Reports, 3 (4): 1153-1163 (2013)

Clinical Cancer Research, 19 (9): 2420-2431 (2013)

Journal of Clinical Investigation, 122 (8): 2857-2870 (2012)

Journal of Comparative Neurology, 431 (4): 444-459 (2001)

Molecular Cancer, 12 (9): 1-17 (2013)

Oncogene, 29 (22): 3228-3240 (2010)

Proceedings of the National Academy of Sciences (PNAS), 109 (51): 21140-21145 (2012)

Public Library of Science (PLoS ONE), 8 (8): e72132 (2013)

Steroids, 74 (13-14): 1015-1024 (2009)

Translational Oncology, 6 (3): 244-255 (2013)

STOCK

Tamoxifen Citrate

Cancer Research, 72 (19): 5048-5059 (2012)

EMBO Molecular Medicine, 5 (5): 723-736 (2013)

STOCK

Tamoxifen (Free Base)

Cancer Research, 73 (13): 5449-5458 (2013)

FASEB Journal, 26 (10): 3993-4002 (2012)

Journal of Experimental Medicine, 209 (9): 1611-1627 (2012)

STOCK

Testosterone

American Journal of Physiology: Renal Physiology, 305 (5): 618-627 (2013)

Arthritis and Rheumatism, 64 (8): 2518-2528 (2012)

Biological Psychiatry, 71 (7): 642-651 (2012)

Biology of Sex Differences, 2 (1): 14 (2011)

Biomed Research International, Volume 2013 (Article ID 913179): 1-8 (2013)

Brain Research, 1429: 43-51 (2012)

Cancer Research, 73 (8): 2587-2597 (2013)

Current Eye Research, 32 (5): 393-398 (2007)

Diabetes, 61 (10): 2597-2608 (2012)

Discrete and Continuous Dynamical Systems Series B, 18 (4): 945-967 (2013)

Dissertation, 1-106 (2012)

Endocrine - Related Cancer, 19 (6): 759-777 (2012)

Experimental Neurology, 181 (2): 301-312 (2003).

Experimental Physiology, 98 (1): 161-171 (2013)

Hormones and Behavior, 61 (5): 678-685 (2012)

Hormone and Metabolic Research, 45 (7): 490-494 (2013)

Hypertension, 59 (3): 726-731 (2012)

International Journal of Andrology, 32 (4): 399-410 (2008)

Investigative Ophthalmology and Visual Science, 33 (8): 2537-2545 (1992)

Journal of Alzheimer's Disease, 15 (1): 129-137 (2008)

Journal of Clinical Investigation, 132 (2): 682-699 (2013)

Journal of Neurobiology, 49 (1): 1-8 (2001)

Journal of Neuroendocrinology, 24 (5): 737-747 (2012)

Journal of Neuroscience, 32 (36): 12312-12324 (2012)

Journal of Neuroscience, 33 (6): 2338-2355 (2013)

Kidney International, 79 (4): 404-413 (2011)

Molecular Imaging, 11 (5): 426-432 (2012)

PRODUCT / JOURNALS

CURRENT AVAILABILITY

Testosterone (cont.)

Nature Protocols, 8 (5); 836-848 (2013)

Neurobiology of Disease, 45 (1): 479-487 (2012)

Prostate, 73 (12): 1251-1262 (2013)

Public Library of Science (PLoS ONE), 7 (11): e49970 (2012)

Public Library of Science (PLoS ONE), 8 (1): e53302 (2013)

Public Library of Science (PLoS ONE), 8 (1): e55062 (2013)

Public Library of Science (PLoS ONE), 8 (2): e55694 (2013)

Public Library of Science (PLoS ONE), 8 (2): e56903 (2013)

Public Library of Science (PLoS ONE), 8 (5): c63723 (2013)

Public Library of Science (PLoS ONE), 8 (5): e64503 (2013)

Public Library of Science (PLoS ONE), 8 (6): e65538 (2013)

Public Library of Science (PLoS ONE), 8 (7): e69398 (2013)

Radiation Oncology, 7 (1): 75 (2012)

Testosterone Propionate

Behavioural Brain Research, 224 (2): 403-407 (2011)

Cerebral Cortex, 22 (8): 1799-1812 (2012)

Journal of Comparative Physiology A, 165 (1): 15-26 (1989)

Journal of Neurobiology, 30 (2): 231-245 (1996)

Journal of Neurobiology, 52 (3): 203-220 (2002)

Stem Cells, 30 (6): 1076-1086 (2012)

L-Thyroxine (T4)

European Respiratory Journal, 41 (1): 104-114 (2013)

Journal of Clinical Investigation, 122 (10): 3737-3741 (2012)

Journal of Translational Medicine, 11 (1): 40 (2013)

Pulmonary Circulation, 2 (4): 434-442 (2012)

Toxicology, 225 (2-3): 119-127 (2006)

STOCK

STOCK

STOCK



RECOMMENDED IMPLANTATION PROCEDURE

Depending on the physical size of the animal, multiple pellets can be implanted to build up the dose. We recommend starting with one pellet on each lateral side of the neck between the ear and the shoulder where there is maximal space between the skin and the muscle.

*Please Note - In order to ensure reliable and continued performance, the pellet and implantation site should not come in contact with any alcohol, ethanol, exogenous fluids or organic solvents. Please make sure your instruments are dry before use.

In order to implant a second pellet in the same incision pocket, the pellets should be side by side and not super imposed/stacked on top of each other.

The ideal site for pellet implantation is on the lateral side of the neck between the ear and the shoulder where there is maximal space between the skin and the muscle. This has three advantages:

- 1) Maximal space between the skin and the muscle so that the pellet sits comfortably
- 2) The animal cannot play with the pellet in that site
- 3) Other animals cannot play with the pellet in that site

*Please Note - the pellets arrive to you sterile. By design, the pellets have a sterile coating so even if one pellet falls on the bench, it is still sterile.

When this technique is properly executed, no antibiotics or stitches are needed and the animal should not bleed. In order to ensure reliable and continued performance, the pellet should not come in contact with any organic solvent or exogenous fluid.

If the pellet is a reasonable size (3mm in diameter - normally 0.001mg/pellet up to 5mg/pellet), it can be implanted using our MP-182 10 Gauge Precision Trochar.

For pellet implantation without using our Trochar, the following technique can be used:

- 1) Lift the skin on the lateral side of the neck of the animal
- 2) Make an incision equal in diameter to that of the pellet
- 3) Make a pocket horizontally with a pair of forceps about 2cm beyond the incision site
- 4) Put the pellet into the pocket with forceps and angle it to the right or to the left



Purchase Order Form

(United States)

Please print or type all information

	i.	Ł	I	ì		H	0	١	7	8	ı	IJ	ľ	V	ŧ	è		ŀ	Ç	6)	5	4	1	2	11	•	C	1	1	1	0	Ì	ľ	ĺ	Ì	1	1	1	€		C)	14		a	
		2		1	V	1	Э,	ľ	t	l	1	9	I	4	1	ľ	r.	ľ	Ļ	a	1	-	1	į		1	Ì	r	a	i			4	S	ı	1	i	tı	2		4	•().	4		
	5	C	١,	276	a a	en.			e i	4	á			1	C	71		, in		9		1	Ĺ		٠.,	7	į,	į,	'n		1	L	¥													

Sarasota, Florida 34236 Phone 941,365.1406

				Fax 941.3	65.1703										
Institution	*			P.O. Number: Date; Investigator: Department:											
Purchasing	Agent:_														
Departmen	f.														
Phone:		Fax	*	Phone:		Fax	F. Solomorous de la Constantina del Constantina de la Constantina								
Email:				Email:											
Cat. No.	# Lots	Quantity/ Lots	Product Des	cription	Dosage	Release Time	Price/ Lot	Total Price							
								\$							
American															
MasterCar		sa letta [Subtotal:											
accepted. Account #			3 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Shipping an		4 5									
Expiration				(Via Federal Express) Total: \$											
Name on C						* *************************************									
Ship To:				Bill To:											


PLEASE COPY THIS FORM FOR FUTURE ORDERING

International Order Form	Innovative Research of America 2 North Tamiami Trail, Suite 404 Sarasota, Florida 34236
Please print or type all information	Phone 941.365.1406 Fax 941.365.1703
Institution:	
Purchasing Agent:	
Department:	
Phone: Fax:	
Email:	
# Quantitu/	Dosage Release Price/ Total Price \$
A Proforma Invoice will be provided for a payment. See Bank Wire information on the American Express, MasterCard, and Visa accepted. Account #:	Shipping and Handling: \$
	s on any orders shipped outside the United States
Ship To:	Bill To:
Attn:	Attn:
Bank Wire Payment Information Payment via bank wire should be directed as follows: BB&T Bank In favor of:	Accounts Payable/Financial Information Contact Name:
1800 Second St., Suite 100 Innovative Research of A Sarasota, Florida 34236 2 North Tamiami Trail Routing # (ABA) 263191387 Sarasota, FL 34236	Phone: Fax:
Elect. Transfers # 263191387 Checking Account: #000	16154

We now have an additional PATENT page on our website where you can search numerous patents issued citing the use of our innovative technology. To view a complete list of patents entered on a daily basis please visit our website: www.innovrsrch.com



IRA PATENTS



Reliable Delivery System for Global Discoveries



Hormone and Drug Pellers for Biomedical Research

Our mission is to standardize the drug delivery technology.
We are dedicated to belping investigators take charge of product delivery by expanding their abilities to do meaningful and reproducible research!

Stock

21 Day Release

60 Day Release

90 Day Release

RESEARCH OAR REPORT OF THE PROPERTY OF THE PRO

Any Product

Any Dose

Any Release

Custom

Innovative Research of America 2 North Tamiami Trail, Fourth Floor Sarasota, Florida 34236 USA

Contact Us:

Tel: (941) 365-1406

(941) 365-1506

(800) 421-8171

Websites www.innoverseh.com

Fax: (941) 365-1703

(941) 365-1803

((300)) 643-4845

(800) 648-6030 📰

Burail us an pelleta@fanovesich.com